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Presentation and Justification 
 
The work for the Doctoral Thesis that I am presenting has been carried-out in the Unitat 
de Recerca en Lípids i Arteriosclerosi, of the Departament de Medicina i Cirurgia of the 
Facultat de Medicina i Ciències de la Salut, of the Universitat Rovira i Virgili under the 
direction of Dr. Josep Ribalta. 
The main interest of the Unitat de Recerca en Lípids i Arteriosclerosi has been the 
study of lipid metabolism, the mechanisms implicated in arteriosclerosis, its clinical 
presentation (cardiovascular diseases) and the associated risk factors, given the strong 
impact they have on the health of the population. Specifically, the line of investigation 
on the genetic predisposition to hypertriglyceridemia is based on the concept that the 
high levels of triglycerides are a key element in the development of cardiovascular 
diseases. In this sense, the focus of this thesis has been on the in-depth study the 
gene which has become the most important modulator of the levels of circulating 
triglycerides, the apolipoprotein A5 (APOA5). The gene was identified in 2001 and, at 
the time of commencing this PhD program in 2003, the mechanisms responsible for the 
strong impact that this gene has on triglycerides was not known. This thesis brings new 
knowledge on the role of the apo A-V. For this we used genetic markers that have 
enabled us to describe new associations of the gene with elements related to the 
metabolism of the triglycerides. We have used an animal model of arteriosclerosis to 
study the regulation of the gene by diet, and a cell model to confirm our hypothesis that 
apo A-V is also expressed in an organ involved in the processing of the triglycerides 
i.e. the intestine. 
 
The thesis is divided into different sections. The Introduction contains an explanation of 
the themes that are necessary in order to put into perspective and to follow the course 
of the work conducted. The greater part of the knowledge on apo A-V is concentrated 
in the section dedicated to genetics in the Introduction, and receives less attention in 
the rest of the sections. The rationale has been that genetic studies are the ones that 
carry the major part of the information on this protein, the importance of which needed 
to be reflected in this thesis. Subsequently, the Hypotheses and Objectives justify the 
conduct of the different experimental studies performed, and which are presented in 
article format. This is followed by the General Discussion of the results obtained and 
the final Conclusions. The References section contains the details of the references 
cited in the previous sections. There is no Methodology section since the techniques 
UNIVERSITAT ROVIRA I VIRGILI 
ROLE OF THE APOA5 GENE IN LIPID AND FAT-SOLUBLE VITAMIN METABOLISM 
Montserrat Guardiola Guionnet 
ISBN:978-84-691-9478-2/DL:T-19-2009 
 
10   Presentation & Justification 
used are routine in molecular biology and, further, are presented in detail in our 
published articles included in this thesis. 
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1. Triglycerides and cardiovascular disease  
 
Cardiovascular diseases are the principal cause of mortality and morbidity in Western 
and industrialized countries because their development are favored by factors strongly 
implanted in these societies, such as diet rich in fats and carbohydrates, stress, 
sedentary life-style and the tobacco habit, among others.  
 
From among all the risk factors for cardiovascular disease (hypertension, thrombosis, 
obesity, and tobacco habit) possibly one of the most relevant is hyperlipidemia. Of 
special importance is the role placed by cholesterol since it is the lipid that accumulates 
in the atheromatous plaque and which finally leads to obstruction of the artery.  
 
The concentrations of cholesterol transported by the low density lipoproteins (LDL) 
correlate directly with the prevalence and incidence of adverse cardiovascular events 
and death, and the therapies directed towards decreasing LDL cholesterol have 
demonstrated great efficacy in the prevention and the treatment of coronary disease 
(1). A key contribution to these notions derives from the Framingham study, which has 
as its clear objective the identification of the factors that promote cardiovascular 
disease and to follow the long-term developments in a large number of participants.  
The original cohort (1948) (2) was composed of 5209 men and women followed-up for 
2 years. Over time this cohort widened with new generations of direct descendents of 
the original participants (The Framingham Offspring Study) (obtained from the website 
http://www.nhlbi.nih.gov/about/framingham/). Several years later (3), the study 
demonstrated that total cholesterol and the content of LDL are the principal inducers of 
arteriosclerosis in the greater part of the population, but that there are other important 
factors of cardiovascular disease risk. The conclusion from this study showed, for the 
first time that the low levels of high density lipoprotein (HDL) are also an important risk 
factor and that individuals, especially women, with high levels of triglyceride (TG) have 
a high relative risk of coronary disease. Other cardiovascular disease risk factors 
described in the study were hypertension, excess bodyweight, hyperglycemia, tobacco 
habit, lack of exercise and stress. This is relevant since it implies that the cholesterol-
coronary artery disease relationship, although very solid, is fulfilled only in 
approximately 50% of cases of arteriosclerotic disease. This doctoral thesis is based, in 
great part, on the hypothesis that a significant proportion of the remaining 50% is 
explained by lipid alterations as well, but specifically related to hypertriglyceridemia 
(hyperTG). 
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14   TG and cardiovascular disease  
The association between the levels of TG and the risk of cardiovascular disease is 
somewhat confused.  
Several epidemiological studies have shown that TG in the circulation are an 
independent risk factor for cardiovascular disease (4, 5, 6). A recent meta-analysis 
performed on >10,000 cases among a population >250,000 participants (7) indicated 
that the TG increases the risk of suffering an adverse cardiovascular event by 72% in 
addition to that carried by the traditional risk factors (cholesterol, glucose, hypertension, 
bodyweight, gender).  
It is difficult to differentiate the risk induced directly by TG from that derived from the 
components of atherogenic dyslipemia (small dense LDL particles, elevated levels of 
apolipoprotein B, low levels of HDLc, remnant particles and postprandial lipemia) that 
characterize the moderately hypertriglyceridemic patient. Increasing evidence suggests 
that all the components of atherogenic dyslipemia can contribute to the development of 
atherosclerosis, and need to be considered in totality as a risk factor (8). 
Plasma triglyceride concentration is a highly variable parameter that correlates with 
other lipids and lipoprotein parameters. As such, the specific contribution of TG to 
cardiovascular disease is consistently under-estimated in multivariate analysis (9).  
Further, the increase in TG does not always imply development of coronary disease 
because the risk depends on the type of lipoprotein (intestinal or hepatic origin) in 
which the TG are transported. For example, while high levels of TG due to lipoprotein 
lipase deficiency are not atherogenic, moderate elevation of very low density 
lipoproteins (VLDL) are associated with a higher risk of cardiovascular disease (10).  
All of this explains the declaration of the National Cholesterol Education Program Adult 
Treatment Panel III (NCEP-ATP III) (11) which states that there are not sufficient data 
to confirm TG as an independent risk factor for cardiovascular disease. 
However, a third of the population presents with pathologies that are related to 
hyperTG (diabetes mellitus type 2, obesity, FCHL,...) (12) and, as such, strengthens its 
possible role in atherosclerosis and justifies the study of factors that regulate its 
metabolism, especially its concentration in the circulation.  
The apolipoprotein A-V gene has been considered a key gene in the control of TG 
levels, and its role in lipid metabolism is, in major part, the subject of the present thesis. 
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2. Lipid metabolism 
 
2.1. Exogenous lipid metabolism  
The fats derived from the diet are mainly composed by TG and smaller quantities of 
cholesterol, cholesterol esters and phospholipids. 
Digestion of fats occurs in the small intestine facilitated by bile salts which increase the 
surface of the lipid particles to enable the hydrolysis by lipolytic enzymes. The bile salts 
are synthesized in the liver from the lipids that are to be excreted, and are secreted via 
the bile into the duodenum where monoacylglycerols, free fatty acids, cholesterol and 
lipophosphoglycerols are formed which are absorbed in the microvilli of the absorptive 
cells of the intestine (the enterocytes) and re-esterified de novo forming TG, 
phospholipids and cholesterol esters in the endoplasmic reticulum.  
 
Lipids are insoluble and to be 
transported in plasma they need to be 
carried as LIPOPROTEINS which are 
macromolecules stable in aqueous 
medium. The hydrophobic nucleus 
transports non-polar lipids (TG and 
esterified cholesterol) and is enveloped 
within a hydrophilic surface containing 
amphipathic lipids (phospholipids and 
non-esterified cholesterol), as shown 
schematically in Figure 1. 
 
Figure 1. Lipoprotein molecule organization 
Classically, the lipoproteins have been classified on the basis of their electrophoretic 
mobility in a basic pH medium; a method that distinguishes three mobile bands 
(corresponding to the mobility of β-globulin, α2-globulin or α1-globulin) and one static 
band. An alternative classification is based on the hydrated density of the lipoprotein 
which enables the lipoprotein to be separated by ultracentrifugation; the densities being 
a function of the lipid and protein contents (summarized in Tables 1 and 2). 
The lipoproteins have four main functions: transport of exogenous TG, transport of 
endogenous TG, transport of cholesterol, and the removal of excess cholesterol. Apart 
from the lipids, the lipoproteins enable the transport of molecules derived from the diet 
such as liposoluble vitamins (vitamins A, D, E and K), among which vitamin E is of 
considerable because, apart from its known antioxidant role (an important process in 
the evolution of arteriosclerosis), its metabolism proceeds in parallel to that of the 
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triglyceride-rich lipoproteins (TRL). The protein component of the lipoproteins are 
formed, principally, by the APOLIPOPROTEINS which are involved in the assembly of 
the lipoproteins, in stabilizing their structure, acting as co-activators of enzymes or 
acting as ligands of receptors for their cellular uptake. The principal apoproteins 
involved in lipid metabolism are summarized in Table 2.  
 
 
 CHYLO VLDL IDL LDL HDL 
PHYSICAL PROPERTIES      
Electrophoretic mobility Origin Pre-β Pre-β β α 
Diameter (nm) 75-1200 30-80 25-35 18-25 5-12 
Molecular weight (Da) 4x106 10-80x106 5-10x106 2-3x106 0.2-0.4x106 
Density (g/ml) <0.93 0.93-1.006 1.006-1.019 1.019-1.063 1.063-1.210 
COMPOSITION      
Protein (%) 2 10 11 23 55 
Phospholipids (%) 9 18 25 20 24 
Free cholesterol (%) 1 7 10 8 2 
Cholesterol ester (%) 3 12 32 37 15 
TG (%) 85 50 25 10 4 
 
Table 1. Characteristics of the lipoproteins 
 
 
Apolipoprotein Molecular weight (kDa) Associated with  
Apo A-I 28 Chylo, HDL 
Apo A-II 17 Chylo, HDL 
Apo A-IV 44 Chylo, HDL 
Apo A-V 40 Chylo, VLDL, HDL 
Apo B48 240 Chylo 
Apo B100 513 VLDL, IDL, LDL 
Apo C-I 7 Chylo, VLDL, IDL, HDL 
Apo C-II 9 Chylo, VLDL, IDL, HDL 
Apo C-III 9 Chylo, VLDL, IDL, HDL 
Apo E 34 Chylo, VLDL, IDL, HDL 
 
Table 2. Characteristics of the apolipoproteins 
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Chylomicron. Intestinal cells synthesize the lipoproteins responsible for transporting 
in the blood the lipids from the diet, mainly, TG, to the liver and other tissues, and are 
termed CHYLOMICRONS. Analytically, they are characterized by not having 
electrophoretic mobility in basic pH medium. They are the largest lipoproteins with 85% 
of their content in the form of TG, and have the lowest density (<0.93 g/mL) (Table 1). 
 
The process of intestinal lipoprotein synthesis (13) can be divided into three stages: 
- Assembly of the primordial lipoprotein 
- Formation of lipid droplets 
- Expansion of the nucleus of the particle 
 
The process can be summarized as follows. The absorbed lipids, mainly TG, begin to 
associate with the key apoprotein in this process, apoprotein B48, while its translation 
is taking place in the ribosomes. 
Apolipoprotein B is a large protein (515 kDa) composed of a series of organized 
domains: NH2 / α-helix1 / lamina-β1 / α-helix2 / lamina-β2 / α-helix3 / COOH. The α-helix1 
domain is homologous to lipovitellin which is a protein that participates in the transport 
of lipids between the liver and the oocyte in oviparous animals. The β-laminas are 
thought to be the direct and irreversible interaction with lipids of the nucleus of the 
lipoprotein. Apo B exists in two forms, apo B100 and apo B48. By a process of 
alternative splicing that converts a glutamin to a stop codon, the resultant apo B48 
corresponds to 48% of the n-terminal part of apo B100. The majority of publications 
(14) show that, in humans, apo B100 is only present in the lipoproteins derived from 
hepatic synthesis (VLDL and its remnants) and that apo B48 is only present in the 
lipoprotein of intestinal origin (chylomicrons and its remnants), although there are some 
studies that describe the presence of B100 in the intestine as well (15). There is only 
one molecule of apo B per lipoprotein particle and, hence, measurement of plasma 
levels of apo B reflects the number of circulating apo B-containing lipoprotein particles.    
MTP is another key protein in the process of synthesis of TRL. It is present in the 
endoplasmic reticulum and, as well, has a n-terminal domain homologous to lipovitallin. 
It enables nascent apo B to become enriched in lipids as a result of transfer of polar 
and neutral lipids from the membrane of the endoplasmic reticulum. Alterations in the 
domains not only of apo B but also MTP are described in subjects with 
abetalipoproteinemia (i.e. those pathologies in which apo B is not synthesized) (16). 
Apo B that is not lipid associated is degraded predominantly via the 
ubiquitin/proteasome system. There are other proteolytic systems that can act on apo 
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B in various stages of the secretion pathway e.g. the immediate uptake of recently-
synthesised VLDL by the LDL receptor, or pre-secretory degradation (17). 
While apo B is being translated by the ribosomes, it becomes enriched with lipids via 
the MTP. For the formation of the lipoprotein particle to be initiated, there needs to be a 
minimum length containing the first two functional domains of the apo B. As a result of 
the increasing length of this apoprotein the TG:phospholipid ratio is also increased, 
forming the TG-rich nucleus. This complex is then directed towards the Golgi apparatus 
where the phospholipids and apolipoprotein A are added. Of special note at this stage 
is the role of apo A-IV in modulating the assembly of the chylomicrons (18). The final 
result is a nascent chylomicron that is released into the lymphatic system connected to 





























Figure 2. Overall scheme of the metabolism of human lipoproteins. The stages of metabolism of 
exogenous lipids are contained within the box outlined in red.  
 
As summarized in Table 1, the nascent chylomicrons are composed, principally, of TG 
and smaller quantities of phospholipids, free and esterified cholesterol, with the protein 
component composed of apo B48, apo A-I, apo A-II and apo A-IV. This makes the 
nascent chylomicrons good acceptors of free cholesterol derived from other 
lipoproteins. This process of interchange takes place in the general circulation and is 
mediated by the lipid transfer proteins (19), phospholipid transfer protein (PLTP) and 
the cholesterol ester transfer protein (CETP) The interchange involves the apo As, apo 
Cs and apo Es between the nascent chylomicrons and HDL, enabling the nascent 
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chylomicrons to mature and to become a substrate for the action of lipoprotein lipase 
(LPL). This process of interchange between lipoproteins is important in maintaining the 
levels of HDL; a low activity of PLTP markedly decreases the lipids and apoproteins of 
HDL. 
CETP is a hydrophobic glycoprotein secreted principally by the liver and circulates in 
plasma bound mainly to HDL. It facilitates the redistribution among circulating 
lipoproteins of cholesterol esters and TG and, to a lesser extent, phospholipids. This 
process results in an equilibration of lipids among the lipoproteins and, overall, the 
CETP transfers cholesterol esters from HDL to the TRL and LDL, and transfers TG 
from the TRL and LDL to HDL. As such, the transfer mediated by CETP indirectly 
promotes the elimination of cholesterol esters from the circulation via the liver (20). 
Because of its key role in the metabolism of HDL, alterations can have an impact on 
the susceptibility to arteriosclerosis, as demonstrated in cases of human CETP 
deficiency (21). This explains the interest in conducting clinical trials assessing the 
effect of CETP inhibitors (including the drug torcetrapib) on cardiovascular disease 
(22). However, the clinical trial conducted in 2006 showed an excessive mortality in the 
group treated with torcetrapib in combination with a statin (23) and the drug was 
withdrawn from the market. 
The process of interchange enables the TRL to acquire apolipoproteins essential for 
the hydrolysis of the TG, such as C-II which is the activator necessary for the enzyme 
LPL, and apo C-III which is the inhibitor of its activity. Although apo C-II is essential for 
the function of LPL, apo C-III is very important because it fulfills a double function of 
inhibiting the LPL and of modulating the uptake of lipoproteins by interrupting the 
recognition of apo E by the hepatic receptors (24, 25). As such, apo C-III is associated 
with the catabolism of the triglyceride-rich lipoproteins. 
LPL is a glycoprotein synthesized in heart, muscle and adipose tissue. For its 
physiological function in the metabolism of the TG it is secreted in the vascular 
endothelium bound to the proteoglycan heparin sulfate. It functions as a homodimer 
hydrolyzing the TG of the circulating lipoproteins that contain apo C-II (26), a process 
that is stimulated by apo A-IV (see Genetics of A-IV section). 
As the chylomicrons circulate they encounter the active LPL bound to the endothelium 
certain tissue (adipose tissue, muscle, mammary glands…). The TG content is 
hydrolyzed resulting in the liberation of the fatty acids which are taken-up by the tissues 
for storage or used to provide energy, and the glycerol part of the molecule is 
integrated into the gluconeogenesis pathway. LPL is the key in the process of receptor 
mediated elimination of lipoproteins (27). 
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The mean life-span of chylomicrons in circulation is approximately 1 hour (although by 
the time they appear in the blood this can be up to 4 hours). After 80-90% of the TG 
has been hydrolyzed and apo Cs and apo As transferred to HDL, the chylomicrons 
become reduced in size, denser and containing mainly cholesterol and apo E, and are 
termed chylomicron remnants. 
Apo E is a key protein in the catabolism of the triglyceride-rich lipoproteins 
(chylomicrons and VLDL) because it is the apoprotein responsible for recognition by 
the specific receptors (the LDL receptor; LDL-R) and the protein related to the LDL-R 
(LRP) in the liver and peripheral cells that facilitate the elimination of the remnants of 
the TRL from the circulation. 
Apo E is synthesized mainly in the liver, but in lesser amounts in other tissue such as 
the intestine. In humans the APOE gene is polymorphic and presents as 3 alleles E2, 
E3 and E4 giving rise to 6 possible genotypes (E2/E2, E3/E3, E4/E4; E2/E3, E2/E4, 
E3/E4). The 3 alleles are distinguished by the presence/absence of Cys and Arg amino 
acids at the polymorphic sites, their affinity for the LDL-R, and their consequent binding 
with lipids and lipoproteins (28):  
- Allele E3 (Cys112 and Arg158) is the most frequent (70-85%) in the general 
population 
- Allele E4 (Arg112 and Arg158) is present at a frequency of 12-18% in the general 
population. It has high affinity for the LDL-R and, compared to E3, is associated with 
higher circulating levels of LDLc and TG. 
- Allele E2 (Cys112 and Cys158) is present at a frequency of 3-12% in the general 
population. It has the lowest affinity for the LDL-R and, relative to E3, is associated 
with the low levels of LDLc and high levels of TG. 
 
In the liver there are receptors on the cell surface such as those of the LDL-R subfamily 
which enable the internalization of the remnant particles of the TRL which have 
become depleted of their cholesterol content and which will be eliminated or 
metabolized. The apolipoproteins (such as apo E and apo B100) are the ligands for 
these receptors (29). As we will see later, apo A-V can recognize and stimulate the 
elimination of these particles.   
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2.2. Endogenous lipid metabolism  
There are fatty acids of diverse origins in the liver: 
- Derived from the circulation by uptake of the remnant particles, or HDL 
- Taken-up from the circulation bound to albumin, derived from the lipolysis in the 
adipose tissue (predominantly fasting, with fat-rich diet or in pathological states such as 
diabetes mellitus)  
- Synthesized de novo from acetyl-CoA derived from glucose, lactose or alanine 
(predominantly in the post-prandial state). 
 
VLDL. The liver secretes the TG of endogenous origin to form part of the VLDL. 
Analytically, they are characterized by electrophoretic mobility in basic pH equivalent to 
that of α2-globulin. TG accounts for 50% of its content the hydrated density separated 
by gradient ultracentrifugation is in the range of 0.93-1.006 g/mL. The process of 
assembly of these particles is very similar to that of the chylomicrons (see section 2.1) 

















































Figure 3. The intracellular assembly of VLDL lipoproteins. Adapted from (30). The process begins in the 
endoplasmic reticulum with the synthesis of apo B100 that interacts with the MTP which will lipidate to form 
the pre-VLDL (if not, it will be degraded by the proteosomal complex). The pre-VLDL is converted to VLDL2 
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Nascent VLDL contains mainly TG, albeit somewhat less than the chylomicrons (see 
Table 1), and, as such, are smaller than the chylomicrons. They contain 
apolipoproteins E, C-I and B100 and, unlike the chylomicrons, do not have apo B48 
(see Table 2). Once in the circulation (Figure 4) they begin to mature by interacting with 
other lipoproteins such as HDL with which it can interchange cholesterol and 
apolipoproteins, involving, above all, the transport proteins such as CETP. When VLDL 
has become enriched with apo E and apo Cs, the LPL anchored to the capillaries 
hydrolyzes the TG from the apolar nucleus, the particle begins to lose part of the 
surface together with apo C and phospholipids are transferred to HDL.  
 
IDL. By the action of LPL, the VLDL is transformed to VLDL remnants or IDL which are 
smaller and denser. More cholesterol is transported and the main apoproteins are apo 
B100 and apo E. The mean life-span of the VLDL particle in circulation is 1-3 hours. 
One part (approximately 50%) of the IDL particles formed are taken-up by the liver and 
eliminated from the circulation or are transformed to LDL as a result of the lipid transfer 
proteins which, in the circulation, facilitate the interchange of their components with 
HDL. The rest of the IDL particles are transformed to LDL by the action of hepatic 
lipase. 
Hepatic lipase is a lipolytic enzyme which has phospholipids as its principal substrate. 
It participates very actively in the remodeling of HDL and LDL. It is anchored in the liver 
and hydrolyses TG that is subsequently internalized in the liver. Apart from the 
hydrolytic activity, it also acts as a ligand for the uptake of lipoproteins via the cell 
surface receptors and proteoglycans (31). 
 
LDL. These particles are, essentially, of plasma origin but can be synthesized in the 
liver, as well (32,33). They are small in size and are composed mainly of cholesterol 
esters and one molecule of apo B100. They are characterized by having β-globulin 
mobility in basic pH, and separated by ultracentrifugation in the density rages of 1.019-
1.063 g/ml. LDL are the principal method of transport of the greater part of the 
cholesterol in the circulation. The mean life-span of LDL is 2-3 days. The process of 
catabolism of LDL takes place principally in the liver (excess cholesterol being excreted 
together with bile) but other lipid components are catabolized via the intestine or are 
used in steroidogenesis (for the production of sex hormones), by macrophages and 




UNIVERSITAT ROVIRA I VIRGILI 
ROLE OF THE APOA5 GENE IN LIPID AND FAT-SOLUBLE VITAMIN METABOLISM 































Figure 4. Overall scheme of human lipoprotein metabolism. The metabolism of endogenous lipids is 
described within the box outlined in red 
 
 
LDL particles are eliminated from the circulation via the LDL receptor (LDL-R) which is 
a transmembrane glycoprotein of 839 amino acids located on the cell surface. Control 
of the levels of plasma cholesterol is via the uptake (by a process of endocytosis) and 
catabolism of the plasma lipoproteins containing apo B100 (present in LDL) and apo E 
(present in the chylomicron and VLDL remnants). The receptor, together with the 
lipoprotein particle, is internalized by endocytosis and, once completed, the receptor is 
recycled to the plasma membrane. As such, its transcriptional expression is regulated 
by the levels of intra-cellular free cholesterol. The defect in LDL-R results in familial 
hypercholesterolemia (FH); the heterozygotes of this condition express half the number 
of functional LDL-R (1 in 500 individuals) and the homozygous individuals express very 
few or no functional cell surface receptors (1 in 106 individuals). Patients with FH have 
double the levels of LDL cholesterol in infancy relative to normal values, and develop 
early coronary disease (at a mean age of 45 years, in males) (34). 
 
LDL and the development of arteriosclerosis 
Cholesterol transported by LDL has a key role in the development of coronary 
ischemia, as has been demonstrated by several epidemiological studies. Briefly, in 
conditions of excess circulating cholesterol, activation of the endothelium of the large 
and medium sized arteries occurs and the lipoproteins are able to infiltrate the arterial 
wall and to accumulate in the extra-cellular matrix. Oxidation of these LDL liberate 
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bioactive phospholipids that activate the endothelial cells to expressing adhesion 
molecules (such as vascular cell adhesion molecule; VCAM-1) which attract various 
blood cells such as monocytes which penetrate and differentiate into macrophages that 
express cell surface scavenger and toll-like receptors. The macrophages play a key 
role in the development of atherosclerosis. 
The scavenger receptors recognize LDL modified by acetylation or oxidation and, 
unlike the normal cell which has intra-cellular cholesterol feedback control of LDL-R 
synthesis it is this lack of intra-cellular feed-back that allows the macrophages to 
continue to accumulate modified cholesterol and to become foam cells which, deposit 
their lipid content in the sub-endothelial space and contribute to the development of the 
atherosclerotic plaque. 
The toll-like receptors do not undergo endocytosis. Instead they initiate a cascade of 
signals that result in the macrophage being activated to liberate, among other 
molecules, nitric oxide (a reactive species of oxygen) and to secrete proteolytic 
enzymes that degrade the matrix resulting in a destabilization of the plaques which 
increases the risk of their rupture and of thrombosis.  
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2.3. Reverse cholesterol transport  
We have seen how the endogenous cholesterol and the exogenous cholesterol of the 
diet are distributed throughout the body. The liver and the steroid hormone producing 
organs can utilize the cholesterol for the synthesis of cellular components, but the rest 
of the tissue of the organism cannot degrade cholesterol and, as such, need to 
dispense with the excess cholesterol since, as we have seen in section 2.2, this can 
lead to adversely affecting the physiological function of the cell.  
 
HDL. The reverse transport of cholesterol is mediated by HDL (depicted in Figure 5). 
HDL particles are characterized as having α1-globulin electrophoretic mobility and with 
high density (1.063-1.210 g/ml) (Table 1). These lipoproteins are very heterogeneous 
and contain different sub-fractions which differ in size, density and composition of 
apolipoproteins and lipids. Nascent HDL are discoidal in structure (pre-β-HDL) and 
derive from synthesis in the liver and the intestine or from the liberation of A-I from TRL 
following processing by LPL (35).  
Apolipoprotein A-I is synthesized principally in the liver, and to a lesser extent in the 
small intestine. It is abundant in plasma (1.0-1.5 mg/dl). It is the principal protein 
component of HDL and its concentration reflects the concentration of circulating HDL. It 
plays an important role in cellular homeostasis of cholesterol. High levels of apo A-I are 
associated with a reduced risk of cardiovascular disease, and epidemiological studies 
sugges that the levels of apo A-I can be a better marker of cardiovascular disease risk 
than the levels of total cholesterol, or of the lipid content of the lipoproteins (36-39). 
 
Reverse cholesterol transport involves the process of capture by HDL of excess 
cholesterol in peripheral cells, and the transport to the liver where the cholesterol is 
eliminated in bile. Hence, the cholesterol transported by HDL has been considered as a 
protective factor against cardiovascular disease.  
The process can be divided into three stages:  
- Efflux of cholesterol from the cells  
- Esterification of cholesterol  
- Metabolic destination of the cholesterol esters formed 
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Figure 5. Overall scheme of human lipoprotein metabolism. Reverse cholesterol transport is described 
within the box outlined in red   
 
Nascent HDL particles have a high capacity to capture cholesterol from peripheral 
tissue (such as arteries) and from macrophages, and which explains the protective role 
against the development of atherosclerosis. The mechanisms responsible for the 
transfer of the cholesterol from the cells to HDL have not been fully elucidated. Two 
hypotheses have been proposed: 
- By receptor-independent diffusion in which HDL with apo A-I, as well as HDL with 
apo A-I plus apo A-II, may participate  
- A receptor-dependent process that requires specific acceptors such as 
apolipoproteins A-I, A-II, A-IV, E and C, interacting with pre-β-HDL particles. In this 
case the lipidation of nascent HDL takes place as a result of the efflux of cholesterol 
mediated by the membrane transporter ABCA1 (ATP-binding cassette A1) (40). 
Mutations in the ABCA1 gene produce Tangier disease. 
Currently, it is accepted that both types of processes could co-exist and that the 
predominance of one of the other process depends on the type of cell involved. 
 
Free cholesterol that is captured is rapidly esterified by LCAT (lecithin: cholesterol acyl-
transferase) which is an enzyme bound to the surface of HDL and activated by apo A-I. 
The esterified cholesterol passes to the nucleus of the particle. With this process of 
esterification, the HDL particle begins to assume the spherical form, becomes much 
larger and transforms into HDL3 and subsequently into HDL2. These particles can 
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interact with the protein ABC-G1 and promote a level of intra-cellular cholesterol 
greater than that of macrophages (41). 
The destination of the cholesterol esters in HDL varies. HDL can be recognized directly 
by hepatic receptors, SR-BI, or by apo E receptors. Once internalized, the cholesterol 
can be used for the assembly of lipoproteins, as substrates for the synthesis of bile 
acids, or secreted directly into the bile. Since there is no uptake of the particle, the HDL 
can be recycled to the circulation to begin the process over again. Another possibility is 
that HDL particles are captured in entirety by the LDL related receptor (LRP) or, in an 
indirect manner, the cholesterol esters contained in the HDL are transferred to the TRL 
via the lipid transfer proteins such as PLTP and CETP.  
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3. Dyslipidemia: focus on hypertriglyceridemia 
 
3.1. Hypertriglyceridemia 
Hypertriglyceridemia is defined as the presence of elevated levels of TG in fasting 
plasma, and is associated with diabetes mellitus, abdominal obesity, insulin resistance, 
or secondary to treatment with some pharmacological agents. The most recent 
recommendations place the upper limit of plasma TG values at 1.7 mmol/L (150 mg/dL) 
since that above this level the small dense LDL particles that are highly atherogenic 
begin to increase (42). These values can be around 20 mmol/L in the more severe 
cases of hypertriglyceridemia.  
HyperTG is the consequence of disequilibrium in the process of production of 
lipoproteins rich in TG in the liver and/or intestine, and of their hydrolysis in the 
circulation.  
Several grades of hypertriglyceridemia between moderate and severe have been 
described and can fluctuate even in the same individual, depending on the metabolic 
status. As shown in Figure 6, there is an inverse relationship between the grade of 
hyperTG and its presence in the general population. Severe hyperTG with considerable 
elevations of circulating TG can occur infrequently, while moderate hyperTG is more 
frequent. As such, primary hyperTG has a much lower influence on the incidence of 






















Figure 6. Inverse relationship between different inherited forms of hypertriglyceridemia and their 
prevalence in the general population 
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The hypertriglyceridemias are classified as primary and secondary according to the 
cause. The primary hypertriglyceridemias are of genetic origin, and are more severe 
than the secondary hypertriglyceridemias which are due to external factors. 
 
3.1.1. Primary hypertriglyceridemias 
FAMILIAL COMBINED HYPERLIPIDEMIA 
This disease is a basic alteration in the metabolism of TG, and is the defect of lipid 
metabolism of considerable clinical importance because it is the most common genetic 
form of hyperlipidemia. It is present in 1-6% of individuals in the populations of 
developed countries and in 20% of the survivors of myocardial infarction. As such, it 
considered as a significant risk factor in the development of cardiovascular disease 
(43). 
The traditional diagnostic criteria are based on the isolated hypercholesterolemia and 
hypertriglyceridemia or combined. Over the past several years and after several 
reviews of the evidence, apo B has consistently remained as a parameter that is 
characteristic of this alteration, together with the overproduction of VLDL and the 
presence of small dense LDL particles (sdLDL) (44).  
There have been 2 strategies employed in the process of identifying the underlying 
genetic alterations and the genetic markers for the diagnosis of FCH: linkage studies 
and association studies which enable conclusions to be drawn regarding a complex 
disease that appears not to have a common genetic basis. This is reflected in the 
multiple lipoprotein phenotypes that exist in the families of affected patient and, as well, 
in the same individual over time. In linkage studies, FCHL has been strongly 
associated with the human chromosome 1 (45) where of note is the upstream 
transcription factor 1 (USF1) which  regulates the expression of the genes involved in 
the metabolism of glucose and of lipids. Further, this chromosome also contains the 
gene for APOA2 which has been associated with high levels of TG as a result of 
accumulation of large VLDL particles, and CRABP2 (46, 47) which we recently 
described as being associated with elevated levels of plasma cholesterol. Several 
association studies have identified gene modulators of hyperlipemia in these FCHL 
patients and of note is the region of the gene complex coding for the apoliproteins A1/ 
C3/ A4/ A5 located on human chromosome 11, and specifically the APOC3 and 
APOA5 genes which have been shown to exercise an influence on the hyperTG in 
FCHL patients (48-51). 
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FAMILIAL DYSBETALIPOPROTEINEMIA 
Present in 1/2000-5000 persons, this is a mixed hyperlipidemia with elevations of 
similar magnitude not only of cholesterol but also TG, secondary to the increase in the 
β-VLDL (which are remnants of the chylomicrons of intestinal origin) and of the VLDL of 
hepatic origin. The accumulation of remnants is a consequence of the homozygous 
defect in the APOE gene which is responsible for the uptake of the remnants by the 
LDL-R. It is only present in carriers of the APO E2/E2 genotype, or rare mutations such 
as that which produces the G127D change. E2/E2 homozygosity is a necessary but not 
sufficient cause of the disease since only 3% of these individuals develop the disease 
(52). The co-adjuvant factor is, in many cases, another genetic defect such as 
mutations in the APOA5 gene (53), or some pharmacological treatment such as with 
retinoids. The patients develop xanthomas and premature coronary disease. 
 
FAMILIAL HYPERTRIGLYCERIDEMIA  
With a prevalence of 5-10%, this disease is characterized by the presence of elevated 
VLDL triglycerides alone. The levels of cholesterol are normal, or only slightly elevated. 
Although the underlying causes have not been fully elucidated, it is found to be 
associated with obesity, insulin resistance, diabetes, hypertension and hyperuricemia. 
It represents a heterogeneous disorder with a phenotype that is highly influenced by 
environmental factors, as has been demonstrated in patients heterozygous for the 
Q139X mutation of the APOA5 gene who are predisposed to hyperTG and, probably, in 
combination with other genetic or pathologic factors such as obesity or diabetes (54).  
A genome-wide scan conducted in 26 families with familial hyperTG (55) identified 
chromosomal zones that strongly influence parameters linked to alterations in the 
metabolism of TG (as we will see later). Other recently-identified influences are 
chromosome 6 which appears to be associated with the size of LDL particles (a 
candidate gene on this chromosome could be superoxide dismutase, which is of 
considerable importance given that the small dense LDL particles have a higher 
susceptibility to oxidation than the larger LDL particles). Chromosome 15 shows some 
association with TG levels (a candidate gene could be that for HL) and a weaker 
association between regions of chromosome 18 and levels of HDL cholesterol have 
been noted (no obvious genes related to the metabolism of HDL metabolism have 
been encountered on this chromosome). 
 
FAMILIAL CHYLOMICRONEMIA 
This is a very rare condition characterized by extremely high levels of TG since birth   
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(1000-10000 mg/dL) (Figure 7). It is characterized by the 
presence of chylomicrons even after 12-14 hours 
postprandial phase. It is due to a defect in the LPL or, 
rarely, to a defect in the enzyme’s activator (APOC2) 
although one patient who did not have either of these 
genetic defects was described as having severe 
hyperchylomicronemia due to a mutation (Q145X) in the 
APOA5 gene  (56). The patients develop xanthomas and 
recurrent pancreatitis, but usually do not develop 
atherosclerosis although this has been described in one 
case (57).    
                        
       Figure 7. Lipemic serum 
 
3.1.2. Secondary hypertriglyceridemias 
Hypertriglyceridemia is a lipid alteration that is characteristic of “an atherogenic life-
style” which implies an unhealthy diet, lack of exercise and is associated with obesity, 
insulin resistance, long-term diabetes mellitus, and cardiovascular disease.  
 
OBESITY 
Obesity is the most prevalent metabolic disease in developed countries, and continues 
to increase alarmingly to epidemic proportions. It carries with it a high mortality from 
cardiovascular disease, resulting directly or indirectly from its association with multiple 
risk factors.  
Overweight is defined as a body mass index (BMI) value between 25 and 30 kg/m2 
and, in the case of obesity, the BMI is >30 kg/m2. The concept of visceral obesity, 
defined clinically as a waist circumference of >88 cm in females and >102 in males, is 
of considerable usefulness because is related to metabolic and cardiovascular 
alterations associated with the metabolic syndrome or insulin resistance. As such, if in 
combination these factors determine the levels of TG (concept termed waist hyperTG) 
this measurement provides a cheap tool for the identification of patients with an 
elevated risk of cardiovascular disease (as will be explained later). 
Adipose tissue is an organ for reserve storage and mobilization of fats and, currently, 
interest is increasing with respect to its function as an endocrine organ since it liberates 
several cytokines such as TNF-α and IL-6 known as pro-inflammatory molecules (58). 
Fats are stored in the form of TG which are derived from circulating chylomicrons or 
VLDL. The TG are hydrolyzed by LPL bound to the capillaries of the adipose tissue. 
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The resultant free fatty acids (FFA) are taken up by the cells, internalized and re-
esterified. Patients with a deficiency in LPL also accumulate TG in the adipose tissue 
(59) and, as such, alternative routes such as the acylation stimulating protein need to 
be postulated (60).  
The defect in the metabolism of the FFA contributes to the insulin resistant status of the 
individuals with visceral obesity. The lack of response to control by insulin leads to 
visceral tissue adipocyte hypertrophy undergoing a high grade of lipolysis, resulting in a 
high flow of FFA to the liver. This alters the hepatic metabolism resulting in an increase 
in the production of glucose and the secretion of TG. Insulin resistance in the liver is 
associated with a lower control of apo B degradation, and an increased production of 
TRL.  
The concept of waist hyperTG (61) suggests the simultaneous use of waist 
circumference and the levels of fasting TG to identify individuals characterized by their 
atherogenic triad (presence of small dense LDL particles, elevated levels of apo B, and 
hyperinsulinemia), which results in an elevated cardiovascular disease risk. 
 
DIABETES MELLITUS TYPE 2 
This is the most common type of diabetes in developed countries. It is strongly linked 
with obesity (80% of individuals with DM2 are obese) (62). Its incidence is 
progressively increasing, and it is forecast by the WHO that it will become an epidemic. 
It only develops in middle-age, although the incidence in young people is increasing. 
Adults with DM2 have a 2- to 3-fold higher risk of dying from cardiovascular disease 
than those adults without DM2 (63). This implies that, in the calculation of 
cardiovascular disease risk, DM2 is equivalent to having suffered an episode of 
ischemic cardiopathy. 
 
DM2 is characterized by insulin resistance and decrease in insulin secretion. The 
resistance to insulin takes place when the organism cannot use the insulin efficiently. 
For example, the liver and muscle have a decrease in the biological effects of response 
to insulin (which essentially maintains glucose levels in the blood, stimulates 
lipogenesis and decreases lipolysis). In an attempt to balance the circulating levels of 
glucose, the pancreas secretes increasing amounts of insulin and, gradually, the 
pancreatic cells become deficient, and begin to decrease in number. Hence, the 
individuals who are insulin resistant have fasting hyperglycemia and hyperinsulinemia 
and, at the same time, have alterations in liver function and concentrations of fatty 
acids in the circulation.  
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Diabetic patients, or those with diabetic dyslipemia, show disequilibrium in the lipid 
parameters in the blood, essentially of total cholesterol. This is accompanied by an 
increase in LDLc in females and hypertriglyceridemia together with a decrease in the 
levels of HDL cholesterol as well as the presence of small dense LDL particles. The 
hypertriglyceridemia in DM2 is due to an increase in the plasma concentration of VLDL, 
with or without chylomicronemia; a lower activity of TG hydrolysis by LPL; an increase 
in lipid interchange via CETP; and a lower flow of FFA to the liver.  




Chronic renal insufficiency presents with considerable alterations of lipoprotein 
metabolism and, as such, is associated with a significant increase in mortality from 
cardiovascular disease in this group of patients.  
The dyslipidemia associated with patients with chronic renal disease is similar to the 
dyslipidemia of patients with insulin resistance and, as such, is characterized by an 
increase in plasma TG, an increase in VLDL particles and small dense LDL, and low 
levels of HDL cholesterol (64). DM is one of the most frequent causes of renal disease. 
Further, dyslipemia contributes to the progression of renal disease. Epidemiologic 
studies and studies conducted in experimental animals have demonstrated that the 
hypercholesterolemia accelerates the progression of renal disease, and that a fat-rich 
diet generates an accumulation of foam cells which produce glomerular sclerosis 
affecting the small blood vessels of the kidneys (65, 66).  
The mechanisms responsible for the hypertriglyceridemia in renal disease are, to-date, 
not clear although a contribution to the disease is the increase in the level of apo C-III 
in these patients, or the decrease in the levels of apo A-V (67). Another explanation 
would be the resistance to insulin that these individuals can present. 
 
METABOLIC SYNDROME 
Since about 30 years ago, there has been evidence of the combination of factors such 
as dysplidemia, hypertension, obesity, glucose intolerance which have been  
associated with an increased risk of cardiovascular disease. This led to the term 
metabolic syndrome (MetS) which describes individuals with an elevated risk of 
cardiovascular disease. The principal lipid alterations in these patients are 
hypertriglyceridemia and low levels of HDL cholesterol.  
There are several criteria that define MetS; the principal ones are summarized in 
Tables 3, 4 and 5. 
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NCEP/ ATPIII 
Plus 3 or more: 
Waist circumference (cm) ♂>102;  ♀>88 
TG (mg/dL) ≥150 
HDLc (mg/dL) ♂<40 ; ♀<50 
Blood pressure (mmHg) ≥130/85 




Central obesity ♂≥94; ♀≥80cm in Europeans, plus any two: 
TG (mg/dL) >150 
HDLc (mg/dL) ♂<40; ♀<50 
Blood pressure (mmHg) ≥130/85 




DM or fasting glucose or defect in glucose tolerance or IR, plus any 2: 
Hip-to-waist ratio ♂>0.90; ♀>0.85 
TG (mg/dL) ≥150 
Or  
HDLc (mg/dL) ♂<35; ♀<39 
Blood pressure (mmHg) ≥140/90 
Urinary albumin excretion (μg/min) >20 
Or  
Albumin-to-creatinine ratio (mg/g) ≥30 
 
Tables 3, 4 and 5. Summary of the criteria that, according to the three principal scientific bodies, define the 
metabolic syndrome. 
NCEP/ ATPIII = National Cholesterol Education Program/ Adult Treatment Panel III 
IDF = International Diabetes Federation 
WHO = World Health Organization 
 
As with DM2, hypertriglyceridemia in MetS is due to an increase in plasma VLDL, 
deficit in LPL activity, increase in CETP activity, and higher flow of fatty acids to the 
liver. 
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Other causes of secondary hypertriglyceridemia have been identified, and which can 
be related to lifestyle, excessive caloric and carbohydrate intake, sedentary behavior, 
and alcohol abuse. Among other consequences, the excessive intake of alcohol inhibits 
oxidation of fatty acids in the liver thus increasing the amount available for the 
synthesis and secretion of TG-rich particles (VLDL). 
Also, there are certain diseases that result in an increase in the levels of TG, such as 
Cushing’s syndrome (68), VIH (69), hypothyroidism (70), or physiological conditions 
such as pregnancy (71). 
Some medications can produce an increase in the levels of circulating TG, such as 
atypical anti-psychotic drugs (72), β-blockers (73), corticosteroids (74), estrogens (75), 
protease inhibitors in the treatment of HIV (76), retinoids (77), tamoxifen (78), and 
thiazide diuretics. In individuals with normal levels of TG, these treatments can have an 
irrelevant effect but, in predisposed individuals, these medications can seriously 
aggravate their hypertriglyceridemia. 
 
3.2. Metabolic consequences of hypertriglyceridemia: the 
atherogenic dyslipidemia 
The increase in the levels of circulating TG are accompanied, in humans, with other 
alterations in lipid metabolism that can explain its association with an increased risk of 
cardiovascular disease, despite the levels of LDL cholesterol being normal. These 
combinations of alterations are defined as atherogenic dyslipemia. 
Atherogenic dyslipemia is characterized by the increase in the hepatic synthesis of 
large-sized VLDL (VLDL1) which results, as well, in an elevation in the concentration of 
plasma apo B (>130 mg/dL). By the action of CETP, VLDL1 generate LDL particles that 
are small and dense (sdLDL) and, as well, decrease the cholesterol transported by 
HDL. The action of hepatic lipase on VLDL, IDL and LDL generate lipoproteins that are 
difficult to eliminate, and are highly atherogenic remnants. In summary, atherogenic 
dyslipemia generates particles that under normal conditions are not abundant in the 
circulation, such as remnants of TRL (RLP) or sdLDL particles. HDL clearance is 
diminished, and is linked to metabolic alterations accompanying post-prandial 
hyperlipemia. 
 
3.2.1. VLDL1  
Recent evidence shows that dyslipemia is principally due to the increase in intra-
abdominal fat. Visceral fat increase also increases non-esterified fatty acids flow 
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towards the liver (79). The liberation of fatty acids from the adipose tissue is mediated 
by the hormone-sensitive lipases (HSL) and adipose TG lipase (ATGL) which catalyze 
the hydrolysis of TG and diacylglycerides. 
HSL is highly expressed in adipose tissue and in steroidogenic tissue where it controls 
the ratio of hydrolysis and storage of TG. In adipose tissue it is activated by hormones 
such as catecholamines and glucagon and is inhibited by insulin (80, 81).  
ATGL which has been identified recently (82) and has lipolytic activity in adipose tissue 
(83). Its precise role, mechanism of action, activator and repressors are not well 
defined, to-date. 
Under normal conditions, the fatty acids that reach the liver are, in great part, re-
esterified and stored in the form of lipid droplets. Their subsequent hydrolysis is the 
source for the hepatic synthesis of lipoproteins and β-oxidation. The increased 
availability of visceral fat is the principal provider for the synthesis of the TG necessary 
for the formation of VLDL and the increased induction of large VLDL assembly. The 
concentration of large VLDL particles (VLDL1) which are increased in subjects with 
diabetes (84) is the principal determinant of the levels of circulating TG, not only in 
























Figure. 8. Comparison between endogenous lipid metabolism in the normal physiologic situation, and 
under atherogenic dyslipidemia  
 
 
3.2.2. Apo B levels 
The increase in the transport of fatty acids to the liver, apart from stimulating the 
synthesis of TG and VLDL particles, also stimulates the synthesis of apo B. 
36   Dyslipidemia: focus on hypertriglyceridemia 
UNIVERSITAT ROVIRA I VIRGILI 
ROLE OF THE APOA5 GENE IN LIPID AND FAT-SOLUBLE VITAMIN METABOLISM 
Montserrat Guardiola Guionnet 
ISBN:978-84-691-9478-2/DL:T-19-2009 
 
The level of apo B reflects the total number of atherogenic lipoproteins that contain apo 
B, although 90% of the apo B of plasma is contained in LDL (86). Recent epidemiologic 
studies show that apo B is a better predictor of cardiovascular disease events than 
cholesterol itself whether total, LDL cholesterol or non-HDL cholesterol (which is 
calculated as the difference between the total cholesterol and HDL cholesterol and can 
be considered to reflect the content of the TRL) (87). The apo B carries greater 
information on the interaction of the cholesterol with the arterial wall than the 
cholesterol itself. Further, the ratio of apo B/apo A-I has been demonstrated to be an 
important marker of cardiovascular disease risk (88). The system based on the 
apolipoproteins has greater value in predicting risk and, as has been shown in many 
studies, the subject does not need to provide fasting blood for its measurement. 
 
3.2.3. Small and dense LDL (sdLDL) 
In the large VLDL particles (VLDL1) there is a greater proportion of apo C-III than apo 
C-II and, so, the LPL is not normally active. As a consequence, there is less hydrolysis 
of TG. The particles derived are poorly recognized by the LDL-R and the LRP which 
are responsible for the elimination of these particles from the circulation. This increases 
the time these lipoproteins continue in circulation and, due to the action of CETP 
(Figure 9), become enriched with cholesterol esters. The HL hydrolyzes the TG that 
they contain and the particles become transformed to small dense LDL (sdLDL). These 
sdLDL particles are highly susceptible to oxidation and are considered as highly 
atherogenic.  
 
To maintain the equilibrium of oxidative status in this situation becomes especially 
important, and the anti-oxidants such as vitamin E play a key role. The sdLDL particles 
modified by oxidation are taken-up by the scavenger receptors situated on activated 
monocytes which become transformed into macrophages and, eventually, become 
foam cells. An elevated level of these particles is present in patients with metabolic 
syndrome.  
Apart from the CETP and HL genes, association studies have demonstrated that 
another known genetic determinant of these particles is the APOA5 gene (89-92). 
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Figure 9. Schematic view of the CETP action on TRL metabolism 
 
3.2.4. Low HDL levels 
As we have seen in the section 2.3, HDL are formed from newly synthesized nascent 
discoidal particle that acquire cholesterol from the cell membranes via the ABC-A1 
transporter. This cholesterol will become esterified via the action of LCAT, and the 
particle is transformed to small spherical HDL3 and, finally, to HDL2 which is also 
spherical but larger. HDL2 can revert to HDL3 with the participation of CETP (the 
enzyme that interchanges cholesterol esters and TG between HDL and the apo B 
containing lipoproteins) together with the SR-B1 (hepatocyte receptors that enable the 
selective uptake of the cholesterol esters) and the HL (enzyme that hydrolyses TG and 
phospholipids) (93). 
Epidemiological evidence indicates that there is an inverse relationship between the 
levels of TG in plasma and the cholesterol transported by HDL. This relationship is 
especially significant in patients with MetS, DM2 and in dyslipemic patients with 
atherogenic dyslipidemia (94-98). As we have commented earlier, during the 
atherogenic dyslipidemia, due to a greater contribution of fatty acids being delivered 
from the visceral adipose tissue to the liver, VLDL particles rich in TG are formed and, 
by the action of interchange protein CETP, the plasma levels of HDLc decrease. This 
results in the HDL being enriched with TG and becoming lipoproteins with rapid 
clearance from the circulation (99) because: 
- The TG that they contain can be hydrolyzed by HL forming small dense HDL 
particles  
- Or during hydrolysis the apo A-I that they contain is lost makes these particles 
become unstable 
- Or because under these conditions a reduction in the activity of the LPL is produce 
and, hence, there is a deficit of surface components derived from the hydrolysis of 
the TRL which serve for the formation of new HDL, and hence, less new particles 
are formed.  
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3.2.5. Remnant lipoproteins (RLP) 
The chylomicrons of intestinal origin contain apo B48. The VLDL of hepatic origin 
contain apo B100. Both lipoproteins are rich in TG and, due to their large size, are not 
associated with a significant increase in cardiovascular disease risk. But, as we had 
seen earlier, hypertriglyceridemia is the principal determinant of structure and size of 
the remnant particles; a significant and independent risk-factor for cardiovascular 
disease (100). 
Remnant particles are formed in circulation when the chylomicrons and VLDL are 
converted to smaller and denser particles by the action, principally, of LPL and, to a 
lesser degree, by HL. These particles are poor in TG, phospholipids and apo Cs and 
rich in cholesterol esters and apo E. Remnant production is greatly influenced by the 
levels of circulating lipids, particularly TG, and of the activity of LPL, and which makes it 
a good candidate for the modulating action of apo A-V, as has been demonstrated in 
the Framingham study (101).  Apo A-V, as we will see later, actively participates in the 
regulation of the TG levels, in part by stimulating the hydrolytic activity of LPL. 
The characteristics of the remnants are what make these particles highly atherogenic. 
As yet it is not clear which precise physical and/or biochemical characteristics are 
responsible for the atherogenicity, but the following have been proposed: 
- Size and number. The accumulation of lipids in the arterial wall, the critical 
point in the initial steps in the development of arteriosclerosis, is directly 
related with the quantity of circulating lipoproteins and indirectly related to 
the size of the particles (102). 
- Apo E. The remnants are eliminated from the circulation via the receptors 
specific for apo E. As such, the total quantity of apo E in each particle, the 
individual isoform of the molecules of apo E, and the presence of other 
apolipoproteins in the particles can be important determinants (103). 
- Oxidizability. The lipolysis of the TG-rich particles increases their 
susceptibility to oxidation, and the uptake of oxidized lipoproteins by 
macrophages is increased (104). 
 
Remnants can be identified, separated and quantified in plasma based on their density, 
charge, size, specific lipid components, composition of apolipoproteins or 
immunospecificity of the apolipoproteins (105).  
It can be difficult to differentiate these particles from their precursors because of the 
similar apolipoprotein composition and size. These particles can be in the postprandial 
circulation for long periods of time or, as well, can be converted to LDL (106).  
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3.2.6. Postprandial metabolism  
Postprandial status is closely linked to the metabolism of TG since the principal 
protagonists are the TRL (chylomicrons) derived from the ingestion of fat. As such, 
atherogenic dyslipimia is even more relevant during the postprandial state because of 
the greater number of these circulating particles contributing to increasing the levels of 
plasma TG.  
Increasing evidence shows that an altered postprandial metabolism plays an important  
role in the development of atherosclerosis. Since people in developed countries are in 
the postprandial state for the greater part of the day, arteriosclerosis has come to be 
considered a postprandial phenomenon (107). The grade and duration of the 
postprandial triglyceridemia can be directly related with the phenomena characteristic 
of atherogenic dyslipidemia, such as the appearance of sdLDL, or the disappearance 
of HDL (108). 
The evidence for mechanisms by which postprandial hypertriglyceridemia can result in 
atherosclerosis has been reviewed by López-Miranda et al (109). The main 
conclusions are: 
- Increase in the concentration and residence time in circulation of the remnants 
of chylomicrons and VLDL that, due to their smaller size, can penetrate the 
arterial wall where they become toxic to the cells. 
- Postprandial changes produced in the endothelium induce endothelial 
dysfunction (one of the initial key events in the development of arteriosclerosis). 
Increase in remnant particles alter the vasodilatation of the endothelium and the 
secretory role of the endothelium and can, for example, decrease the secretion 
of nitrous oxide which is a compound that regulates vascular tone and a 
decrease of which induces vascular relaxation. 
- Postprandial TRL induce the expression of pro-inflammatory cytokines and 
soluble adhesion molecules (such as inter-cellular adhesion molecule-1 or the 
vascular cell adhesion molecule-1). 
- Because of the longer residence time of the TRL, the chylomicrons and VLDL 
compete for the binding to LPL and this can promote the formation of the 
sdLDL. 
 
The smoking habit, diet, intake of excessive alcohol, and the serum levels of creatinine 
have been independently associated with the quantity of postprandial lipoproteins and, 
as with intra-abdominal obesity, have also been associated with an increase in 
postprandial lipemia. 
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3.2.7. Hypotriglyceridemic treatment 
The optimal levels of circulating TG are 150mg/dL. The current recommendations for 
the treatment of hyperTG are summarized by the NCEP-ATP III (11). 
The origin of hypertriglyceridemia can be due to an unhealthy lifestyle which results in 
excess visceral adipose tissue the resolution of which, usually, is a low-fat hypocaloric 
diet and physical exercise, since these measures improve insulin sensitivity. This is 
basic in the pathogenesis of hypertriglyceridemia because, as we have seen, insulin 
resistance increases the flow from the periphery of free fatty acids (FFA), and 
lipogenesis stimulated by insulin which leads to an increase in the hepatic secretion of 
TRL and which results in difficulties in clearance of the TG from the circulation. 
However, this treatment is difficult to achieve in practice. 
In the cases of severe hypertriglyceridemia with the attendant overall elevated risk of 
cardiovascular disease, if there is an insufficient response to lifestyle changes, various 
hypolipemic agents can be used. At the clinic level, the type of treatment and the 
objectives differ according to the TG levels. When the levels of circulating TG are <500 
mg/dL, the principal objective is to reduce the levels of LDL cholesterol and, as a 
secondary objective to reduce the levels of TG by lifestyle changes and/or 
pharmacological treatment. When the TG levels are >500 mg/dL, the principal objective 
of treatment with hypolipemic drugs is to prevent pancreatitis. However, as we shall 
see later, the criteria continue to be revised. 
 
FIBRATES 
The fibrates have a considerable effect on circulating lipids and, as the principal effect 
on the levels of TG and of HDLc, are especially indicated for the treatment of hyperTG 
associated with atherogenic dyslipemia.  
The fibrates are agonists of the PPARα transcription factors that are highly expressed 
in tissues, and with an elevated catabolism of fatty acids.  
As we have seen in section 4, the family of PPAR nuclear receptors is composed of 3 
sub-types of receptors termed -α, -β/ -δ and -γ which are coded-for by different genes. 
Their ligands are, principally, the fatty acids and their derivatives and, in the case of 
PPARα, bind to exogenous ligands such as fibrates. Once activated, 
heterodimerization takes place with another nuclear receptor termed RXR (retinoid X 
receptor). Altered transcription of the genes occurs. The specific element in the DNA 
sequence is a repeated hexameric sequence separated by 1 or 2 nucleotides 
(PuGGTCA). 
The fibrates promote the activation of the PPARα in the liver and the 
hypotriglyceridemic effect results from modifying the rate of expression of certain target 
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genes which are very important in the regulation of the levels of circulating TG (revised 
by Fruchart et al (110)). The principal points are: 
- Reduction in the secretion of VLDL by activation of genes that code for 
enzymes limiting the process of fatty acid oxidation, such as fatty acid 
transporter protein which facilitates the transport of the fatty acid across the cell 
membrane, and acyl-CoA synthetase which facilitates esterification and 
precludes their efflux from the cell. 
- Increase in the lipolysis of plasma TG of the TRL. The fibrates act principally on 
the hepatic production of LPL, although they increase the lipolytic activity, as 
well. Further, they suppress the expression of the LPL inhibitor (APOC3) and, 
as we shall see in the following section, they regulate the expression of APOA5 
that stimulates the activity of LPL in vivo and in vitro. 
- Reduction in the quantity of sdLDL, mediated by the control of key genes in the 
formation of these particles such as LPL and CETP. 
- Increase in the HDL cholesterol. Many of the key proteins in the reverse 
cholesterol transport are controlled by the PPARs. The activation of PPARα by 
the fibrates stimulates the transcription of genes such as, for example, the 
APOA1 (a key protein in the formation of the HDL particles) and that of APOA2 
which is, as well, an element of HDL. 
- In some cases of treatment with fibrates, there can be an increase in the levels 
of LDLc. In this case the treatment needs to be changed. 
 
NIACIN (NICOTINIC ACID) 
Niacin, or nicotinic acid, is a water soluble vitamin which, for about 50 years, has been 
used as a pharmacological agent for the treatment of hyperlipidemia. The effects on 
lipids take place, principally, following the inhibition of lipolysis in the adipocytes, 
inhibiting the production of cAMP (111), and reducing the levels of free fatty acids 
(FFA).  The result is a decrease in the hepatic production and secretion of VLDL. Also, 
there is an inhibition of the uptake of HDL-apo A-I by the hepatocytes and, since there 
are more HDL apo A-I. there is an increase in the reverse transport of cholesterol, thus 
enabling a greater elimination of cholesterol from the vascular wall (112). Results from 
clinical studies suggest that the increase in the levels of HDLc promoted by niacin can 
be a good strategy to reduce the clinical events and to regress arteriosclerosis lesions 
(revised by Guyton JR.(113)). 
Nicotinic acid treatment improves the lipid profile by decreasing the levels of TG up to 
about 50%, LDLc up to 20%, and increasing the levels of HDLc up to 25%; albeit with 
several secondary effects such as frequent skin rash and flushing and pruritis together 
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with elevation of liver enzymes and the increase in the levels of uric acid; these latter 
effects are less frequent. 
 
Drug Total Cholesterol LDL-C HDL-C TG 
Fibrate ↓ 15% ↓ 0-15% ↑ 6-20% ↓ 25-50% 
Niacin ↓ 25% ↓ 10-15% ↑ 15-35% ↓ 20-50% 
Statin ↓ 15-60% ↓ 20-60% ↑ 3-15% ↓ 10-40% 
Thiazolidinediones ↑ or neutral ↑ or neutral ↑ 10% ↓ 20-30% 
Fish oil (ω3 FA) ↑ or neutral ↑ or neutral ↑ or neutral ↓ 20-50% 
 
Table 6. Summary of the effects of hypotriglyceridemic drugs on lipid parameters 
 
STATINS 
The statins are the most powerful drugs for lowering the levels of LDLc. The 
mechanism is via the inhibition of 3-hydroxy-3-methylglutary-coenzyme A which is the 
rate limiting enzyme in the biosynthesis of cholesterol. The statins are less effective 
than niacin or fibrates with respect to the reduction in the levels of TG, or in increasing 
the levels of HDLc. In high doses, however, the recently-designed statins can reduce 
the TG levels but are not considered the reference treatment for the high levels of 
circulating TG. The mechanisms by which the statins can affect the levels of TG are not 
known, but it is believed that this could be an effect derived from the decrease in the 
levels of cholesterol in the liver, which would result in reduction of VLDL.  
 
As commented-upon earlier, the principal target of treatment, with the exception of 
subjects with extremely high levels of TG, is LDLc and, secondarily, hyperTG. The 
characteristics hyperTG of the atherogenic dyslipidemia are accompanied by 
moderately elevated levels of LDLc and, as clinical evidence demonstrates, is more of 
a risk for cardiovascular disease that cholesterol. There is no useful clinical evidence 
indicating a relationship between treatment with fibrates and reduction in 
cardiovascular disease risk. Consequently, the FIELD study chose to treat moderate 
hypercholesterolemia resulting from the hyperTG. 
The FIELD study (Fenofibrate Intervention and Event Lowering in Diabetes) (114) is an 
intervention study with fenofibrate carried-out in about 10,000 patients with DM2 
followed-up for 5 years, and was designed to obtain consistent data on the capacity of 
fibrates to reduce the cardiovascular disease risk in patients with DM2. The principal 
variable of interest was the cardiovascular disease mortality. After 2 years of follow-up 
there were no differences detected between the study groups. The investigators 
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proceeded to modify the variables-of-interest to that of fatal and non-fatal coronary 
events. In general, the results obtained were confusing, even in relation to the efficacy 
of the control of lipids.  
Fortunately, over the past few years, interest in clinical studies in populations with high 
levels of LDLc has been replaced by populations with moderate levels of LDLc. This 
change results from statins having been administered without taking into account other 
parameters of lipid alterations and, as well, because the percentage of subjects with 
atherogenic dyslipidemia has greatly increased in all countries. Further, the majority of 
clinical studies conducted in subjects with moderately elevated levels of LDLc do not 




The first option in the treatment of DM2 is the administration of thiazolidinediones 
(116). Their effects on circulating TG levels are greater in subjects with non-diabetic 
MetS (117). The thiazolidinediones are ligands that are selective for PPARγ the nuclear 
receptors, and the isoform of PPARs abundantly expressed in the adipose tissue which 
are, as well, encountered in the pancreatic cells, in the vascular endothelium, and in 
macrophages. Once activated, the thiazolidinediones: 
- Promote the decrease in inflammation, decreasing C-reactive protein 
- Promoting the up-take of glucose, increasing the number of type 4 glucose 
transporter receptors 
- Promote adipocyte differentiation; the uptake of fatty acids from the circulation 
and their storage in the adipose tissue; the decrease in intra-vascular activity of 
LPL in the adipose tissue; the decrease the levels of leptin (which is the 
hormone that is produced in adipose tissue and which regulates intake and 
energy expenditure) causing an increase in appetite and decreasing the 
metabolism; increasing the levels of adiponectin (which is the adipose tissue 
hormone that regulates the metabolism of the fatty acids and in inversely 
correlated with body fat). 
Clinical studies show that treatment with thiazolidinediones decreases fasting and 
postprandial concentrations of glucose, as well as the levels of circulating FFA and 
insulin concentrations. Also, in the liver, there is a decrease in the concentrations of 
FFA and TG which are sources for the formation of VLDL. However, there are no 
published data on the molecular mechanisms explaining the effect of thiazolidinediones 
on lipid parameters in humans. 
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Dyslipidemia: focus on hypertriglyceridemia   45 
OMEGA 3 FATTY ACIDS 
The first evidence that demonstrated the relationship between ω-3 fatty acids and the 
levels of circulating TG was established by a study which proposed to evaluate why  
Eskimos had a lower rate of morbido-mortality from cardiovascular disease despite 
having a diet rich in fat. The results showed an inverse relationship between these fatty 
acids (present in large quantities in fish) and the levels of TG (118). 
This type of polyunsaturated fatty acid is recognized by many nuclear receptors that act 
as transcription factors regulating the expression of multiple genes implicated in the 
control of lipid metabolism, such as SREBP-1c, PPARs, LXR, FXR and HNF-4α, and 
which can explain, via different mechanisms, its hypotriglyceridemic effects. The 
hypotriglyceridemic effects are due, principally, to a decrease in the hepatic secretion 
of TG. Hence, with less TG-rich particles in circulation, the chylomicrons compete for 
binding to the LPL and, hence, the ω-3 fatty acids promote the catabolism of 
chylomicrons. Also, they stimulate the activity of LPL (119) and this results in an overall 
acceleration of TRL elimination from plasma.  
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4. Genetics of hypertriglyceridemia: focus on the 
APOA1/ C3/ A4/ A5 gene cluster 
 
We have already seen that the apolipoproteins constitute the components of the 
lipoprotein particles, and are responsible for: 
- Stabilizing the structure of the lipoprotein  
- Guiding the lipoproteins through the circulation, enabling their recognition by 
proteins, receptors and enzymes necessary for their metabolism and subsequent 
elimination from the circulation 
 
In 1985, the genes for the apolipoproteins A1, C3 and A4, were identified as a complex 
of 17 kb located on the long arm of human chromosome 11 (120). These genes 
regulate lipid metabolism and, as such, have been studied in depth in relation to 
cardiovascular disease, in humans as well as in animal models. Association studies 
have demonstrated the importance of this region in the control of TG metabolism, more 
specifically, in its transport and hydrolysis (121). 
 
4.1. Components of APO A1/ C3/ A4 cluster  
Apolipoprotein A-I is synthesized mainly in the liver and, to a lesser extent, in the small 
intestine. It is the principal protein component of HDL. In mice transgenic for the human 
gene, apo A-I has been described as having a protective effect on the development of 
atherosclerotic lesions while in the deficient mice there is an increase in the 
progression of these lesions. There are different genetic polymorphisms of this 
apolipoprotein (Milano, Marburg, Munster and Giesen) in which the change of an amino 
acid in the sequence is associated with a decrease in the levels of HDL cholesterol 
(122). For example, the apo A-I Milano has been described in a town in Northern Italy 
and the change of an Arg by a Cys in position 173 produces an anomalous protein that 
is associated with elevated levels of TG, low levels of HDL and normal levels of 
circulating cholesterol. Despite this poor lipid profile, the individuals who are carriers of 
this gene do not have evidence of any increased presence of arteriosclerotic lesions. 
Subsequently, when recombinant apo A-I Milano was administered in patients with 
chronic coronary syndrome, a significant regression in coronary arteriosclerosis was 
produced (123), suggesting that it can have a potential therapeutic use (124).  
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Apolipoprotein C-III is synthesized mainly in the liver, and to a lesser extent in the small 
intestine. In circulation it is bound to the triglyceride-rich lipoproteins (chylomicrons and 
VLDL) and HDL, and its best known function is to inhibit the hydrolytic activity of LPL. 
The plasma concentrations of the protein correlate strongly with the levels of TG. 
Transgenic mice that over-express the human gene present with hypertriglyceridemia, 
while those that are deficient for the gene present with a decrease in the levels of TG 
relative to wild-type mice due, essentially, to a more rapid post-prandial clearance of 
TG (24). 
 
Apolipoprotein A-IV is synthesized mainly in the small intestine. It is located in 
chylomicrons and HDL although, in fasting state, it is found principally in HDL. Its 
function it has not been well elucidated, to-date, but there are indications that it could 
play a role in the intestinal absorption of lipids since the intestinal synthesis and 
secretion of the protein increases during this process (125). Data from animal models 
suggest that it acts as a cofactor for lecithin: cholesterol acyl transferase (LCAT) in the 
reverse transport of cholesterol. In mice transgenic for the APOA4 gene and fed an 
atherogenic diet, the plasma levels of TG, total cholesterol, HDLc and free fatty acids 
are increased while non-esterified cholesterol is decreased. Also, these mice have 
considerably lower aortic lesions than control animals, and their HDL promote a higher 
efflux of cholesterol from human monocytes loaded with cholesterol. This suggests that 
the levels of apo A-IV can influence the metabolism of HDL, and its effects on 
atherogenesis (126, 127). 
 
As such, taking account the functions of human apolipoprotein cluster, it is logical to 
think that the defects in the sequences of these genes can affect the synthesis and/or 
function of the proteins, resulting in alterations in the lipid metabolism that can promote 
the development of cardiovascular disease. 
As such, since their discovery, there have been described allelic variants in these 
genes that can be used as genetic markers of cardiovascular disease risk or of 
intermediate markers for better and more rapid identification of risk of the disease, as 
has been described in several long-term studies over the past two decades (reviewed 
at 121). Several single nucleotide polymorphisms (SNP) described in the cluster are 
associated with the levels of TG, the published literature focusing on the influence of 
markers of APOC3. Of note among the polymorphisms of APOC3 is the G3238C 
change detectable using the restriction enzyme SStI in the 3' region of the gene, and 
the C-482T in the site of insulin recognition in the promoter region that is related to a 
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lack of regulation of insulin can lead to over-expression of the gene and, as such, to the 







5' flanking XmnI (C−2500T) 
Kessling AM  (128) 
Antonarakis SE  (129) 
Paulweber B (130) 
APOA1 gene 
Intron 2 HaeIII (C317T) Groenendijk M (131) 
PstI 
Ordovas JM (132) 








Groenendijk M (131) 
3' UTR SstI (G3238C) Dammerman M (133) 
Exon 3 C1100T 
Xu CF (134) 





Dammerman M (133) 
Surguchov AP (137) 
Shoulders CC (138) 
Groenendijk M (139) 
Li WW (140) 
Hegele RA (141) 
T−2854G 
Waterworth DM (142) 





Paul-Hayase H (144) 
Kessling AM (145) 
Xu CF (146) 
Gln380-His Tenkanen H (147) 
APOA4 gene  
Thr347-Ser Boerwinkle E (148) 
 
Table 7. Most frequent genetic variants of the human APOA1/C3/A4 cluster associated with alterations in 
the levels of circulating TG 
 
 
Table 7 summarizes the association studies of genetic variants in the A1-C3-A4-A5 
cluster region that have shown relationships with levels of circulating TG. The 
extensive evidence of variability in the region related to hypertriglyceridemia contrasts 
with the lack of functional variants that can explain these associations. In this context, 
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the implication has been to identify a gene adjacent to the cluster that codes for a new 
apolipoprotein, the apo A-V. 
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CHROMOSOME: 11q23  
GENE: APOA5 
PROTEIN: apo A-V 
SIZE: 366 aa, 41213 Da 
FAMILY: apo A-I/ A-IV/ E 
 
General characteristics of the gene in humans  
Obtained from GeneCards, Weizmann Institute of Science (www.genecards.org). 
 
4.2.1. APOA5 gene identification  
In 2001, Pennacchio et al (149) searched for potentially functional sequences around 
the APOA1-C3-A4 cluster that were evolutionally conserved. In comparing human and 
mouse sequences they identified a new gene about 30 kb from the cluster. 
They demonstrated that the genomic sequence in the mouse consisted of 3 exons and 
coded for 368 amino acids, the sequence of which had considerable homology to that 
of mouse apo A-IV (24% identity, 49% similarity). The equivalent human sequence 
coded for 366 amino acids and had high degree of homology to the mouse sequence 
(27% identity 48% similarity) and, so, was termed apo A-V. They predicted a protein 
structure with various amphipathic helical domains and an n-terminal signal peptide, 
characteristics of the proteins that bind to lipids. 
The analysis of the gene expression profile in different mouse (heart, brain, spleen, 
lung, liver, skeletal muscle, kidney and testicles) and human tissues (heart, brain, 
placenta, lung, liver, skeletal muscle, kidney and pancreas) showed that it was 
expressed mainly in the liver in both species.  
To examine its function, transgenic mice and mice deficient in the human gene were 
generated. They analyzed the levels of circulating cholesterol and triglycerides in both 
animal models and observed that the transgenic mice had a third of the level of TG, 
and the KO mice, or the mice deficient for the gene, had four-fold more TG that the 
normal control mice. 
The distribution of the plasma lipoproteins in the mouse models showed that the apo A-
V of the mouse is distributed in VLDL and HDL and that the VLDL particles were 
elevated in the KO mice and decreased in the transgenic mice, relative to the normal 
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controls. The size of the particles were very similar in all the animals, which implies that 
there were greater numbers of VLDL particles in the KO mice and lower numbers in the 
transgenic mice. 
To extend this interesting work, they identified 4 genetic variants in humans which they 
assigned as SNP 1-4 and which they used in association studies (Table 8). In 
approximately 500 Caucasian normolipidemic subjects they observed a significant 
association between the minor alleles of the SNPs 1-3 and higher levels of plasma TG 
(increased by 20-30%) and the TG of VLDL. The 3 SNPs were in linkage 
disequilibrium, but not so with the SNP4 nor the marker of APOC3 SstI, the most 
consistent association to TG in this region. Hence, neither SNP4 nor SstI were 
responsible for the effect on TG of the APOA5 haplotype in this population. The results 
obtained with the SNP3 were replicated in a second population stratified by levels of 
TG. They observed a higher frequency of the heterozygous genotype in the group of 
subjects with higher levels of TG. As such, they proposed using the polymorphisms of 
APOA5 as prognostic indicators of susceptibility to hypertriglyceridemia, and the 
modulation of the apo A-V as a possible strategy to reduce the risk of cardiovascular 
disease associated with TG. 
 
 Polymorphic site Minor allele frequency (%) SNP ID 
SNP1 c.1259T>C 9.1 rs2266788 
SNP2 IVS3+476G>A 8.4 rs2072560 
SNP3 -1131T>C 9.2 rs662799 
SNP4 -12238T>C 36.3 --- 
 
Table 8. Summary of the nucleotides, minor allele and identifier rs of the 4 SNPs studied. Adapted from 
Pennacchio et al (149) 
 
Almost simultaneously to the publication by Pennacchio et al, there was another 
publication describing the discovery of the apo A-V (150). In this case the objective was 
to explain the molecular mechanisms underlying liver regeneration in hepatectomized 
rats. For this purpose the genes that were over-expressed 6 hours after the resection 
of 70% of the liver were selected. The choice of 6 hours was because this represents 
the mean time (between 4 and 8 hours) post-hepatectomy that the genes of the cell 
cycle are activated. Of all the genes that they observed to be over-expressed relative to 
the control levels, there were 3 unrecognized genes which were of interest because the 
most over-expressed was RAP-3 (regeneration-associated protein). They also studied 
the profile of expression of the gene in various mouse (skeletal muscle, spleen, liver, 
kidney, heart, brain and lung) and human (brain, heart, skeletal muscle, colon, spleen, 
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thymus, heart, colon, kidney, small intestine, placenta, lung and leukocytes) tissues 
and showed that RAP-3 was expressed principally in the liver. They observed that the 
sequence of RAP-3 was very closely homologous to the cDNA of mouse and rat, and 
that the human cDNA was identical to certain parts of the 11q23 region where the 
apolipoprotein A1-C3-A4 cluster is located.  
The protein sequence was observed to be very homologous between species (73%) 
and had certain homology with apo A-IV and apo A-I. There were α-helix domains 
identified as well as a signal peptide that could be liberated. This implied that the 
protein could be secreted into the circulation. They raised monoclonal antibodies and 
detected a concentration of the protein in plasma of the normal mouse of 1μg/ml 
bound, mainly, to large HDL. As such, they hypothesized that at the moment in which 
RAP-3 is most over-expressed (at 6h post-hepatectomy) there would be, as well, the 
highest levels of HDL. However, they observed the converse i.e. that the level of HDL 
protein was decreased and the level of HDL cholesterol remained constant. As such, 
they postulated that it could have a specific function during regeneration, possibly as 
an antagonist to the hepatic uptake of lipids 
 
Van der Vliet et al in 2002 (151) published a study comparing the lipid profile in mice 
with normal levels of expression of APOA5, and mice that had 20-fold expression of the 
gene using adenovirus vectors. They showed that those that over-expressed the gene 
had, apart from the effect already described on the levels of TG (decrease of 70% due 
to the lower content in the VLDL), a decrease of 40% in the levels of cholesterol 
(mainly in the HDL fraction). 
 
In summary, a new gene, APOA5 has been identified in the A1-C3-A4 cluster that 
appears to have a key function in the regulation of the circulating levels of lipids. It is 
important to highlight that although the initial studies in animal models clearly showed 
its importance in the metabolism of TG, the overall physiological function and 
mechanism of action are still unknown.  
 
4.2.2. Implication of apo A-V in TG metabolism: in vitro studies and 
animal models  
In 2003 there were two studies which used computer modeling of structural data to 
speculate on the function of apo A-V. The studies described that, due to its 
composition, the apo A-V is a protein that is highly insoluble and that it is 
interchangeable, as with other proteins (such as, for example, apolipoproteins A-I, C-III 
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and A-IV), it can form lipid molecules together in combination with phospholipids and, 
as such, maintain its solubility in plasma by interacting with the lipoproteins. It was 
described as being bound to HDL and its capacity to activate the enzyme LCAT and to 
stimulate cholesterol efflux from the cells via the transporter ABC-A1 was investigated. 
The conclusions were that it was not implicated in any of these processes (152). 
Weinberg et al (153), documented its highly hydrophobic nature and suggested that, in 
plasma, it needed to be bound to lipoproteins. Taking into account that the 
concentrations in plasma is very low around 0.1% of that of apo A-I (150), the authors 
proposed that the negative correlation between the expression of APOA5 and the 
levels of TG detected in animal models was mediated intra-cellular rather than intra-
vascular processes. This makes biological sense if we take into account that the apo A-
V participates in the process of liver regeneration, and that certain homology has been 
observed between the c-terminal end of the sequence of the APOA5 gene and that of 
mouse MTP, and which suggests a possible participation in the process of synthesis 
and secretion of TGL particles. 
 
Despite the lack of functional studies, the predictions based on the sequence analyses 
postulate that apo A-V delays the second stage of the assembly of VLDL particles 
making it difficult for the particle to expand, or restricting the nascent secretion pathway 
(154). 
 
Two subsequent studies described one of the mechanisms by which apo A-V affects 
the levels of circulating TG. Schaap et al (155) used adenovirus transfection to 
increase the levels of APOA5 expression in mice. They observed an increase in the 
clearance of circulating TRL which was dependent on the hydrolytic action of LPL and 
the presence of apo C-II (principal activator of LPL). They concluded that recombinant 
apo A-V stimulated the hydrolytic activity of LPL in vitro. Also, they analyzed the role of 
apo A-V on the synthesis of particles and observed that over-expressing the gene 
gives rise to a decrease in the size and the content of the VLDL, but without affecting 
their rate of production. This accord with the postulate by Weinberg et al (153) which 
proposes that apo A-V restricts the process of lipidation or secretion of the TRL in the 
liver. 
  
Fruchart-Najib et al (156) enriched human VLDL particles with recombinant apo A-V 
and also observed that the hydrolytic activity of LPL was stimulated by the apoprotein. 
They generated mice transgenic for the human APOA5 gene and observed that, in the 
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fasting state, the protein is preferentially associated with the HDL particles and was 
transferred to VLDL in the post-prandial state.  
Two further studies explored the process of activation of LPL by the APOA5 gene, by 
using animal models of mice that over-expressed the human gene and in knockout 
(KO) mice. They concluded that apo A-V accelerated the catabolism of chylomicrons 
and VLDL without affecting their production and that in vitro and in vivo the LPL can be 
bound to a proteoglycan that is activated by the apo A-V (157). However, an in vitro 
study by Lookene et al concluded that apo A-V is not capable of directly activating LPL, 
but this finding was probably due to the absence of proteoglycans in the design of their 
experiment (158).  
Similarly, 2 mutations were identified in the gene which resulted in the formation of a 
truncated protein in the positions 148 and 139 (Q148X and Q139X). These were 
associated with alterations in the catabolism of the TRL due to an inability to activate 
LPL leading to severe hypertriglyceridemia (159, 160). Following a similar line of work, 
Sun et al demonstrated that the domain of apo A-V that is necessary for the interaction 
with LPL is localized between the amino acid residues 192 and 238 (161). 















Figure 10. Possible mechanisms of action of apo A-V. The apo A-V is transported in the TRL (chylomicrons and VLDL) 
and in HDL (162). Apo A-V is synthesized in the liver and is secreted together with VLDL, such that the protein present 
in chylomicrons need to derive from synthesis in the intestine together with the particles or that post-prandially are 
transferred from the HDL to the chylomicrons of intestinal origin (156). Once in circulation, it facilitates the binding of the 
TRL to the proteoglycans making the particle accessible to the hydrolytic enzyme LPL. It is not clear if the apo A-V 
stabilizes the dimeric conformation of the LPL or if it is bound to the allosteric site of the LPL to stimulate its activity and 
to promote the formation of fatty acids from the TG contained in the particles. In any case, the presence of mutations 
such as Q145X or Q139X causes the protein to lose its function and results in an accumulation of the triglyceride-rich 
particles in the circulation. 
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A further hypothesis is that apo A-V can be the key protein in the interaction between 
chylomicrons and GPIHBP1, which is known to play an important role in the hydrolytic 
process of chylomicrons (163) since it is localized in the lumen of the capillaries and 
can bind with LPL, and also since mice deficient in this protein develop 
chylomicronemia (164). 
Recently, another mechanism of control of circulating levels of TG has been identified. 
Grosskopf et al (165) showed that a deficit of apo A-V attenuates the elimination of 
remnants of the TRL, since they have a lower affinity for the LDL receptor. Nilsson et al 
(166) characterized this interaction between apo A-V and the receptors of familial LDL-
R and observed that binding is with the LDL receptor related protein (LRP) and the 
type-1 receptor mosaic (SorLA). 
 
In summary, in vitro studies as well as studies in animal models have demonstrated 
that apo A-V stimulates TG hydrolysis via LPL; the process requiring the presence of 
apo C-II. Apo A-V is bound to the proteoglycan heparin sulfate and, further, facilitates 
the elimination of the remnants of the TRL. 
 
 
4.2.3. Apo A-V and inflammation  
Apart from its role in regulating the levels of plasma TG, several research groups have 
explored the possible involvement of the gene in other processes linked to 
hypertriglyceridemia, such as inflammation. Apo A-V, together with apo A-IV, are 
proteins that are present in high concentrations in HDL of mice that present with acute 
phase reaction related with the process of infection and inflammation (167). During the 
acute phase response there is an increase in hypertriglyceridemia produced due to an 
increase in hepatic synthesis of TG and of the secretion of VLDL. The changes in many 
of the proteins associated with HDL during the acute phase response serve as a 
defense, and are not related with lipid metabolism.  
Studies in mice as well as in humans have corroborated these findings i.e. that during 
the acute phase response, plasma apo A-V is not inversely correlated with the levels of 
TG, and that the hepatic expression of APOA5 is regulated principally by changes in 
the stability of mRNA (168). 
Apo A-V can, as such, have other functions not so intimately linked to lipid metabolism, 
but may be equally important in the development of cardiovascular disease. 
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4.2.4. APOA5 gene variants: impact on TG metabolism  
Since the discovery of the APOA5 gene, there have been many association studies 
with polymorphisms of the gene. There have been 5 haplotypes defined by 7 
polymorphisms described (Table 9). The haplotypes APOA5*2 and APOA5*3 are the 
most interesting because of their association with higher concentrations of TG. The 
majority of studies have focused on the 2 polymorphisms -1131T>C (corresponding to 
the SNP 3 of the original study by Pennacchio) and the c.56C>G (also known as 
S19W) (169-177). 
 











APOA5*1 T A G T C C G 69% 
APOA5*2 Rare Rare Rare Rare C C G 4% 
APOA5*3 T A G T Rare C G 4% 
APOA5*4 T A G T C Rare G --- 
APOA5*5 T A G T C C Rare --- 
 
Table 9. Summary of gene variants determining the commonest APOA5 haplotypes. Frequency 
determined in Caucasian populations. Adapted from (176). 
 
Since the APOA5 gene is located very near the APOA1-C3-A4 gene cluster on 
chromosome 11q23 (figure 11), there have been many studies suggesting that the 
effect of apo A-V on the TG levels may reflect a linkage disequilibrium with functional 
variants of other genes in the cluster. The Sst-I variant has previously been shown to 
be associated with elevated levels of TG and is in strong linkage disequilibrium with -
455T>C and -482 C>T, both located in the response-to-insulin site in the promoter of 
APOC3 (133). While other (178, 179) studies have demonstrated that the S19W variant 
of APOA5 is independent of the effect of APOC3 on the effect on TG levels, there have 
been studies showing that -1131T>C is in strong linkage disequilibrium with the -
482C>T variant in APOC3. Hence, it became necessary to conduct studies on 
functionality of the principal variants of the APOA5 gene. 
 
A1 C3 A4 A5




Figure 11. Map of the gene cluster. Arrows indicate the direction of transcription, and numbers indicate 
gene size or distance.  
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Talmud et al (180), in 2005, published an extensive study describing the studies of 
functionality for most frequent variants of APOA5. In the case of the S19W 
polymorphism in the signal peptide region they demonstrated that it was necessary for 
the secretion of the protein and, as such, was functional. But in the case of the -
1131T>C variant, using studies of luciferase activity, they did not find any significant 
differences in the activity between the normal and the mutated vectors (-1131T and -
1131C, respectively), although both showed almost double the luciferase activity 
compared to the control vector. Further, since -1131T>C variant is in complete linkage 
disequilibrium with the -3A>G mutation i.e. the Kozak region of the promoter, they 
designed constructs that covered the two variants. They did not detect significant 
differences between the normal construct and that which contained the changes 
although, again, the constructs had higher luciferase activity than the control 
constructs. They came to the conclusion that the -1131T>C variant did not modify the 
transcriptional activity of the promoter. However, a few years later while studying the 
combination of three variants that describe the APOA5*2 haplotype and which are in 
complete linkage disequilibrium (-1131T>C, -3A>G, and c.1259T>C), they observed 
that these polymorphisms act cooperatively and that together they show significant 
differences in luciferase activity (181).  
In conclusion, identification of the -3A>G as being functional implied that, probably, the 
associations described for the SNP -1131T>C reflect the effect of -3A>G. 
 
The polymorphisms in APOA5 have been analyzed in several different population 
studies and have corroborated the influence of the gene on lipid metabolism, especially 
that of TG (Table 10). 
 
Population Sample size Reference Associated with 
n= 501 Pennacchio LA (149) TG, VLDL mass 
n= 419 Pennacchio LA (177) TG, VLDL mass, apo B 
n= 2808 Talmud PJ (178) TG, HDLc 
n= 89 Ribalta J (182) -- 
n= 500 Li GP (183) TG, TC, HDL-C 
n= 2391 Lai CQ (101) 
TC, TG, HDL-C, LDL-C, apo 
B, RLP-C, RLP-TG, LDL 
diameter, apo A-I, VLDL 
n= 196 Ishihara M (184) TG, apo A-V 
Healthy normolipidemic 
n= 299 Sundl I (185) 
VLDL-C, IDL-C, TG, VLDL-
TG, vit E, apo B/apo A-I 
Schoolchildren n= 552 Endo K (186) TG, HDLc 
General population n= 893 Nabika T (187) TG 
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n= 2660 Pennacchio LA (177) TG 
n= 408 Ribalta J (182) TG 
n= 3971 Lai CQ (188) TG, LDL-C, HDL-C 
n= 558 Austin MA (89) TG, LDL size, apo B 
Hubacek JA (189) TG 
n= 2559 
Hubacek JA (190) HDL-C 
n= 285 Hubacek JA (191) TG 
n= 3831 Klos KL (192) TG 
n= 1119 Hubacek JA (193) -- 
n= 3020 Hodoglugil U (194) TG 
n= 2148 Lai CQ (195) TG, RLP, VLDL size, LDL size 
n= 794 Chandak GR (196) TG, TC 
n= 117 Hubacek JA (197) TC 
n= 2273 Elosua R (174) IMT, TC, TG, HDL-C, obesity 
n= 2490 Talmud PJ (198) TG, apo A-V 
n= 1183 Hallman DM (173) TG 
n= 3794 Yamada Y (199) TG, HDL-C 
n= 2280 Corella D (200) obesity 
n= 3124 Grallert H (170) TG, TC, HDL-C, LDL-C 
n= 2500 Hubacek JA (201) TG 
 
n= 477 Liao YC (202) TG, HDL-C 
n= 88 Masana L (203) Fasting TG, AUC-TG 
n= 158 Jang Y (92) 
TG, dense LDL, CRP, 
isoprostanes, DNA damage, 
PPL CHYLO-TG, PPL 
VLDLTG 
n= 51 Moreno R (204) 
PPL TG, PPL TRL-TG, PPL 
TRL-C, PPL TRL-RP 
n= 88 Moreno R (205) 
PPL TG, PPL TRL-TG, PPL 
TRL-C, apo B100 
Oral fat load 
n= 259 Olano-Martin E (206) 
Fasting TG, AUC-TG, IAUC-
TG, HDL-C 
Oral fat and glucose load n= 774 Martin S (207) 
TG, waist to hip ratio, SBP, 
AUC-insulin, peak insulin. 
n= 459 Pennacchio LA (149) TG 
n= 103 Ribalta J (182) 
TG, VLDL-TG, IDL-TG, VLDL-
C, VLDL, apo B 
n= 627 Aouizerat BE (208) 
TG, VLDL-TG, VLDL-C, LDL-
TG, HDL-TG, HDL-C 
n= 83 Vrablik M (209) TG 
n= 915 Evans D (210) TG, HDL-C 
n= 290 Kao JT (211) TG 
Dyslipidemic 
n= 167 Baum L (212) TG, HDL-C 
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n= 221 Bertolini S (213) TG 
n= 127 Esteve E (90) sdLDL  
n= 372 Talmud PJ (214) 
TG, VLDL mass, IDL-TG, IDL-
C, IDL-free C, IDL-
phospholipids 
n= 298 Mar R (91) TG, LDL size 
n= 202 Jiang YD (215) TG 
n= 308 Chaaba R (216) TG 
n= 285 Yan SK (217) 
TG, HDL-C, apo C-II, apo C-
III, apo E 
n= 606 Aberle J (218) Weight 
n= 72 Evans D (219) -- 
n= 215 Dallinga GM (220) Apo A-V 
n= 71 Zhai G (221) TG, LDL-C 
n= 100 Choi JR (171) TG 
n= 201 Maasz A (222) TG 
n= 157 van der Vleuten GM (172) 
TC, TG, apo B, HDL-C, 
sdLDL, RLP-C 
n= 902 Qi L (223) TG, HDL-C 
n= 791 Lai CQ (224) TG, HDL-C 
n= 119 Henneman P (225) Apo A-V 
n= 279 Niculescu LS (226) BMI, TG, HDL-C, glucose 
n= 1708 Dorfmeister B (227) TG 
n= 1017 Yamada Y (228) TG, HDL-C 
n= 169 Girona J (229) 
Vit E, TG, apo A-I, VLDL-TG, 
HDL-TG 
n= 213 Kisfali P (230) TG 
 
n= 308 Chien KL (231) TG 
Pregnant women n= 483 Ward KJ (232) 
TG, total cholesterol, maternal 
height, fetal length 
n= 308 Szalai C (233) TG 
n= 537 Lee KW (234) TG, FER-HDL, HDL-C 
n= 312 Bi N (235) TG 
n= 483 Liu H (236) TG, HDL-C 
n= 1703 Ruiz-Narvaez EA (175) TG, HDL-C 
n= 442 Dallongeville J (237) TG 
n= 211 Hsu LA (238) TG, HDL-C 
n= 232 Tang Y (239) TG 
n= 1034 Vaessen SF (240) TG, apo A-V 
CAD 
n= 669 Martinelli N (179) TG, HDL-C, apo C-III 
n= 229 Guardiola M (241) BMI, lipodystrophy, TC, TG 
HIV 
n= 438 Arnedo M (242) TG, HDL-C 
Elderly  n= 371 Chen ES (243) Obesity 
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 n= 1419 Yamada Y (199) TG, HDL-C 
Nephropathy n= 367 Baum L (244) TG, HDL-C 
n= 284 Papassotiropoulus A (245) TC 
n= 302 Havasi V (246) TG 
n= 106 Barbosa FA (247) -- 
n= 189 Smith RC (248) TC 
Mental diseases 
n= 403 Maasz A (249) TG 
 
Table 10. Summary of the association studies conducted with the APOA5 gene variants 
 
Apart from the consistent associations with the TG levels, several studies have shown 
that the variants in APOA5 are associated with other parameters of interest in the study 
of cardiovascular disease and the associated risk factors such as the levels of total and 
HDL cholesterol, levels of cholesterol and TG in circulating remnant particles, levels of 
C-reactive protein, of isoprostances, size and density of LDL, insulin sensitivity and β-
cell function,... (reviewed in (250)).  
 
4.2.5. APOA5 gene variants: impact on apo A-V protein levels 
Since 2005 there began to be published studies determining the concentrations of 
circulating apo A-V. O'Brien et al (162) described that apo A-V concentrations in 
humans were very low (Table 11) and that, as has been indicated, they are observed 
bound principally to the TG-rich lipoproteins (chylomicrons and VLDL) and HDL. 
Taking into account the inverse relationship between the gene and circulating TG 
levels described in several studies in animal models (149-151, 251, 156, 252, 165), 
and taking into account as well the results of functional studies, we would expect to 
observe an inverse relationship between the circulating concentrations of apo A-V and 
TG. However, the majority of studies have shown no correlations, or even positive 
correlations (220, 253, 254); findings that suggest that the secreted protein is not the 
route by which the apo A-V regulates the concentrations of TG and, perhaps, that the 
relevant function of apo A-V in intra-cellular. 
 
Apolipoprotein Plasma concentration 
Apo A-I 100-150 mg/dL 
Apo C-III 8-15 mg/dL 
Apo A-IV 30-50 mg/dL 







Table 11. Plasma concentrations of apolipoproteins that form the cluster  
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A study conducted in 196 healthy individuals and in 106 diabetic Japanese patients 
showed that the individuals who were carriers of the wild type variant -1131T>C had 
higher concentrations of protein than the carriers of the less frequent -1131C allele 
(184). In another study, the carriers of the -1131C and c.56G alleles were associated 
with lower levels of circulating apo A-V and to a higher risk of cardiovascular disease; 
the affect was independent of the TG levels and of linkage disequilibrium with APOC3 
variants (240). A third study that analyzed the two most commonly observed 
polymorphisms noted that only the carriers of the S19W variant had higher levels of A-
V in plasma. The authors concluded that the effects described for the -1131T>C 
marker are due to the linkage disequilibrium between the APOC3 gene markers (198). 
 
4.2.6. APOA5 gene regulation: implication of nuclear receptors  
The expression of the apo A-V gene is under the control of nuclear receptors; 
transcription factors that respond to hormones and certain molecules such as drugs, or 
vitamins that act as ligands. The binding with its ligand promotes certain conformational 
changes, and activates a metabolic cascade to maintain homeostasis of lipids by 
controlling transcription, by binding directly to DNA of certain genes implicated in 
metabolism, as well as the storage, transport and elimination of lipids. 
The principal receptors implicated in lipid metabolism are PPAR, FXR, LXR, SREBP 
and ROR. The majority of these regulatory elements are strongly related to the 
regulation of levels of circulating TG. Over recent years, several authors have tested 
whether the effect of these nuclear receptors on the TG are mediated via APOA5. 
 
PPAR. PPARs are a sub-family of transcription factors that regulate the expression of 
certain genes involved in TG levels regulation (255, 256) via response to ligand binding 
(fatty acids are natural ligands for PPARs) and, following the binding, leading to a 
trans-activation or a trans-repression of target genes. Thus, the modulation of gene 
transcription is due to the binding of a heterodimer to a specific DNA sequence; the 
peroxisome proliferator responsive element. This consensus sequence consists of a 
direct repeat of a hexamer AGGTCA separated by a nucleotide (DR1) with a 5' 
extension (AACT). This system sequence recognition is, in considerable part, common 
for the other types of nuclear receptors. 
The sub-family is composed of three different types (-α, -β/-δ and -γ), and each one is 
encoded separately (chromosomes 22q13, 6p21 and 3p25, respectively) and have 
different tissue distribution patterns (PPAR-α and -γ are predominantly expressed in 
liver and adipose tissue, while PPAR-δ is ubiquitously present throughout the 
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organism, but to a lesser extent in the liver). They have different regulatory functions in 
the energy metabolism (Figure 12).  
These nuclear factors are of clinical interest since they are molecular targets for 
fibrates (main pharmacological agents to regulate TG levels) and for thiazolidinediones 
(used in hypoglycemic therapies) (116). 
 
In 2003, the activity of the promoter of the APOA5 was described as being stimulated 
by the binding of the nuclear transcription factor PPARα (257). Further, it was 
demonstrated in cynomologus monkeys that the administration of a PPARα agonist 
over 14 days increased the levels of A-V protein in plasma and, as would be expected, 
decreased the circulating levels of TG (258). An association study demonstrated that 
the carriers of the S19W variant had a better treatment response with fenofibrate in 















body insulin sensitivity Fatty acid oxidation
Energy uncoupling
 
Figure 12. The PPAR isoforms regulate lipid and glucose metabolism through their action on different tissues 
 
FXR. FXR is identified as a nuclear receptor activated by bile acids and expressed, 
above all, in the enterohepatic system. It protects the organism from the consequences 
of elevated concentrations of bile acids. It is related to the metabolism of cholesterol 
since it inhibits the synthesis of bile salts (Figure 13). FXR has been described as a key 
regulator in the control of plasma TG levels (259) and, when activated by a specific 
ligand, promotes a 50% decrease in plasma TG levels in rodents (260). In 2003, Prieur 
et al demonstrated that FXR was a regulator of TG levels which, in large part, was 
mediated by the control of APOA5 expression (261). 
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LXR. LXR is expressed in the liver, but also in other tissues involved in lipid 
metabolism such as adipose tissue, kidney, intestine, macrophages. It is a nuclear 
receptor that binds cholesterol derivatives and, in response to an increased 
concentration of cellular oxysterols, modulates the expression of genes involved in 
cholesterol metabolism (Figure 13). Further, it regulates a number of genes involved in 
fatty acid and TG metabolism by up-regulating another nuclear receptor, the SREBP-
1c. In 2004 a study was published demonstrating that one of these target genes is 
APOA5, and that LXR via SREBP-1c negatively regulates the levels of expression of 




















Figure 13. The nuclear receptors only act in coordination and, for example, represent the transcription 
factors implicated in homeostatic control of cholesterol. SREBP stimulates the formation of LDL-R and the 
key process in the synthesis of cholesterol (HMG-CoA reductase) and, in response to the presence of 
cholesterol derivatives, the LXR stimulates the formation of bile acids; a process that is also controlled by 
FXR.  
 
SREBP. The SREBP is composed of three isoforms: SREBP-1a and SREBP-1c which 
are coded by the same gene on human chromosome 17 and, due to alternative 
promoters, form transcripts with 6 different exons; SREBP-2 which is located on 
chromosome 22 (262). These transcription factors are known principally for their roles 
in the control of cholesterol homeostasis. In vivo studies using animal models have 
shown that SREBP-1c is preferentially involved in the control of metabolism of bile 
acids and TG, and is the only member of the family that is activated by LXR and insulin 
(263). The activation of SREBP-1c is also modulated by food intake; a characteristic 
that may relate apo A-V with nutritional status.  
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Insulin. Insulin is a molecule implicated in the response to nutritional status and, as 
such, is an important factor in the regulation of metabolism of carbohydrates and lipids 
in the liver, adipose tissue and muscle. In relation to the lipids, it is implicated in the 
oxidation of fatty acids in the liver, in lipogenesis, in the synthesis of proteins, and in 
the export of fatty acids in the lipoproteins from the liver to the extra-hepatic organs, 
among the functions. Also, the possible regulatory role in APOA5 expression by insulin, 
has been described (264). The authors suggested that the metabolic mechanism 
occurs as a function of upstream stimulatory factors (USF). Insulin activates 
phosphatidylinositol 3-Kinase (PI3K) which phosphorylates the USF that affects the 
DNA sequence of the APOA5 gene causing a decrease in the transcription levels. Also, 
insulin infusion reduces the levels of apo A-V protein. 
 
ROR. The retinoic acid-related orphan receptor (RORα) (265) was considered not to 
have any exogenous activator, although recently it has been described that cholesterol 
or its derivatives are its natural ligands. Once activated, RORα is involved in many 
aspects such as smooth muscle cell differentiation, inflammation, lipid metabolism and 
the regulation the levels of plasma cholesterol. RORα-deficient animal models have a 
high susceptibility to arteriosclerosis. Although its physiologic function has not been 
clearly established evidence suggests that it modulates the expression of genes such 
as APOA1 (266) and APOC3 (267). It has been shown to stimulate APOA5 promoter 
transcriptional activity (265, 268) and the modulation of the expression of other 
components of the apolipoprotein cluster needs to be investigated. 
 
TH. Hypothyroidism is a disease associated with elevated levels of circulating TG 
which, in turn, is associated with low activity of LPL. Hence, thyroid hormone status has 
been widely investigated in relation to the metabolism of the triglyceride-rich particles. 
The relationship between the hormone and TG leads one to believe that the thyroid 
hormone can regulate the expression of APOA5. For example, treatment of human 
primary hepatocytes with T3 increases the levels of mRNA and, as well, of apo A-V 
protein and results from the binding of a response element in the APOA5 promoter 
(269). 
 
HNF-4α. The fatty acids, as well, are ligands for HNF-4α which is expressed 
principally in the liver, but as well in the kidney, intestine and the pancreas. It plays a 
key role in the differentiation of the hepatocytes during development in the liver and, as 
well, in the regulation of the expression of genes implicated in the metabolism of 
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Genetics of hyperTG   65 
glucose and of lipids, including the APOA1-C3-A4 cluster, APOB, MTP, among others. 
The inhibition of HNF-4α in human hepatocytes results in the down-regulation of 
APOA5 and indicates that this nuclear receptor directly regulates human APOA5 
promoter activity (270). 
 
Apart from the transcription factors, there have been studies assessing the role of 
enhancer of APOC3. The APOC3 enhancer is a common regulator element of the 
human apolipoprotein A-I/ C-III/ A-IV/A-V cluster which regulates the specific tissue 
expression of APOA1, C3 and A4 genes (271). Studies conducted in mice transgenic 
for the whole cluster region show that the APOA5 is the only one of the cluster that is 
not co-regulated by the enhancer of APOC3 (272) and it is postulated that this can 
explain the big differences in the levels of circulating protein between the components 
of the cluster. A conclusion is that the control mechanism of APOA5 expression is more 
complicated than originally thought.  
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Since apolipoprotein A-V is a key modulator of plasma triglyceride levels it should also 
have an effect on different aspects highly linked to TG metabolism, such as fat-soluble 
vitamins or the effect of certain TG levels-modifying drugs, and its effect should be 






The proposed objectives to test this hypothesis were: 
1. Use variability at the APOA5 locus to study its influence on lipid, lipoproteins, fat-
soluble vitamins and oxidative status; and the interaction with drugs in different 
populations. 
1.1. In healthy men (complete lipid, lipoprotein and fat-soluble vitamins profile) 
1.2. In diabetic patients (complete lipid, lipoprotein and oxidative status profile) 
1.3. In HIV patients (treated with protease inhibitors)  
 
2. Study the APOA5 gene function 
2.1. Study if APOA5 gene is modulated by diet (in KO-APOE mice) 
2.2. Study whether it is expressed in the intestine (in TC7/ Caco2 cells) 
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This section summarizes the 5 studies carried out in the course of this thesis 
development, and which are written in article format. Two of these studies are 
presented as the articles used for assessment of the thesis (Clinical Chemistry 2006; 
Clinical Chemistry and Laboratory Medicine 2008), and the other studies are presented 
as annexes (Journal of Lipid Research 2007; Clínica e Investigación en Arteriosclerosis 
2007; Biochimica et Biophysica Acta, Submitted 2008). The data are grouped in two 
sections; association studies and functional studies. 
 
ASSOCIATION STUDIES: 
Data acquisition for the thesis began by evaluating the influence of the APOA5 gene on 
TG metabolism described in the literature extant at that time. For this purpose we used 
association studies of the -1131T>C gene variant in our population samples. This 
variant has been the most commonly used in studies conducted in different populations 
which were well-characterized with respect to different aspects of lipid metabolism. The 
results of our findings were: 
1) Increased concentrations of circulating vitamin E in carriers of the 
apolipoprotein A5 gene -1131T>C variant and associations with plasma lipids 
and lipid peroxidation.  
Isabella Sundl, Montse Guardiola, et al. 
Journal of Lipid Research 2007;48:2506-2513.  
2) The apolipoprotein A5 gene -1131T→C polymorphism affects vitamin E plasma 
concentrations in type 2 diabetic patients.  
Josefa Girona, Montse Guardiola, et al.  
Clinical Chemistry and Laboratory Medicine 2008;46:453-457.  
3) Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly 
influenced by the APOA5 -1131T>C gene variation. 
Montse Guardiola, Raimon Ferré, et al.  
Clinical Chemistry 2006;52:1914-1919. 
 
FUNCTIONAL STUDIES: 
Paradoxically, while there was growing evidence on the influence of APOA5 on TG 
levels, very little was known about its physiological role. Hence, we designed two 
studies directed towards gaining an insight into the functionality of the gene. The 
results were presented in the following articles: 
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4) La grasa saturada en la dieta disminuye la expresión hepática de APOA5 en 
ratones deficientes en APOE [Saturated fatty acid diet decreases the 
expression of APOA5 in APOE deficient mice]. 
Montse Guardiola, Mònica Tous, et al. 
Clínica e Investigación en Arteriosclerosis 2007;19:22-29.  
5) The APOA5 gene is expressed in human intestinal tissue and responds to fatty 
acid and fibrate exposure in vitro. 
Montse Guardiola, Adriana Alvaro, et al.  
Submitted Biochim et Biophys Acta 2008. 
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INCREASED CONCENTRATIONS OF CIRCULATING VITAMIN E IN 
CARRIERS OF THE APOLIPOPROTEIN A5 GENE - 1131T>C VARIANT 
AND ASSOCIATIONS WITH PLASMA LIPIDS AND LIPID 
PEROXIDATION. 
 
Sundl I, Guardiola M, Khoschsorur G, Solà R, Vallvé JC, Godàs G, Masana L, 
Maritschnegg M, Meinitzer A, Cardinault N, Roob JM, Rock E, 
Winklhofer-Roob BM, Ribalta J. 
 
J Lipid Res 2007;48(11):2506-13. 
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When we started the first study, there had not been any previous publications on the 
association of the APOA5 gene in relation to a detailed lipid profile (complete lipid, 
lipoprotein and apolipoproteins), nor in relation to the vitamins carried by the 
lipoproteins, especially vitamin E (a fat-soluble molecule strongly linked to TRL 
metabolism, and with a well-documented lipid antioxidant function). We genotyped a 
population sample of 297 male non-smokers from France, Austria and Spain. This 
population sample was part of the Vitage study aimed at identifying lipids and vitamin 
changes in the course of ageing. The population sample had 2 main characteristics: 
strict selection criteria for the absence of disease, and detailed lipid and vitamin 
profiles. We hypothesized that, in this group of healthy subjects, the confounding effect 
of metabolic factors on the genetic influence would be minimal and would help highlight 
the real influence of the APOA5 gene.  
The frequency of the minor allele (-1131C) among the healthy men was 0.08, which is 
similar to that in many Caucasian populations. In our population sample of healthy 
men, the presence of the C allele was associated with significant alterations in several 
lipid-related parameters. Carriers of the C allele presented with 15% higher circulating 
TG levels, mainly due to an increased content in VLDL fraction; higher cholesterol 
levels in VLDL and IDL fractions; and almost 9% higher circulating fatty acids, without 
any difference in fatty acid intake between genotypes. They also presented with higher 
amounts of circulating apo B levels which is a marker of the number of apo B-
containing lipoprotein particles and, as such, had higher circulating levels of VLDL and 
LDL lipoproteins. The influence of APOA5 genetic variant on lipid metabolism remained 
following adjustment for the BMI, age and dietary intake. 
Vitamin E consists of 8 different isoforms of tocopherols and tocotrienols. We found 
that only plasma α-tocopherol (but not γ-tocopherol, LDL α- and γ-tocopherol, nor total 
vitamin E from buccal mucosa cells) was significantly increased by 9.1% in C allele 
carriers compared with homozygote T-carrying subjects, even after adjustment for BMI 
and age, but not when adjusted for total lipid levels. This indicated that TG and vitamin 
E increased in similar proportions. The adjustment for cholesterol or total lipids is 
appropriate since vitamin E is closely associates with lipids and depends on lipid or 
lipoprotein metabolism for delivery to tissues (253). Since vitamin E is a well-
documented antioxidant molecule, we also analyzed the effect of APOA5 genotype on 
antioxidant status, as measured by plasma malondialdehyde concentration (a marker 
of the lipid peroxidation rate). We observed no statistically significant differences with 
respect to genotype, and confirmed that TG and vitamin E increased proportionally. 
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Conclusions from Study 1: The results demonstrated that TG elevation associated with 
the -1131C variant was mostly due to an increase in the VLDL fraction; both at the level 
of TG enrichment and particle number, as suggested by increased VLDL-apo B. 
Increases in VLDL resulted in increased amounts of VLDL-associated vitamin E, which 
did not confer increased antioxidant protection. 
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THE APOLIPOPROTEIN A5 GENE -1131T-->C POLYMORPHISM 
AFFECTS VITAMIN E PLASMA CONCENTRATIONS IN TYPE 2 DIABETIC 
PATIENTS. 
 
Girona J, Guardiola M, Cabré A, Manzanares JM, Heras M, Ribalta J, Masana L. 
 
Clin Chem Lab Med. 2008;46(4):453-7. 
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The first population sample studied was specifically selected to be free of any known 
disorder. We wished to confirm our results in diabetic patients since these patients 
present with atherogenic dyslipidemia. The defects are defined mainly by alterations in 
TG metabolism (high TG levels, low HDLc levels, presence of sdLDL particles) as well 
as increased oxidative stress. This latter status is believed to play an important role in 
the development of type 2 diabetes (DM2) with major attention being focused on lipid 
oxidation, specifically on that of LDL particles. Data we generated on these patients 
included a complete lipid, lipoprotein and oxidative status profile as well as vitamin E 
levels and parameters related to LDL oxidation. 
We genotyped the -1131T>C polymorphism in 169 DM2 patients diagnosed in 
accordance to the American Diabetes Association criteria (274). Patients with type 1 
diabetes mellitus, secondary diabetes mellitus, morbid obesity (BMI >40 kg/m2), familial 
hypercholesterolemia, diabetic retinopathy and/or nephropathy, malignancy, liver 
disorders, acute or chronic inflammation and smokers (at least one cigarette in the 
previous year), were excluded. Among the 169 diabetic subjects, 73 had evidence of 
atherosclerosis as indicated a clinical history of coronary heart disease, stroke or 
peripheral vascular disease involving at least one significant arteriosclerotic plaque 
(>40% stenosis) measured by carotid and femoral echo-Doppler, and/or an ankle 
brachial index ≤0.9 or ≥1.3.  
We observed that the minor allele frequency was similar to that described in other 
studies conducted in Caucasian populations (approx. 0.07). There were no statistically 
significant differences between carriers and non-carriers of the minor allele with respect 
to BMI, blood pressure, glucose, glycated hemoglobin, and presence of 
atherosclerosis. Supporting the results described in our previous study, we found that 
subjects carrying the rare allele at position -1131 had a significant increase of 21% in 
circulating TG levels, mainly due to differences in VLDL and HDL fractions. Also, they 
had 8% higher plasma apo A-I levels and 12% higher apo C-III levels. These results 
were confirmed even when adjusted for the hypolipidemic treatment that the patients 
were receiving. 
Lipid oxidation is a crucial mechanism in the evolution of diabetes, as well as 
atherosclerosis. Among the parameters measured (vitamin E, LDL dienes formation, 
lipoperoxides, oxidized LDL, oxidized LDL antibodies) in assessing oxidative status, we 
only found significant differences in vitamin E levels in relation to genotype. The 
differences remained statistically significant when normalized for cholesterol, but not 
when normalized for TG levels. In these diabetic patients, the carriers of the C allele 
had 11.3% higher concentrations of vitamin E compared with TT subjects, and the 
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frequency of rare allele carriers was higher among the group of subjects with higher 
circulating vitamin E concentrations (2.6-fold higher). 
 
Conclusions from Study 2: We confirmed that TG levels increases associated with the -
1131C allele are due to increased VLDL particles; the influence of this genetic variant 
being more important in diabetic patients than in healthy subjects. 
We confirmed, as well, that the resultant increase in circulating vitamin E levels was not 
associated with changes in oxidation status. 
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PROTEASE INHIBITOR-ASSOCIATED DYSLIPIDEMIA IN HIV-
INFECTED PATIENTS IS STRONGLY INFLUENCED BY THE APOA5-
1131T->C GENE VARIATION. 
 
Guardiola M, Ferré R, Salazar J, Alonso-Villaverde C, Coll B, Parra S, Masana L, 
Ribalta J. 
 
Clin Chem. 2006;52(10):1914-9. 
UNIVERSITAT ROVIRA I VIRGILI 
ROLE OF THE APOA5 GENE IN LIPID AND FAT-SOLUBLE VITAMIN METABOLISM 
Montserrat Guardiola Guionnet 
ISBN:978-84-691-9478-2/DL:T-19-2009 
 
Hypertriglyceridemia is the main side-effect of a number of drugs, including retinoic 
acid and protease inhibitors (PI). Over recent years there has been increasing interest 
in assessing an individual's genetic inheritance in relation to response to certain 
therapeutic agents. We hypothesized that APOA5 is likely to exacerbate such 
predisposition to hyperTG. We investigated the possible modulatory effect of APOA5 
genetic variation (-1131T>C) on the well-described dyslipidemic effect of PI which was 
being used as antiretroviral therapy in our hospital. The study sample contained 229 
HIV-positive patients, >18 years of age, without AIDS-related opportunistic diseases at 
the commencement of the study and, from whom, we had clinical and biochemical data 
from five years of follow-up. The lipid parameters were compared in two sub-groups: 
those receiving PI (n=148) and those not receiving PI (n=81). Only the results from the 
first 3 years of treatment were published because there were fewer patients with 
detailed lipoprotein profiles at years 4 and 5 of follow-up. This is probably because, in 
the past, it was not usual to analyze lipid parameters in HIV patients, or were measured 
only in those patients with the most evident dyslipidemia. 
Our results indicated that, although all patients at baseline (commencement of therapy) 
had similar plasma TG levels, the group of patients treated with PI and carriers of the -
1131C allele had significantly higher TG levels following treatment (43% higher after 
one year, 38% increase after two years, and 44% after three years) relative to non-
carriers of this allele. These values remained significant even after adjustment for age, 
gender, BMI, and the presence of lipodystrophy. A similar effect was observed for total 
cholesterol levels. C allele carriers treated with PI had 16% higher cholesterol levels 
after one year of treatment, 21% increase after two years and 20% after three. We also 
found a tendency towards lower HDL cholesterol levels among the group of C allele 
carriers treated with PI, but which did not reach statistical significance. Of note is that, 
after 3 years of treatment, patients treated with PI and carriers of the APOA5 -1131C 
allele had a dyslipidemic profile that was associated with a significant difference in the 
atherogenic index, as measured by the total cholesterol/HDL cholesterol ratio among 
genotypes i.e. HIV patients with the C allele treated with PI had a 78% increase in the 
atherogenic index compared to patients who were wild-type allele carriers. 
 
Conclusions from Study 3: This is the first published pharmacogenetic study assessing 
the hyperTG effect of the -1131C promoter variant of APOA5 gene and the response to 
highly active antiretroviral therapy. The magnitude of such hyperTG is greater than that 
of healthy subjects and of diabetic patients and confirms the notion that the effect of 
APOA5 largely depends on the metabolic background of the subject (data summarized 
in Figure 14). 
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Figure 14. Plasma TG levels among study subjects segregated according to -1131T>C variant of the 
APOA5 gene. Healthy male carriers of the C allele present with a 15% increase in TG levels compared to 
TT subjects; the increase being higher in type 2 diabetic patients (21%) and greater in HIV-infected 
patients (44%). 
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LA GRASA SATURADA EN LA DIETA DISMINUYE LA EXPRESIÓN 
HEPÁTICA DE APOA5 EN RATONES DEFICIENTES EN APOE 
[Saturated fatty acid in the diet decreases the hepatic expression of 
APOA5 in APOE deficient mice] 
Guardiola M, Tous M, Vallvé JC, Rull A, Masana L, Joven J, Ribalta J. 
 
Clin Invest Arterioscl. 2007;19(1):22-9. 
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Study 4 was aimed at investigating whether the APOA5 gene expression was 
responsive to dietary fat, a major determinant of TG homeostasis. We took advantage 
of an animal model, the APOE knock-out (KO) mouse. The model (KO-APOE) would 
enable us to study not only APOA5 expression in relation to diet but also to explore its 
possible relationship with atherosclerosis. 
 
Studying the development process of atherosclerosis, the pathogenic mechanisms, 
and the genetic-environmental factors involved in humans presents difficulties that can 
be partially overcome using animal models. Mice are good experimental animals since 
they are small, easy to use, with a short generation time and cheap. However, normal 
mice do not usually develop atherosclerosis because their plasma cholesterol levels 
are low and the cholesterol is carried mainly in HDL particles. The genetically modified 
APOE deficient mice develop higher cholesterol levels, distributed mainly among 
lipoproteins with particle sizes corresponding to VLDL or IDL. The plasma TG levels 
are not affected and their lipid metabolism resembles human. As a result, APOE 
deficient mice can quickly and reproducibly develop arteriosclerosis, even when fed a 
normal diet. When they receive fat- and cholesterol-rich diets, their cholesterol levels in 
plasma and the atherogenesis process increase proportionally and, as such, have 
been used extensively to study arteriosclerosis. 
We analyzed the hepatic APOA5 gene expression in 72 APOE-KO mice separated into 
different groups depending on the diet received: standard chow (control animals), 
saturated fat-rich diet (20% palm oil) alone, diet supplemented with 0.25% cholesterol. 
In each group, the mice were sacrificed at different ages (16, 24, and 32 weeks). This 
study design enabled us to analyze the effect of diet and age on the expression of 
APOA5, and to relate these effects to circulating inflammation markers. We also 
measured the extent of atherosclerotic lesion area in the aorta. 
We found that after administration of saturated fat-rich diet, alone or supplemented with 
cholesterol, APOE deficient mice had significant increase in circulating cholesterol 
levels relative to control mice (fed with standard chow), but without differences in 
relation to circulating TG levels. However, the amount of lipids (cholesterol and TG) 
contained in the liver were higher when mice were fed the atherogenic diets. The 
administration of such diets also affected the extent of aorta lesion as well as degree of 
steatosis; both of which were greater relative to control mice. 
Adding palmitic acid to the diet promoted the decrease in APOA5 hepatic expression 
by 75% in the group of mice aged 16 weeks, 35% in those aged 24, and 45% in those 
aged 32, compared to that in control mice. Nevertheless, the supplementation with 
0.25% cholesterol counterbalanced the effect of palmitic acid on APOA5, and which 
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was similar to that of control mice. These effects were also found in mice at different 
ages. 
Subsequently, we re-grouped the data on all the mice in relation to age at which they 
were sacrificed, and irrespective of the type of diet received. We found that APOA5 
expression in liver increased significantly with age, and this effect was also found when 
evaluating each diet-group separately. 
Correlation analyses were performed to assess whether the expression differences due 
to diet were related with any lipid or atherosclerotic parameter measured in the study. 
We found that hepatic APOA5 gene expression was not related with any of the lipids 
measured in these mice, but was positively correlated with the extent of aortic lesion 
and with plasma concentrations of monocyte chemotactic protein-1 (the key 
inflammatory marker in mice). The positive correlation was found only in those animals 
fed with fat-rich diet, and was negatively correlated in mice fed with normal chow, or 
with the diet supplemented with cholesterol. 
 
Conclusions from Study 4: The results obtained demonstrated, for the first time, that 
the expression of APOA5 could be modified by the type of diet consumed and, as a 
result, there is a different behavior in relation to inflammatory parameters and 
arteriosclerosis. However, these results were obtained in an animal model that had 
been genetically modified (APOE deficient mice) having a defect in the TG secretion 
pathway in hepatocytes. This effect of diet on APOA5 gene expression needs to be 
explored in depth in humans. 
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THE APOA5 GENE IS EXPRESSED IN HUMAN INTESTINAL TISSUE AND 
RESPONDS TO FATTY ACID AND FIBRATE EXPOSURE IN VITRO. 
 
Guardiola M, Alvaro A, Vallvé JC, Rosales R, Solà, R, Girona J, Duran P, 
Esteve E, Masana L, Ribalta J. 
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Based on the hypothesis that apo A-V may participate in the synthesis and/or secretion 
process of TG-rich lipoproteins, we designed Study 5 to evaluate APOA5 gene 
expression in small intestine. 
RNA from tissue samples from different parts of the human small intestine obtained 
from BD Biosciences Clontech were used to assess whether apo A-V is present in the 
intestine which, together with the liver, would be responsible for TG-rich particle 
formation. Also, to assess whether APOA5 expression is affected by dietary fatty acids 
or whether pharmacologic agents may affect its expression rate, we used the human 
intestinal cell line TC-7 (a sub-clone of the well-characterized Caco-2 cells) incubated 
with different types of fatty acids at different concentrations (long-chain fatty acids: 50, 
100, 200 and 300μM; short-chain fatty acids: 2 and 5 mM) over 24h. A synthetic 
PPARα agonist was tested at 100μM incubation concentration over 24h. We also 
measured the expression of APOB and MTP genes (critical in the TRL synthesis and 
secretion process) and APOC3 gene (also important in regulating TG metabolism) 
which have been proposed as playing antagonistic roles in relation to the APOA5 
regulation of TRL. 
We detected APOA5 expression in the intestine. Our results indicated that the studied 
genes were differently expressed among the different parts of the human intestine i.e.  
APOA5 is expressed mainly in duodenum and colon, while APOB is highly expressed 
in duodenum, jejunum and ileocecum, but not in colon. Similarly, MTP is highly 
expressed in duodenum and jejunum, but not in colon, while APOC3 is mainly found in 
jejunum. Correlation analyses indicated an inverse relationship between APOA5 and 
APOC3, but which did not quite reach statistical significance (r = -0.555). 
Having been able to detect APOA5 gene expression in the intestine, albeit at very low 
levels, we proceeded to design experiments in which we incubated the human 
intestinal TC-7 cell line with different types of fatty acids. We observed that APOA5 
expression is down-regulated by mono- and polyunsaturated fatty acids, while 
saturated fatty acids up-regulate APOA5 expression. The effect of saturated fatty acids 
vs. the effect of polyunsaturated on APOA5 expression was significantly different. Of 
note was that the short-chain fatty acid butyrate increases APOA5 expression almost 
4-fold relative to control cells (no butyrate in the incubation), while APOB is down-
regulated by increasing butyrate acid concentrations. When incubating TC-7 cells with 
a PPARα agonist (Wy 14,643) we observed, as expected from other published studies, 
that APOA5 expression was increased by 60%, while the expression of APOB, MTP 
and APOC3 were decreased by 50, 30 and 45%, respectively.  
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Conclusions from Study 5: For the first time in the published literature, we identified 
APOA5 in tissue derived from human small intestine. We demonstrated that the 
expression of APOA5 can be modulated by dietary and pharmacological stimuli, and 
that its concentration is inversely correlated with the APOC3 gene. 
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Circulating TG levels have been repeatedly proposed as an independent risk factor for 
cardiovascular disease; a disease that is currently one of the main causes of death in 
industrialized countries. Plasma TG levels are strongly influenced by environmental 
(diet, lifestyle habits...) and by genetic factors. The main objective of this thesis was to 
contribute to the knowledge of TG metabolism modulation, through the study of APOA5 
gene which has been described as an important gene in lipid metabolism, chiefly in the 
regulation of TG levels. We have hypothesized that its influence may affect other 
aspects tightly linked to TG metabolism, such as vitamin transport and medication-
induced hypertriglyceridemia. Since apo A-V modulates TG levels, we also 
hypothesized that its expression would be modulated by dietary elements and, as such, 
should be identifiable in the intestine. 
 
As mentioned earlier in the Introduction section, distinct polymorphisms in the APOA5 
have been recently identified as having strong influence on TG metabolism leading to 
increases the plasma levels in a wide range of human populations, and with some 
differences with respect to ethnicity and gender (250). Using association studies, our 
purpose was to contribute to the knowledge of APOA5 on lipid metabolism. For this we 
evaluated the -1131T>C promoter variant, which has been widely used as a genetic 
marker, in populations with different metabolic background with well-characterized lipid 
and lipoprotein profiles. Also, we conducted pharmaco-genetic studies to detect 
potential interactions between the gene and drugs affecting TG levels.  
 
Initially, we confirmed the association of the gene with parameters of the lipid 
metabolism by analyzing the prevalence and effect of the rare allele in two populations 
with different metabolic background (healthy males and patients with type 2 diabetes) 
in whom comparable information was available: complete lipid, lipoprotein and 
apoprotein profiles together with detailed oxidative status parameters. 
Results from both studies confirmed what has been published by others i.e. APOA5 
significantly alters parameters related to TG metabolism even in healthy individuals. 
We described that the elevations of plasma TG are due to an elevation of TG content 
of the VLDL fraction. 
In general, an increase in circulating TG levels result from an increase in the hepatic 
synthesis or by inhibition of the hydrolytic activity by LPL. Although the precise function 
of apo A-V has not, as yet, been clarified, the published literature (153, 156, 165) 
indicates that it may affect triglyceride-rich lipoprotein (TRL) lipidation, synthesis and 
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secretion processes as well as its catabolism and the clearance of its remnants from 
circulation. Therefore, it is likely to be involved in all important steps of TRL 
metabolism. From our results we can speculate that synthesis and clearance 
mechanisms may be involved in the TG-elevating effect. This is based on our findings, 
firstly, that healthy male carriers of the C allele have higher circulating apo B levels 
which is indicative of the amount of circulating TRL particles. This can be the result of 
increased synthesis, decreased catabolism, or both. The increased concentrations of 
FFA may support the possibility of increased synthesis since they are known to 
stimulate VLDL synthesis and secretion in the liver. Secondly, in both populations we 
found increased levels of apo C-III in plasma, which is an inhibitor of the TG-hydrolytic 
activity of LPL. Increased TG associated with the C allele is accompanied by increased 
apo C-III. Since the TG/apo C-III ratio is not different between genotypes, this would 
appear to be a consequence of the high TG, rather than a cause. Finally, the higher 
levels of apo B-containing lipoproteins in healthy subjects who are carriers of the -1131 
C allele could probably explain why we detected an association with cholesterol levels 
in VLDL and LDL fractions when not differences between genotypes were observed 
with respect to total cholesterol levels. 
In agreement with our results are several publications describing the association with 
lipid metabolism, most of them showing the significant effect on TG levels, and with 
some discrepancy when evaluating other lipid metabolism parameters such as total 
cholesterol, HDL cholesterol, and circulating apolipoproteins levels. A certain 
discrepancy may be expected since the studies were performed in different population 
samples. The probably indicates, as has been proposed by other authors, that apo A-V 
influence on lipid parameters is highly dependant on other factors such as ethnic 
origins, metabolic background, gender, treatment, etc.  
In support of our observations are the results from the Framingham Study population 
(101) describing significant associations with increased total cholesterol and TG levels, 
cholesterol from LDL particles, presence of remnant particles, higher amount of 
intermediate VLDL particles and smaller LDL size, and increased circulating apo B and 
apo A-I levels.  
The apo B levels are indicative of the amount of circulating particles which likely reflect 
the influence of apo A-V on synthesis and secretion of the TRL or, alternatively, an 
influence on their clearance from circulation; both aspects being influenced by APOA5 
gene. With respect to the association between APOA5 and particle diameter, it is likely 
to be a consequence of the effect that TG have on CETP and, therefore, not directly 
linked to APOA5. 
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Other studies have published significant effects between APOA5 gene variants and 
HDL-cholesterol levels (234, 183, 190). It is reasonable, taking into account that the 
mechanism by which apo A-V mediates changes in TG concentrations could also affect 
HDL metabolism due to the well-documented strong inverse correlation existing 
between TG and HDL levels (see Introduction section) to detect differences with 
respect to genotype and circulating apo A-I levels. We have also described an 
association with apo C-III levels (indicative of the degree of inhibition of TG hydrolysis 
in circulation) resulting in increased TG levels, and with a higher concentration of total 
fatty acids related to increased VLDL production rate by the liver. Therefore, the effect 
on TG and apo B levels may be directly linked to APOA5, while the association with 
apo A-I, particle size, HDL and apo C-III concentrations are probably a consequence 
since, on adjusting for TG in multivariate analysis, most of these associations 
disappear. 
 
We have been the first to describe that this effect on TG metabolism is accompanied 
by increased circulating vitamin E concentrations (in both our study populations with 
different metabolic backgrounds) but which do not relate to any differences in oxidative 
status. 
Vitamins are essential organic micronutrients required at quite low concentrations for 
various physiological functions such growth and the nutritional balance that defines 
health. Vitamins are divided into two groups depending on their solubility: fat-soluble 
(A, D, E, K) and water-soluble vitamins (B, C). 
Fat-soluble vitamins are absorbed from the diet and, due to their hydrophobic nature, 
require proteins or lipoproteins for their transport in circulation. This implies that fat-
soluble vitamins are strongly correlated with serum lipid parameters and which led us 
to hypothesize that genetic markers associated with lipid parameters would also be 
associated with fat-soluble vitamin levels. There are few studies describing lipid-related 
genetic markers associated with levels of fat-soluble vitamins in circulation. When we 
commenced our study, only Ortega et al (276) had described an association between 
apo E genotype and circulating vitamin E levels in Spanish children. Since our study 
was published, Borel et al (277) described a significant association between SNPs in 
some genes related to lipid metabolism (APOA4, APOB, APOE, LPL, SR-BI) on 
vitamin E and carotenoids levels in subjects displaying moderate risk for cardiovascular 
disease. 
 
Our population sample composed of healthy males was part of the VITAGE Project 
(Contract QLK1-CT-1999-00830) (278) which was designed to evaluate the status and 
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metabolism of vitamin A, vitamin E, and carotenoids during ageing; the rationale being 
that ageing is often associated with degenerative diseases such as certain cancers, 
neurological disorders and cardiovascular diseases. The main objective was to provide 
evidence regarding changes in status, metabolism, and function of fat soluble vitamins 
during non-pathological ageing. Thus, in our healthy population we could also evaluate 
the potential association between APOA5 gene polymorphism and other fat soluble 
vitamins (vitamin A, α-carotene, β-carotene, lycopene, lutein, criptoxanthine and 
zeaxanthine), as well as tocopherols (data not published). Among the fat-soluble 
vitamins studied, the APOA5 gene was associated only with α-tocopherol. There was 
no significant effect with respect to any other vitamins including the vitamin E isoform γ-
tocopherol. Carriers of the C allele had 9.1% higher vitamin E levels in healthy men 
and 11.3% higher levels among diabetic patients. 
We speculate that APOA5 is not associated with the other fat-soluble vitamins studied 
because vitamin A is transported with retinol binding protein which is not strongly linked 
to lipoprotein metabolism. The other vitamins are found at very low concentrations in 
circulation (less than one µmol/ L) and, as such, it is possible that there may need to be 
great differences for the differences to reach statistical significance. However, it cannot 
be ruled out that such association may exist in a larger population sample. 
Vitamin E correlates strongly with TG metabolism which is regulated by APOA5 gene 
and this may point to why APOA5 may be having an impact on plasma vitamin E 
plasma levels. Vitamin E is a fat-soluble antioxidant molecule comprising eight different 
isoforms, including α-, β-, γ-, and δ- tocopherols and tocotrienols. The vitamin E 
isoforms are absorbed equally with dietary lipids and enter the circulation via the 
chylomicrons from which the action of LPL is to transfer the vitamins to extra-hepatic 
tissues in the course of TG hydrolysis, and with the phospholipid transfer protein 
exchanging them between different lipoprotein classes. When the vitamins reach the 
liver, the α-tocopherol transfer protein preferentially recognizes the α-tocopherol forms 
incorporates them into VLDL particles. The other vitamin E forms are excreted into bile, 
metabolized and excreted into urine (see Figure 15). Consequently, α-tocopherol, 
which also shows the highest biologic activity, is the major form of vitamin E in human 
plasma and tissue. Hence, from what we have summarized on APOA5 (see 
Introduction section), the most important steps in vitamin E metabolism may be 
influenced by APOA5 gene variants. 
We found that the hypertriglyceridemic effect of APOA5 is explained, mainly, by an 
effect on VLDL fraction. APOA5 also induces higher levels of α-tocopherol, which is the 
isoform of vitamin E preferentially selected in the liver to enter circulation incorporated 
within VLDL particles.  
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Figure 15. Representation of vitamin E metabolism; α-, β-, γ-, δ- are different vitamin E isoforms; α-TTP= 
alpha tocopherol transfer protein. 
 
To summarize, C allele carriers have higher amounts of circulating TG levels and 
number of TRL particles which have been linked to a greater cardiovascular risk. 
Conversely, higher amounts of vitamin E have been inversely correlated with mortality 
from ischemic heart disease (279). This is perhaps explained by the best-known 
function of vitamin E which is to scavenge reactive oxygen species, i.e. inhibiting lipid 
peroxidation, a physiological phenomenon well-documented as being directly involved 
in cardiovascular disease development.  
We expected to find differences in lipid peroxidation parameters that had been 
measured in our two population samples (in the healthy population sample we had data 
from plasma malondialdehyde, LDL dienes formation, F2 isoprostanes, plasma total 
peroxides, glutathione peroxidase and urinary deoxyguanosine (data not published). In 
the diabetic population sample we had data from LDL dienes formation, lipoperoxides, 
LDLox and antibodies for LDLox-. In both populations the increased vitamin E 
concentrations associated with the C allele did not alter the individual antioxidant 
capacity. Our results are not in accordance with those of Jang et al (92) who found that 
C allele carriers had significantly higher levels of CRP, F2 isoprostanes and DNA 
damage. The population reported by Jang et al included smokers, while our population 
samples were composed entirely of non-smokers, a situation that significantly affects 
the oxidative status of the subject. Also the different genetic backgrounds, as 
evidenced by the marked differences in the frequency of this particular polymorphism 
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(approx 0.08 vs. 0.28 in Spanish and Korean populations, respectively), is likely to be a 
major factor in explaining the differences observed.  
The lack of differences in the antioxidant capacity in relation to higher vitamin E levels, 
may be explained by the strong linkage that exists between vitamin E and TG. There is 
an increase in the amount of the oxidative substrate (TG) but also an increase in the 
amount of the antioxidant (vitamin E). This was confirmed by normalizing vitamin E for 
different lipid parameters and the lipid/vitamin E ratios remaining the same in plasma 
as well as the LDL fraction. 
The differences in the absolute amounts of circulating vitamin E may be important due 
to the various functions of vitamin E, independently of their antioxidant capacity. For 
example, vitamin E also acts as an intracellular trafficking signal, as a genetic regulator 
modulating the expression of genes involved in tocopherol uptake and degradation (α-
TTP, CYP3A, …), on genes involved in lipid uptake and arteriosclerosis (SR-BI, CD36, 
…), on genes modulating extra-cellular proteins such as metalloproteinases, on genes 
involved in cellular adhesion and inflammation (ILs, ICAM1, …), and also on genes of 
cellular signaling and cell cycle (PPARγ, cyclines, …). Finally, vitamin E also 
contributes to anti-inflammatory and immunological mechanisms (reviewed by Azzi A. 
(280, 281). Is likely that this findings may involve, as has been recently published,  apo 
A-V with inflammation (167, 168) and, as such, contributing via different mechanisms, 
to the development of cardiovascular  disease. 
 
 
From the literature and from our own results (182), -1131T>C gene variant predispose 
to hyperTG and that the higher the stimulus, the higher the response of the variant. We 
confirmed these observations with the healthy as well as the diabetic patient sample. 
One potent inducer of hyperTG is the exposure to certain drugs/medications such as 
protease inhibitors. Hence, following our study of APOA5 gene variants in relation to 
lipid metabolism, we hypothesized that the APOA5 -1131 T>C gene marker would 
influence TG metabolism in HIV-infected patients receiving anti-retroviral therapy. We 
explored this possibility in a pharmaco-genetic study involving 229 HIV-infected 
patients followed-up over 5 years. When we initially analyzed the results of the 
genotyping, the APOA5 variant did not appear to have a significant effect on TG 
metabolism. However, when the subgroup of patients receiving protease inhibitors (PI) 
was considered separately, it became evident that carriers of the -1131 C allele were at 
much higher risk of developing severe and sustained hypertriglyceridemia, leading to 
the worsening of their lipid profile. Of note is that all patients had similar values for TG 
and cholesterol levels when commencing their treatment but, following anti-retroviral 
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treatment for one, two and three years, we detected significant differences among C 
allele carriers treated with PI, compared to the rest of the patient group. Numerically, 
this implies that C allele carriers have at the end of 1 year of PI treatment, a mean of 
43% higher TG levels and 16% higher total cholesterol levels. After 3 years of 
treatment these levels are 44% and 20% of TG and cholesterol, respectively. Of note is 
that the patients carrying the C allele but not receiving PI therapy had lipid levels that 
were similar to carriers of the wild type allele. 
In general, elevated lipid levels may be explained by increased lipoprotein synthesis, or 
the decrease in lipoprotein catabolism, or a combination of both. The protease inhibitor-
related hyperlipidemic effect is, in part, mediated by a direct interaction between the 
medication and the sterol regulatory element-binding protein (SREBP); one of the 
regulatory elements in the expression of certain genes involved in the lipid metabolism, 
resulting in an increased lipoprotein synthesis (282). APOA5 is one of the target genes 
for the SREBP, but the mechanism by which it strongly regulates TG levels is still 
unclear. Apo A-V has been shown to influence VLDL synthesis and secretion in the 
liver and, as well, to stimulate TRL catabolism via the clearance of remnants from the 
circulation. As such, the likely alteration in the apo A-V protein activity due to the 
presence of the -1131T>C variant (181) may be responsible, at least in part, for the 
hyperlipidemic phenotype observed in the HIV patients treated with PI (see Figure 16 


















Figure 16. SREBP transcription factors recognize the response element in APOA5 gene promoter 
sequence and inhibit its transcription. The amount of SREBP in the nucleus is controlled by specific 
cleavage, and enabling an appropriate apo A-V production rate. Once in cytoplasm, apo A-V could control 
VLDL synthesis and secretion, or stimulate the uptake of circulating remnants. Protease inhibitors bind to 
the SREBPs preventing their specific cleavage. Hence, we postulate that SREBPs are accumulated in the 
nucleus during the anti-retroviral therapy and suppress longer APOA5 gene transcription. This could result 
in a greater VLDL synthesis and secretion process, or to a lower stimulation of remnant uptake. The 
outcome would the development of the dyslipidemia observed in HIV-patients treated with PI. 
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It is well documented that HIV-patients receiving anti-retroviral therapy have an 
increased risk for cardiovascular disease due to the metabolic complications 
associated with their treatment (283). Because the atherogenic ratio (total 
cholesterol/HDL-cholesterol) in our study sample reached the highest quintile of risk 
among the C allele carriers treated with PI, we decided to assess whether the presence 
of the atherogenic dyslipidemia due to the APOA5 polymorphism was indeed involved 
in raising the cardiovascular disease risk. We measured the endothelial intima and 
media thickness (IMT) in the aorta of these patients at two different time-points of 
follow-up. The IMT has been widely described as a surrogate measure of the 
atherosclerosis burden (284). We did not find any statistically significant differences in 
relation to genotype (unpublished results) but we believe that this may be explained on 
the measurements having been conducted within too short a follow-up period. Our 
highly significant findings of association between APOA5 with the atherogenic lipid 
profile had been observed after three years of treatment and, as such, perhaps 
significant differences in IMT would, as well, become more evident after a similar 
period of treatment of three years or more .  
In support of this assumption are the findings in a subgroup of the Framingham study 
population of APOA5 gene variations being significantly associated with carotid artery 
IMT; the effect being influenced by obesity (174). However, in a smaller population 
composed of FCHL families, no significant association was found between IMT values 
and -1131T>C or S19W APOA5 gene markers (172). Further, with respect to the 
negative association between APOA5 gene marker and the sub-clinical atherosclerosis 
measured in our HIV population sample, we need to take into account that the 
relationship between A5 and the CVD risk has been studied over the long-term, and  
the results are far from consistent (see Introduction section). 
A similarly designed study involving HIV patients was published in 2007. Several 
selected genotypes from different key genes for the lipid metabolism (ABCA1, APOA5, 
APOC3, APOE, CETP, LPL, MTP, and TNF among others) were studied in a group of 
HIV patients treated with antiretroviral therapy for almost five years. The objective was 
to identify associations between the lipid parameters and genetic variants. The 
conclusions from the study were that APOA5 gene, together with variants in ABCA1, 
APOC3, APOE and CETP genes, contributed to the dyslipidemia linked to the 
antiretroviral therapy (242). 
 
To summarize: all classes of drugs/medications used as antiretroviral treatment have 
been associated with atherogenic changes in the patients’ lipid profile (285). Even 
though antiretroviral therapy has been associated with other well-documented risk 
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factors for cardiovascular disease, the accumulation of TRL remnant particles (286) 
over the extended chronic administration of this treatment and the presence of a key 
genetic variant would exacerbate this pro-atherogenic status. Our results, and their  
confirmation, would suggest that the measurement of APOA5 be used as a marker for 




The role of APOA5 as a modulator of the metabolic derangements associated with  
drug treatment is supported by another recent pharmaco-genetic study evaluating 
APOA5 gene variants and their effects on fenofibrate treatment.   
Fibrates have been the main option over several decades for the treatment of 
hypertriglyceridemia. The molecular mechanisms underlying the lipid lowering effects 
are still unclear but it is understood that fibrates activate one isoform of the nuclear 
receptor peroxisome proliferator-activated receptor (PPARα) that modulates the 
expression of genes. APOA5 is one of the target genes for PPARα and, in 
hepatocytes, its expression is stimulated by PPARα agonists (Wy14643, fenofibrate or 
GW9003). As such, of interest would be the action of fibrates on TG metabolism and 
their modulation by APOA5 gene variants. This was the main objective of the study by 
Lai et al (224). They reported an association between 2 common variants in the 
APOA5 gene (-1131T>C and 56C>G) and TG and HDL-cholesterol plasma 
concentrations (at baseline and postprandial) in response to fenofibrate treatment in 
791 subjects from a general population (GOLDN Study). Their results showed that 
subjects with APOA5 -1131T>C genotype have no significant differences in response 
to fenofibrate therapy. Conversely, carriers of the G allele of the 56C>G genotype have 
a greater ability to decrease TG and increase HDL-cholesterol in response to the 




Despite all the evidence showing association between APOA5 and the predisposition 
to hyperTG, very little is known about the underlying function. This is aggravated by the 
overall data on plasma apo A-V and TG levels. Most evidence from population 
association studies and animal model data show a consistent inverse correlation 
between apo A-V and circulating TG concentrations but which, on occasion, has been 
shown to be positive or even non-existent. Different possibilities have been invoked to 
explain these contradictory findings. The lack of sensitivity of the measurement of very 
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low concentrations of apo A-V in circulation may be responsible of this disagreement 
but also the possibility that apo A-V may be recycled (157) would suggest that the great 
differences between the amount of protein and the lipoproteins is not so critical. Also 
apo A-V may not be the key factor relating to the TG levels observed (220, 225, 254) 
since these associations may be explained by a strong linkage disequilibrium (LD) with 
other genetic variants of the APOA1/C3/A4 gene cluster. Finally, the results from 
animal models should be interpreted with caution since different regulators may be 
specific for different species. However, we and others, believe that the role of apo A-V 
may be identified within cells, rather than in plasma. 
We planned two studies to explore this option, but which did not focus on its effect on 
TG levels. We then proceeded to investigate the function of APOA5 using animal 
models and cell culture experiments. 
 
In 2006 we studied the effect of an atherogenic diet on hepatic APOA5 expression 
using the APOE deficient mouse model which, when administered a Western-type diet, 
develops atherosclerosis. 
We described, in the article published in Clínica e Investigación en Arteriosclerosis that 
the mice, when fed a diet rich in saturated fat, had a 50% decrease in the hepatic 
expression of APOA5 compared to wild-type mice and that the effect was attenuated 
when the diet was supplemented with cholesterol.  
The exact mechanism by which dietary fatty acids or cholesterol could modulate the 
hepatic expression of APOA5 gene in APOE deficient male mice is unclear, but it is 
consistent with the regulatory role that certain nuclear transcription factors exert on 
APOA5 gene i.e. most of them are activated by either fatty acids, or cholesterol, or 
both. As we have seen earlier in the Introduction section, APOA5 gene expression is 
regulated by many transcription factors known to affect TG metabolism (287) such as 
peroxisome proliferator-activated receptor (PPARα), sterol regulatory element binding 
protein (SREBP), liver X receptor (LXR), hepatocyte nuclear factor 4-α (HNF-4α) and 
retinoic acid receptor-related orphan receptor-α (RORα), among others. The main 
features of each of these nuclear receptors have already been commented-upon 
previously. 
Many published studies reinforce the assumption that APOA5 gene may be modulated 
by dietary components.  
Firstly, several studies in humans have evaluated whether the relationship between 
dietary composition and plasma lipids are genetically determined by the APOA5 gene. 
Ordovas has reviewed all these studies (288) and highlighted that APOA5 is a major 
gene involved in TG metabolism and the effect is modulated by dietary factors, mainly 
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the fat composition. Some studies conducted in animal models also described a 
modulatory effect of dietary components on APOA5 gene expression, or on A-V protein 
levels. A recent (289) indicated that, in normal mice, oxidized fatty acids, which are 
also ligands for PPARα, decreased TG levels in plasma and, as expected, increased 
APOA5 gene expression and decreased APOC3 gene expression via a PPARα-
independent mechanism. In Zucker rats, an animal model for hypertriglyceridemia and 
insulin resistance, the modulatory effect of ω-3 PUFA on APOA5 expression is 
mediated via SREBP-1 nuclear factor. However, in this case,  mechanism proposed is 
that of co- or post-translational regulation, since liver and plasma apo A-V were not 
affected (290). The administration of squalene, an intermediate in the biosynthesis of 
cholesterol biosynthesis, for 10 weeks in APOE deficient mice has an impact on 
APOA5 gene expression and protein levels in a gender-dependent manner (291) i.e. in 
males, squalene significantly increases APOA5 gene expression in liver and decreases 
the hepatic fat content. The plasma TG levels were unaffected. In females, the hepatic 
expression of APOA5 was slightly increased, the fat content was unaffected, and there 
were lower levels of TG and the number of VLDL particles. 
 
After we had observed the effect of a diet rich in saturated fat on hepatic expression of 
APOA5 (the down-regulatory effect reached the 75% in youngest mice) we measured 
the levels of circulating lipid, specially TG levels since, with a genetic background of 
100% decrease in APOA5 gene expression (in KO-APOA5 mice), the TG levels have 
been described as being 4 times higher relative to wild type mice (149). Of note is that 
we found no variation in plasma TG levels among the different animal groups in relation 
to the type of diet. It is important, however, to highlight that the defect of APOE gene 
leads to a substantial intra-cellular accumulation of lipids, especially TG, due to 
impairment of VLDL-TG secretion (292) and, as such, any potential influence of the 
APOA5 gene on VLDL secretion system would be altered. 
 
Another result of note was the significant increase in APOA5 gene expression in 
relation to age in all animals, irrespective of the type of diet received. An explanation 
for this observation could be that this animal model, when fed an atherogenic diet, 
develops inflammation, atherosclerosis, and severe steatosis with advancing age and 
which can account for hepatic lipid accumulation (293). As such, the increase in 
APOA5 expression with age would be a reflection of the age-related deterioration of the 
liver. 
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We published data indicating that APOA5 expression in the liver of APOE deficient 
mice was correlated with inflammatory parameters; the relationship between APOA5 
and inflammation having already been established. APOA5 gene has been studied in 
relation to acute-phase response (the cascade of reactions triggered by inflammation 
or infection) leading to increased TG levels and decreased HDLc levels in plasma. Apo 
A-V has been identified as a positive acute-phase protein which increases in plasma 
during inflammation induced by endotoxin-injected mice (167). A more recent study 
described a biphasic behavior with time of APOA5 gene expression in human hepatic 
HepG2 cells incubated with pro-inflammatory cytokines (tumor necrosis factor, TNFα; 
or interleukin, IL1β) and, as well, of plasma apo A-V and hepatic levels in mice injected 
with lipopolysaccharide; the result being an early decrease in mRNA and protein levels 
followed by a significant increase subsequently (168). 
Secondly, we published data indicating that APOA5 expression in the liver of APOE 
deficient mice was correlated with the arteriosclerosis lesion area and, the correlation 
between APOA5 gene and the atherosclerotic lesion area was documented. This would 
make sense in the light of the data from association studies describing a significant 
effect on CHD incidence and/or prevalence (89, 188, 189, 211, 233, 236). 
Thirdly, steatosis is the most common liver disease in industrialized countries. It is 
present in one third of the general population, and the incidence increases in patients 
with risk factors for cardiovascular disease and metabolic syndrome. The steatosis 
represents the hepatic consequence of relative over-nutrition and altered dietary 
composition, within the setting of sedentary behavior. During steatosis, there is up to a 
10-fold accumulation of TG relative to normal. This could be due, among other 
explanations, to a greater fatty acid mobilization to the liver, or a diminished fatty acid 
oxidation, or increased intra-hepatic synthesis of fatty acids, TG or lipoproteins. The 
liver has the capacity to regenerate itself in response to cellular damage (294) and the 
energy necessary for this regeneration is obtained from lipids that have been 
accumulated during the first hours of the damage-limitation process; a period when 
APOA5 gene has been described, in the liver of a rat model of hepatic regeneration as 
being up-regulated more than 3-fold.  
As such, we believe that the hepatic alteration undergone by APOE KO mice fed with 
atherogenic diet is responsible of the increase in the expression of APOA5, as has 
been postulated for the control of lipid uptake by the liver during the hepatic 
regeneration.  
In conclusion, APOA5 gene expression is affected by dietary components in the APOE 
KO mouse and that it is correlated with inflammatory parameters and/or atherosclerosis 
lesions. 
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With the APOA5 gene potentially implicated in steatosis development, we proceeded to 
analyze the hepatic APOA5 gene expression in 65 rats that received intra-peritoneal 
injections of 0.5 ml of carbon tetrachloride (CCl4) diluted 1:1 (v/v) in olive oil 
(unpublished data). CCl4 activates collagen synthesis, promotes fibrosis and steatosis 
in the liver via its effect on the morphology and/ or function of the lipoproteins which, as 
a result, fail to act as efficient vehicles for the transport of lipids from the liver into the 
circulation (295). We found that APOA5 expression following CCl4 administration was 
30% higher than in control rats (p=0.019). Of note is that we found that hepatic APOA5 
expression levels were strongly and positively correlated with APOB expression levels, 
and inversely correlated with circulating cholesterol and TG levels in rats under CCl4 
exposure in a steatotic state. This suggests a role for APOA5 in the control of TRL 
release from the liver, as has been postulated in rats in the liver regeneration process 
(150).  
 
Finally, to investigate further the function of apo A-V we designed studies for conduct in 
human intestinal tissue samples, and in human intestinal-cell culture.  
The data published to-date regarding apo A-V levels in circulation suggested that its 
main function occurs predominantly at the intra-cellular level. Thus, in view of the 
results of the regulatory effect of dietary fat on APOA5 expression in the liver, our 
purpose was to test whether we could also find APOA5 expression in the other key 
organ for the lipoproteins synthesis, the intestine and which is also involved in the 
processing of dietary components. 
We studied APOA5 gene, together with other genes involved in synthesis and 
secretion of TRL in intestine and liver (APOB and MTP) and in the metabolic regulation 
of TRL (APOC3). We used tissue samples from human intestine, and also in vitro 
culture of intestinal cells. We have been able to detect APOA5 gene expression and 
protein in human intestine. However, our results do not agree with published data (149, 
150, 261) evaluating APOA5 in different animal tissues and/or different cell cultures. 
The conclusion for such data was that APOA5 is only expressed in the liver. This 
divergence of findings could be the result of methodological differences. 
 
Initially, we analyzed the expression of the genes in the different intestinal tissue 
sections and found that each gene is differentially expressed along the extent of the 
intestine with APOA5 expressed mainly in duodenum and colon, and where significant 
and inverse correlation was observed with APOC3 gene expression. Apo A-V and apo 
C-III, two members of the apolipoprotein gene cluster on chromosome 11, are 
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considered to play antagonistic roles in the metabolism of TRL, at least in mice (296, 
297, 149, 298), but our results suggest that this may also be valid in humans. Also, we 
found that APOA5 and C3 gene expression are inversely correlated in the in vitro 
model of human intestinal cells. 
We further compared the expression levels measured in the intact human small 
intestine samples and samples obtained from human liver, and found that APOA5 gene 
is expressed about 3x104-fold lower in intestine. However, our calculations indicate that 
the protein level in intestinal cells is about one third that detected in human hepatic 
cells. An explanation for these differences between hepatic and intestinal expression 
levels can be based on the postulated functions of apo A-V i.e. the regulation of TRL 
synthesis and/or secretion processes would be more important in the liver since this 
organ is key in the control of lipid homeostasis and, as well, it is the liver that is 
responsible for uptake of remnants from the circulation via the LDL-R family. 
 
Secondly, we observed that APOA5 is expressed at low levels in human intestine. To 
obtain further evidence of the possible functionality of APOA5 gene in human small 
intestine we developed a series of experiments TC-7 cells from human colon 
carcinoma, a well-established intestinal cell model. The objective was to test whether 
the low expression levels are potentially affected by factors known to modulate TG 
levels, such as dietary fatty acids or a PPARα agonist. Hence, we tested different 
concentrations of long-chain fatty acids (known specific ligands for PPAR nuclear 
transcription factors to which APOA5 is responsive) on intestinal APOA5 expression in 
the CaCo2 / TC-7 cell model. We observed that monounsaturated and polyunsaturated 
fatty acids tended to decrease intestinal APOA5 expression while saturated fatty acids 
tended to increase the expression. This would imply that apo A-V would down-regulate 
intestinal lipid mobilization in a situation of high saturated fat intake.  
However, this is does not accord with what we had reported from APOE-KO mice 
studies in which we observed that saturated fat significantly decreases hepatic APOA5 
gene expression. One possible explanation for this discrepancy could be that the same 
stimuli produce different effects on gene expression and, as has been described for 
APOA1 gene (299), would depend on the tissue being explored. Also, we need to take 
into account that some difference could be expected when results in genetic modified 
mice are compared to those obtained in humans. 
Since APOA5 gene was relatively high transcribed in colon, we proceeded to assess 
the modulatory effect of short-chain fatty acids (e.g. butyrate) on intestinal APOA5 
expression. Over recent years the colon has come to be considered as a digestive 
organ, since bacterial fermentation takes place here in eliminating substrates that have 
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not been digested by human enzymes within the small intestine. These substrates 
include the dietary soluble fibers. Short-chain fatty acids are generated as a result of 
this fermentation in the colon, and these have important functions in relation to energy 
production, lipid and glucose metabolism. The three main short-chain fatty acids are 
acetate, propionate and butyrate. Acetate is the primary substrate for cholesterol 
synthesis but propionate which has hypolipidemic effects inhibiting cholesterol 
synthesis may also be generated (300). As such, the serum acetate : propionate ratio 
is positively related to serum cholesterol levels (301). With respect to lipid metabolism, 
butyrate has a lowering effect on triglycerides and cholesterol (302), it decreases 
hepatic and intestinal protein expression of apo B, MTP, apo A-I (303) and stimulates 
APOA4 gene expression. The result is an increased in the A-IV protein secretion and, 
as such, a modulation of reverse cholesterol transport (304). 
Butyrate, in our cell culture experiments, induced a 4-fold increase in APOA5 
expression and, as expected, APOB expression tended to decrease with increasing 
concentrations of butyrate. Without knowing the precise function of apo A-V in the 
intestine, we could speculate that the established hypolipidemic effects of butyrate are 
in accordance with the down-regulatory effect on APOA5 gene transcription. 
 
Finally, as expected from results published in human hepatocytes (257), we found that 
APOA5 gene expression in intestinal TC-7 cells is also up-regulated by a PPARα 
agonist (Wy 14643). However APOB, APOC3 and MTP gene expression was 
decreased. The PPARα activated by the agonist hetero-dimerizes with other nuclear 
transcription factors such as retinoid X receptor (RXR), up-regulates LPL and APOA1, 
and down-regulates APOC3 (305) the result of which is a decrease in plasma TG 
concentrations i.e. a combined action of reduced triglyceride synthesis as well as 
increased catabolism.  
 
In summary, our results demonstrate that APOA5 is not exclusively synthesized in the 
liver, but is to by found also in the intestine, where is expressed at low levels and is 
responsive to fatty acids and fibrates. Although the precise intestinal function of apo A-
V is not clear, we can postulate that it may influence the absorption of lipids obtained 
from the diet and which are to be incorporated into chylomicrons in the form of TG. This 
expression occurs mainly in the first third of the intestine where lipid absorption takes 
place. Alternatively, the apo A-V may influence lipidation of chylomicrons or, perhaps, it 
is present in the intestine merely for incorporation into chylomicrons prior to entry into 
the circulation. 
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Increased concentrations of circulating vitamin E in
carriers of the apolipoprotein A5 gene 21131T.C variant
and associations with plasma lipids and lipid peroxidation
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Abstract The aim of this study was to investigate the ef-
fects of the apolipoprotein A5 (APOA5) 1131T.C gene
variant on vitamin E status and lipid profile. The gene vari-
ant was determined in 297 healthy nonsmoking men aged
20–75 years and recruited in the VITAGE Project. Effects
of the genotype on vitamin E in plasma, LDL, and buccal
mucosa cells (BMC) as well as on cholesterol and triglyc-
eride (TG) concentrations in plasma and apolipoprotein A-I
(apoA-I), apoB, apoE, apoC-III, and plasma fatty acids were
determined. Plasma malondialdehyde concentrations as a
marker of in vivo lipid peroxidation were determined. C
allele carriers showed significantly higher TG, VLDL, and
LDL in plasma, higher cholesterol in VLDL and interme-
diate density lipoprotein, and higher plasma fatty acids.
Plasma a-tocopherol (but not g-tocopherol, LDL a- and g-
tocopherol, or BMC total vitamin E) was increased signifi-
cantly in C allele carriers compared with homozygote T allele
carriers (P 5 0.02), but not after adjustment for cholesterol
or TG. Plasma malondialdehyde concentrations did not
differ between genotypes. In conclusion, higher plasma
lipids in the TC1CC genotype are efficiently protected
against lipid peroxidation by higher a-tocopherol concentra-
tions. Lipid-standardized vitamin E should be used to reliably
assess vitamin E status in genetic association studies.—
Sundl, I., M. Guardiola, G. Khoschsorur, R. Solà, J. C. Vallvé,
G. Godàs, L. Masana, M. Maritschnegg, A. Meinitzer, N.
Cardinault, J. M. Roob, E. Rock, B. M. Winklhofer-Roob,
and J. Ribalta. Increased concentrations of circulating vita-
min E in carriers of the apolipoprotein A5 gene 21131T.C
variant and associations with plasma lipids and lipid per-
oxidation. J. Lipid Res. 2007. 48: 2506–2513.
Supplementary key words polymorphism & single nucleotide poly-
morphism & a-tocopherol & g-tocopherol & triglycerides & cholesterol &
plasma fatty acids & lipoproteins
Apolipoprotein A5 (APOA5) is located near the region
of the APOA1/C3/A4 gene cluster on chromosome 11 in-
volved in the regulation of triglyceride (TG) metabolism.
The role that APOA5 plays in such regulation has been
demonstrated extensively in genetically modified animal
models (1–3) and in a large number of association studies
(4–10). Mice overexpressing the APOA5 gene have 65%
lower plasma TG, whereas the APOA5 knockout mouse
develops ?4-fold higher TG concentrations (1). Associa-
tion studies using different APOA5 markers have clearly
shown that apolipoprotein A-V (apoA-V), despite its low
plasma concentrations (11), is probably the strongest deter-
minant of circulating TG concentrations (4–10). The most
frequently analyzed variant is 21131T.C, and the C allele
has been consistently associated with higher TG levels
(4–10). The exact function of apoA-V is not known, al-
though in vitro evidence shows that it may control plasma
TG by downregulating hepatic VLDL synthesis and stimu-
lating LPL activity (1, 12).
Circulating TG are transported within lipoproteins to-
gether with other lipophilic compounds such as vitamin E
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(13). Consequently, TG concentrations are closely related
to vitamin E concentrations, resulting in higher plasma
vitamin E concentrations in hyperlipidemic subjects com-
pared with normolipidemic subjects when not corrected
for plasma lipids (14).
Vitamin E is an essential fat-soluble nutrient compris-
ing eight different isoforms, including a-, b-, g-, and y-
tocopherols and their respective tocotrienols, which differ
in both number and position of methyl groups on the
chroman ring and in having a saturated (tocopherols)
or unsaturated (tocotrienols) side chain. Together with
dietary lipids, all of these vitamin E isoforms are absorbed
equally from the gastrointestinal tract and secreted into
chylomicrons. In the liver, the a-tocopherol transfer pro-
tein preferentially recognizes RRR-a-tocopherol for incor-
poration into lipoproteins, whereas the other vitamin E
forms are excreted into bile and metabolized and excreted
into urine (15, 16). Consequently, a-tocopherol, which also
shows the highest biologic activity, is the major form of
vitamin E in human plasma and tissue.
The best known function of vitamin E relates to its ca-
pacity to scavenge reactive oxygen species, thus acting as a
chain-breaking antioxidant inhibiting lipid peroxidation.
As an example, a-tocopherol inhibits LDL oxidation ini-
tiated by copper ions in an ex vivo model (17). Beside
these antioxidant actions, vitamin E also possesses anti-
inflammatory functions, such as inhibition of platelet ad-
hesion, inhibition of monocyte proatherogenic activity,
and improvement of endothelial functions (18).
Transfer of circulating vitamin E from lipoproteins into
tissue is regulated by mechanisms that also control lipid
metabolism. The enzyme LPL is able to transfer tocopherols
during TG hydrolysis to extrahepatic tissues (19), whereas
the phospholipid transfer protein exchanges a-tocopherol
between different lipoprotein classes (20). Furthermore,
vitamin E transported in LDL is delivered to cells via a
receptor-mediated uptake of LDL (21). Consequently,
lipid, lipoprotein, and vitamin E concentrations correlate
strongly with each other, indicating that their metabolic
pathways are tightly linked. Therefore, it is conceivable that
environmental and genetic factors affecting lipid metabo-
lism would affect vitamin E status.
The hypothesis of the present study was that the APOA5
genotype not only influences lipid metabolism but, as a
result of the mechanisms described above, also alters vita-
min E metabolism in humans. To test this hypothesis, we
investigated the effects of the APOA5 variant 21131T.C
on lipid status in a population of 297 healthy male non-
smoking subjects aged 20–75 years and whether these
changes have repercussion on vitamin E status. A detailed
lipoprotein profile, including total lipids and apolipo-
proteins plus the lipid and apolipoprotein contents of all
lipoprotein fractions, was determined along with vitamin E
concentrations in plasma, LDL, and buccal mucosa cells
(BMC). In addition, we studied the effects of the APOA5
variant-associated differences in vitamin E and lipid status
on malondialdehyde, a biomarker of in vivo lipid peroxi-
dation, which has been used successfully in patients with
increased plasma lipids (22).
METHODS
Study subjects
In this cross-sectional study, 299 healthy male nonsmoking
subjects (0 cigarettes/day for .6 months), aged 20–75 years
(stratified by age), were recruited in Clermont-Ferrand, France
(n 5 99), Graz, Austria (n 5 100), and Reus, Spain (n 5 100) as
part of the European Commission-funded research and technol-
ogy development project of the 5th Framework Program, specific
research and technology development Program Quality of Life
and Management of Living Resources, Key Action 1, Food, Nutri-
tion, and Health, entitled Vitamin A, Vitamin E, and Carotenoid
Status and Metabolism during Ageing: Functional and Nutri-
tional Consequences, acronym VITAGE (Contract QLK1-CT-
1999-00830) (23). After informative sessions, a trained medical
doctor conducted a personal interview to obtain information on
anthropometric measurements, personal history, lifestyle, use of
medications, physical activity, smoking habits, and use of dietary
supplements containing vitamins or trace elements. Exclusion
criteria were familial hypercholesterolemia, chronic diseases
(including diabetes, cancer, cardiac insufficiency, neurological
diseases, inflammatory diseases and chronic diseases of the liver,
lung, or thyroid, nonstable hypertension, dementia, and infec-
tious diseases known to affect the immune system, such as human
immunodeficiency virus and hepatitis C), vaccination during the
past 2 months, alcoholism or drug addiction, competitive sports
activities, and the consumption of special diets or dietary sup-
plements in the past 3 months. The study protocol was approved
by the Ethics Committees of the three recruiting centers, and
written informed consent was obtained from all participants.
Sample collection
Collection of blood samples and preparation of plasma and buffy
coats. After an overnight fast, venous blood was drawn into plastic
tubes containing EDTA to obtain EDTA plasma (Sarstedt, Ltd.,
Nümbrecht, Germany), protected from light, and centrifuged
immediately at 1,500 g at 8jC for 10 min. Plasma was separated
and divided into aliquots. For LDL isolation, a 60% sucrose solu-
tion was added to plasma to obtain a final concentration of 0.6%
(24). For genomic DNA isolation, buffy coat was collected from
blood drawn on EDTA. All samples were stored at 280jC until
determination of analytical variables.
Collection of BMC. After rinsing the mouth with drinking
water, BMC were collected as described by Gilbert et al. (25).
Briefly, study subjects were asked to brush the inside of their
cheeks with a soft toothbrush 20 times on one side and rinse the
mouth with 25 ml of isotonic table salt solution (0.9% sodium
chloride) and then repeat the procedure on the other side. The
two rinsing volumes were collected in a single tube and cen-
trifuged at 1,400 g for 10 min at 4jC. The supernatant was
discarded, and the cell pellet was washed with 15 ml of cold
phosphate-buffered saline solution. After vortexing, the sample
was centrifuged as above and the supernatant was removed. The
cell pellet was resuspended in 1.2 ml of cold PBS, flushed with
nitrogen, and stored at 280jC until determination of vitamin E.
Five day food records. For dietary assessment, subjects recorded
all food items and drinks consumed during a 5 day period. On
the basis of these food records, the intake of total fat, saturated
fatty acids (SFA), MUFA, and PUFA was calculated. For calcu-
lation of nutrients, the REGAL food composition tables (26, 27)
and the software package of the Austrian food composition table
Ernährungswissenschaftliches Programm (dato Denkwerkzeuge,
Vienna, 1997) were used.
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Determination of plasma lipids
Determination of TG and cholesterol. TG and cholesterol concen-
trations in plasma and lipoprotein fractions were measured using
enzymatic kits (F. Hoffmann-La Roche, Ltd.) adapted for a Cobas
Mira centrifugal analyzer (F. Hoffmann-La Roche) with Precilip
EL: and Precinorm: (F. Hoffmann-La Roche) as quality controls.
Immunoturbidometry was used for measurement of the apolipo-
proteins using specific antiserum purchased from F. Hoffmann-La
Roche (for apoA-I and apoB), Daiichi Chemicals (for apoE and
apoC-III), and Incstar Corp. (for lipoprotein [a]).
Sequential preparative ultracentrifugation. Lipoproteins were
separated by sequential preparative ultracentrifugation using
a Kontron 45.6 fixed-angle rotor in a Centrikon 75 (Kontron
Instruments). The following lipoprotein fractions were isolated:
VLDL (d , 1.006 g/ml), intermediate density lipoprotein (IDL;
d 5 1.006–1.019 g/ml), and LDL (d 5 1.019–1.063 g/ml). Total
HDL cholesterol was measured subsequent to the precipita-
tion of the apoB-containing lipoproteins with polyethylene glycol
(Immuno AG).
Determination of plasma total fatty acids. The determination of
the fatty acid content in plasma was based on an esterification
procedure and a subsequent GC analysis of the fatty acid methyl
esters as described by Sattler et al. (28). Briefly, 450 ml of EDTA
plasma and 100 ml of internal standard (10 mg of heptadecanoic
acid and 100 mg of butylated hydroxytoluene (BHT) in 10 ml of
methanol) were added to a Teflon screw-capped tube, vortexed
for 10 s, and then kept at 280jC for a minimum of 30 min. The
deep-frozen suspension was freeze-dried on the lyophilisator
(Virtis; Servo Laboratories, Graz, Austria) for ?15 h. Thereafter,
1 ml of boron trifluoride-methanol complex and 500 ml of tolu-
ene were added and vortexed for 20 s Transesterification was
performed at 110jC for 90 min. After the transesterification step,
2 ml of purified water was added and the fatty acid methyl
esters were extracted three times with n-hexane. The hexane ex-
tracts were dried in a Speed-Vac (Bachhofer; Servo Laboratories)
at room temperature for 30 min, redissolved in 450 ml of
dichloromethane, and subjected to GC analysis (Hewlett-Packard
5890 Series II; Agilent Technologies, Vienna, Austria). Separa-
tion of fatty acid methyl esters was achieved on a DB-23 column
(Agilent Technologies) with a length of 30 m and a diameter
of 0.250 mm. The mobile phase was a mixture of helium and
hydrogen gas. The oven temperature at injection was 150jC and
was increased to 222jC (3jC/min) and kept at this temperature
for 3 min, then increased further to 238jC (3jC/min) and kept
at this temperature for 3 min, and finally increased to 255jC
(20jC/min). The areas under the GC peaks were quantified by
integration, and the internal standard described above was used
for calculation of the amounts of fatty acids. Nineteen plasma
samples of the patients were processed along with a control sam-
ple from the plasma pool for long-term quality control. Coeffi-
cients of variation for the different fatty acids were between 0.38%
and 8.3% within run and between 1.7% and 8.6% between run.
Determination of vitamin E
LDL isolation. LDL was isolated as described by Bergmann
et al. (24). Briefly, 1.5264 g of solid potassium bromide was added
to 4 ml of defrosted EDTA plasma, which had been mixed with
sucrose as described above. Separation of LDL was achieved
by single-step discontinuous gradient ultracentrifugation in a
Beckman NVT65 rotor (Beckman Coulter, Servo Laboratories) at
60,000 rpm for 2 h at 10jC (29). Thereafter, the LDL band was
isolated and filtered through a 0.20 mm sterile filter (Corning,
Inc., Corning, NY) into an evacuated glass vial (BD Vacutainer;
Belliver Industrial Estate, Plymouth, UK) and processed on the
same day. LDL density was determined using an Anton Paar DMA
48 density meter (A. Paar, Ltd., Graz, Austria). The cholesterol
content of LDL was determined using a kit from Roche Diag-
nostics Ltd. (F. Hoffmann-La Roche).
Determination of a- and c-tocopherols in plasma and in LDL. The
determination of tocopherols in plasma and in LDL was per-
formed as described by Aebischer, Schierle, and Schuep (30).
Briefly, EDTA plasma or isolated LDL was diluted with deionized
distilled water and deproteinized with 400 ml of absolute ethanol.
To extract lipophilic compounds, 800 ml of n-hexane/BHT
(350 mg of BHT in 1,000 ml of n-hexane) was added and centri-
fuged, and the clear supernatant was transferred by a dispenser/
dilutor system (Micro Lab 500B Dilutor; Hamilton, Martinsried,
Germany) to an Eppendorf tube to be dried on a Speed-Vac
(Savant, New York, NY). The residue was then redissolved in a
mixture of methanol and 1,4-dioxane (1:1), diluted with ace-
tonitrile, and injected into the HPLC system (Hewlett-Packard
1100A; Agilent). Separation was achieved on a reverse-phase col-
umn; the mobile phase was a mixture of acetonitrile, tetrahydro-
furan, methanol, 1% ammonium acetate solution, and 10 mg of
L(1)-ascorbate; the flow rate was 1.6 ml/min. Vitamin E was de-
tected using a fluorescence detector (Jasco model FP-920; Biolab,
Vienna, Austria) at extinction of 298 nm and emission of 328 nm
(a- and g-tocopherol). The areas under the HPLC peaks were
quantified on an HP Chemstation (Hewlett-Packard 35900E;
Agilent). The coefficients of variation within run were 1.26% for
a-tocopherol and 0.80% for g-tocopherol in plasma and 0.70%
for a-tocopherol and 1.4% for g-tocopherol in LDL. The coeffi-
cients of variation between day were 1.81% for a-tocopherol and
2.78% for g-tocopherol in plasma and 2.54% for a-tocopherol
and 2.98% for g-tocopherol in LDL. Six plasma and LDL sam-
ples of the subjects were processed along with two control sam-
ples from the plasma and LDL pools, respectively, obtained
from a number of healthy subjects to be used for long-term
quality control along with a standard solution. The detection
limit was 0.012 mmol/l for a- and g-tocopherol. The tocopherol
content of LDL was expressed as moles of tocopherol per mole
of LDL.
Determination of total vitamin E in BMC. Vitamin E was extracted
from a resuspension of BMC in PBS (1 ml) as described by Borel
et al. (31). Briefly, after a short sonication (15 s; Labsonic U; B.
Braun), a-tocopheryl acetate (Fluka, l’Isle d’Abeau, France) was
added to samples as an internal standard. The proteins were
precipitated with ethanol precipitation. Then, the vitamin E was
extracted twice with hexane. The extract was evaporated to dry-
ness under nitrogen, dissolved in methanol-dichloromethane
(65:35, v/v), injected into a C18 column (5 mm, 250 mm 3 4.6 mm;
Nucléosil; Interchim, Montluçon, France), and assayed by reverse-
phase HPLC (HPLC apparatus: Waters 996 UV-vis DAD; Waters
SA, St-Quentin-en-Yvelines, France). Pure methanol, at a flow-
rate of 2 ml/min, eluted a-tocopherol in 5.0 min and tocopheryl
acetate in 6.3 min. The compounds were detected by ultraviolet
light (292 nm), then quantified by internal and external calibra-
tion using daily-controlled standard solutions. Vitamin E concen-
trations were standardized for protein, as determined by Lowry
et al. (32).
Determination of malondialdehyde in plasma
Plasma malondialdehyde concentrations were determined by
HPLC as a biomarker of in vivo lipid peroxidation. The method
described by Khoschsorur et al. (33) was used.
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According to the nomenclature and methodology used by
Pennacchio and colleagues (1), the single nucleotide polymor-
phism 21131T.C was used as the genetic marker. Genotyping was
performed with primers AV-1 (5¶-GATTGATTCAAGATGCATT-
TAGGAC-3¶) and AV-2 (5¶-CCCCAGGAACTGGAGCGAAATT-3¶),
which forced a MseI (New England Biolabs, Beverly, MA) site for
enzymatic restriction.
Statistical methods
Statistical analyses were carried out with SPSS version 14.0. The
Chi-square test was used to test for Hardy-Weinberg equilibrium.
Normal distribution of data was checked with the Kolmogorov-
Smirnov test. Comparisons of age and body mass index (BMI)
were made with Student’s t -test. ANOVA was performed to com-
pare the mean values of lipid, lipoprotein, apolipoprotein, and
vitamin E data adjusted for age and BMI, because of well-known
associations between plasma lipids, age, and BMI. Linear regres-
sion analysis was performed between plasma and LDL vitamin E
concentrations. Log-transformation was performed when vari-
ables were not normally distributed. Results are expressed as
means 6 SD or box-and-whisker plots. P , 0.05 was considered
statistically significant.
RESULTS
Demographic data of the study population
We studied a total of 297 nonsmoking healthy males
aged 20–75 years from France, Austria, and Spain. Genetic
material was missing for two subjects; thus, two subjects
had to be excluded from statistical analysis. There were no
differences in mean age, age distribution, and BMI among
countries (Table 1); therefore, all subjects were pooled for
genetic analyses of lipid and vitamin concentrations.
Frequencies of the 21131T.C polymorphism in the
APOA5 gene
Among the 297 subjects, 251 had the common geno-
type (T/T), 45 were heterozygote (T/C), and 1 subject was
homozygote (C/C). For association analyses, all carriers of
one or two copies of the C allele were pooled. The C allele
was carried by 15.5% of the subjects, resulting in an allele
frequency of 0.08, which was similar to that found in the
Caucasian general population (6). The observed frequen-
cies of the 21131T.C genotypes were not different from
those predicted by the Hardy-Weinberg distribution.
There were no differences in the allele frequencies be-
tween Spain, France, and Austria (Table 1).
Characteristics of the study subjects according to
APOA5 genotype
There were no differences in age between homozygote
carriers of the T allele (45.8 6 15.1 years) and carriers of
the C allele (48.0 6 17.1 years). BMI did not differ between
the TT (25.0 6 2.66 kg/m2) and the TC1CC (24.7 6
2.65 kg/m2) genotypes.
Effects of the APOA5 genotype on lipoprotein profile
Carriers of the C allele had 15.2% higher plasma TG
concentrations (P 5 0.01) attributable to increases in
VLDL-TG (P 5 0.001), whereas IDL-TG, LDL-TG, and
HDL-TG did not differ significantly between the genotypes
(Table 2). This was accompanied by a 10% increase in the
lipoprotein lipase inhibitor apoC-III in the TC1CC
genotype (17.06 3.27 mg/dl) compared with the TT geno-
type (15.4 6 3.30 mg/dl) (P 5 0.002). Total cholesterol
concentrations were not different between carriers and
noncarriers of the C allele. However, carriers of the C
allele showed significantly higher cholesterol concentra-
tions in the VLDL (P 5 0.002) and IDL (P , 0.05) frac-
tions, whereas there were no differences in the LDL and
HDL fractions (Table 2). Circulating apoB-containing
lipoproteins were also 11% higher in carriers of the C al-
lele (apoB-100; P 5 0.006) as a result of an accumulation
of VLDL and LDL particles, as assessed by their apoB
content (VLDL, P5 0.008; LDL, P5 0.03). In contrast, the
APOA5 genotype did not have an effect on HDL (Table 2).
There was no difference between the TT and TC1CC
genotypes in plasma lipoprotein [a] (23.5 6 21.7 vs. 23.1 6
20.0 mg/dl) and apoE (3.50 6 0.872 vs. 3.48 6 0.691 mg/dl).
Effects of dietary intake and of the APOA5 genotype on
plasma fatty acids
There were no differences in total fat intake or in intake
of SFA, MUFA, and PUFA between the genotypes. After
dichotomizing dietary PUFA intake according to the study
population mean (16.2 6 6.95 g/day), there was no effect
of high or low PUFA intake on TG concentrations, plasma
VLDL, and VLDL-TG. Total plasma fatty acids were
8.6% higher in carriers of the C allele compared with
homozygote carriers of the T allele (10.4 6 2.31 vs. 11.3 6
2.32 mmol/l) (P 5 0.007). The distribution of fatty acids
TABLE 1. Characteristics of the study population
Characteristics France (n 5 97) Austria (n 5 100) Spain (n 5 100) Total (n 5 297) Pa
Anthropometric variables
Age (years) 46.6 6 15.1 45.5 6 15.1 46.3 6 16.0 46.1 6 15.4 NS
BMI (kg/m2) 24.6 6 2.58 25.2 6 2.71 25.1 6 2.66 25.0 6 2.66 NS
Genotype
TT (%) 84.5 86.0 83.0 84.5 NSb
TC/CC (%) 15.5 14.0 17.0 15.5 NSb
C allele frequency 0.08 0.07 0.09 0.08 NSb
BMI, body mass index. Anthropometric variable values are shown as means 6 SD.
a France versus Austria versus Spain.
b By Chi-square test.














UNIVERSITAT ROVIRA I VIRGILI 
ROLE OF THE APOA5 GENE IN LIPID AND FAT-SOLUBLE VITAMIN METABOLISM 
Montserrat Guardiola Guionnet 
ISBN:978-84-691-9478-2/DL:T-19-2009 
 
among SFA, MUFA, and n-3 or n-6 PUFA expressed as
mol% did not differ between the genotypes.
In vivo lipid peroxidation according to APOA5 genotype
Plasma malondialdehyde concentrations did not show
a significant difference between the TT and TC1CC
genotypes, either when the concentrations (TT, 0.68 6
0.34 mmol/l vs. TC1CC, 0.75 6 0.38 mmol/l) or when the
ratios of malondialdehyde to cholesterol (TT, 0.144 6
0.074 mmol/mmol vs. TC1CC, 0.155 6 0.086 mmol/mmol)
were used.
Effects of the APOA5 gene on vitamin E status
Carriers of the C allele had significantly higher (9.1%)
plasma a-tocopherol concentrations compared with non-
carriers (P5 0.02) (Fig. 1). Because there was a significant
relation between plasma a-tocopherol concentrations and
TG concentrations (r 5 0.50, P , 0.001) and cholesterol
concentrations (r 5 0.75, P , 0.001), standardization was
performed. The difference in a-tocopherol concentra-
tions between the genotypes was not statistically significant
when standardized for TG and cholesterol (both sepa-
rately and in combination), nor when measured in the
LDL fraction. g-Tocopherol concentrations as well as total
vitamin E concentrations measured in BMC did not differ
significantly between carriers and noncarriers of the C
allele (Table 3). There was a close relation between plasma
and LDL a- and g-tocopherol concentrations in both
genotypes (a-tocopherol, r 5 0.45, P , 0.001 in T/T, r 5
0.64, P, 0.001 in C/T and CC; g-tocopherol, r5 0.93, P,
0.001 in T/T, r 5 0.94, P , 0.001 in C/T and CC).
DISCUSSION
The hypothesis of this study was that, through its action
on lipid metabolism, the APOA5 gene would have an ef-
fect on the metabolism and distribution of the fat-soluble
vitamin E and thus could alter the status of this most
potent lipophilic antioxidant. In the study subjects (i.e.,
healthy male nonsmoking volunteers), the APOA5 variant
21131T.C had a significant impact on plasma vitamin E
concentrations, such that the carriers of the C allele ex-
hibited high a-tocopherol but not g-tocopherol concen-
trations in association with increased TG concentrations
compared with carriers of the T allele. TG concentrations
are well known to be a major determinant of circulating
vitamin E concentrations (14); therefore, standardization
Fig. 1. Differences in plasma a-tocopherol concentrations (P 5
0.02; upper panel) and a-tocopherol standardized for triglyceride
concentrations (not significant; lower panel) between apolipopro-
tein A5 (APOA5) genotypes. Results are expressed as box-and-
whisker plots.
TABLE 2. Lipoprotein profiles according to APOA5 genotype
Cholesterol TG ApoB/ApoA-I Content
Lipoprotein TT (n 5 251) TC 1 CC (n 5 46) Pa TT (n 5 251) TC 1 CC (n 5 46) Pa TT (n 5 251) TC 1 CC (n 5 46) Pa
mmol/l mmol/l mg/dl
Plasma 4.82 6 0.932 5.06 6 0.878 NSd 1.05 6 0.522 1.21 6 0.582 0.01d,e 70.6 6 17.2b 78.2 6 17.4b 0.006d
133.5 6 18.9c 135.9 6 17.89c NSd
VLDL 0.298 6 0.248 0.397 6 0.290 0.002d,e 0.568 6 0.419 0.751 6 0.505 0.001d,e 3.16 6 2.18b 4.15 6 2.58b 0.008d,e
IDL 0.193 6 0.106 0.224 6 0.113 0.048d,e 0.093 6 0.337 0.105 6 0.442 NSd,e 2.73 6 1.37b 3.11 6 1.57b NSd,e
LDL 2.68 6 0.728 2.89 6 0.652 NSd 0.237 6 1.00 0.188 6 0.048 NSd,e 54.4 6 14.6b 59.7 6 13.4b 0.03d
HDL 1.33 6 0.308 1.33 6 0.296 NSd 0.094 6 0.031 0.103 6 0.041 NSd,e 112.6 6 17.4c 114.8 6 16.6c NSd




d P value standardized for BMI and age.
e On log-transformed data.
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for TG concentrations was performed. After standardiza-
tion, the effect of the genotype disappeared, indicating
that increased vitamin E concentrations are a function of
increased TG concentrations. This relationship is further
supported by the highly significant linear regression of a-
tocopherol concentrations on TG concentrations in the
present study.
APOA5 and vitamin E
The reason for this differential effect of the 21131T.C
variant of the APOA5 gene on plasma a-tocopherol com-
pared with g-tocopherol concentrations may relate to the
fact that, although intestinal absorption of the different
vitamin E isoforms is similar, a-tocopherol transfer protein
in the liver preferentially binds the a-tocopherol, which
is then incorporated into nascent VLDL particles (15, 16).
Although this metabolic pathway is responsible for the
enrichment of a-tocopherol in lipoproteins and, conse-
quently, also in tissues, g-tocopherol is either excreted via
bile or metabolized in the liver to be excreted as the water-
soluble g-carboxyethyl-hydroxychroman in the urine
(15, 16). Because in vitro data suggest that apoA-V may
influence hepatic VLDL synthesis (34), the incorporation
of a-tocopherol into VLDL could be modulated by the
21131T.C genotype. This results not only in higher TG
concentrations in the carriers of the C allele but also in
higher a-tocopherol concentrations. In contrast, because
of the lack of incorporation of g-tocopherol into nascent
VLDL, g-tocopherol concentrations are not affected by
the genotype. This could explain the absence of genotype-
related differences in both plasma and LDL g-tocopherol
concentrations observed in the present study.
The extrahepatic tissue uptake and distribution of vita-
min E is directed mainly by LPL (19). Because apoA-V
stimulates LPL activity (2, 35), the APOA5 genotype could
also influence the distribution of vitamin E between plasma
and tissues. Our results indicate that increased a-tocopherol
concentrations are entirely attributable to increased plasma
lipid concentrations. Given that there was no difference in
LDL-TG content between the genotypes, it is not surpris-
ing that there was also no difference in LDL a-tocopherol
concentrations. Because micronutrient concentrations in
BMC have been suggested to reflect vitamin E status better
than plasma concentrations (36), we determined vitamin
E in BMC. There were no differences between the APOA5
genotypes in BMC vitamin E, in agreement with LDL vita-
min E concentrations and vitamin E plasma concentra-
tions standardized for lipid concentrations.
APOA5 and lipids and lipoproteins
The crucial role of apoA-V in TG metabolism has been
demonstrated in several transgenic and knockout animal
models (1–3) as well as in epidemiological studies investi-
gating single nucleotide polymorphisms at the human
APOA5 locus (5, 9, 10). In the present study, we aimed to
study its effect on a population of subjects of different ages
specifically recruited to qualify as healthy and with a com-
plete lipid and lipoprotein profile. Carriers of the C allele
had increased TG concentrations compared with wild-type
subjects, which were mainly attributable to increases of
TG in the VLDL fraction. Carriers of the C allele also had
higher VLDL and IDL cholesterol and higher apoB con-
centrations, indicating a significantly higher number of
apoB-containing lipoproteins. Similar observations have
been made previously (2, 37). However, it remains to be de-
termined whether increased synthesis, decreased clearance
of TG-rich lipoproteins, or both are the underlying mech-
anisms of the effects of apoA-V on lipid status. Our results
support both possibilities, because carriers of the C allele
had increased plasma concentrations of free fatty acids and
apoC-III. Although increased concentrations of free fatty
acids are known to induce hepatic synthesis of VLDL, in-
creased concentrations of apoC-III can impair the ability to
hydrolyze TG as well as the removal of lipoprotein remnants.
This could explain all of the observed features associated
with the 21131T.C gene variant, namely, increased VLDL,
increased TG, and increased IDL (VLDL remnants).
Increased plasma fatty acid concentrations did not
show a specific pattern of increased fatty acids. Recently, a
modulating effect of dietary n-6 PUFA on plasma lipids
in carriers of the C allele was shown (38). However, in the
present study, such an effect was not observed.
TABLE 3. Vitamin E profile according to APOA5 genotype
APOA5 Genotype
Vitamin E Status TT (n 5 251) TC 1 CC (n 5 46) Pa
Plasma a-tocopherol (mmol/l) 28.7 6 6.34 31.3 6 7.43 0.02b,c
Adjusted for cholesterol NSb,c
Adjusted for TG NSb,c
Adjusted for cholesterol and TG NSb,c
Adjusted for apoB NSb,c
Plasma a-tocopherol to cholesterol (mmol/mmol) 5.96 6 0.907 6.15 6 1.03 NSb,c
Plasma g-tocopherol (mmol/l) 1.38 6 0.835 1.46 6 0.689 NSb,c
Plasma g-tocopherol to cholesterol (mmol/mmol) 0.285 6 0.154 0.290 6 0.126 NSb,c
LDL a-tocopherol (mmol/l) 8.28 6 1.10 8.51 6 1.25 NSb
LDL g-tocopherol (mmol/l) 0.329 6 0.180 0.329 6 0.138 NSb,c
Buccal mucosa cell total vitamin E (ng/mg protein) 119.0 6 95.8 110.0 6 55.6 NSb,c
Values shown are means 6 SD.
a ANOVA.
b P value standardized for BMI and age.
c On log-transformed data.
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This study was not designed to test the hypothesis that
differences in vitamin E status attributable to the APOA5
variant 21131T.C would affect biomarkers of oxidative
stress and inflammation. Only healthy volunteers were
enrolled who had passed strict inclusion/exclusion cri-
teria, such that they did not have increased markers of
inflammation such as C-reactive protein, leukocyte count,
or bands. At the same time, they had to be nonsmokers,
with BMI , 30 kg/m2, and free of acute or chronic dis-
eases, making an increased oxidative stress status very
unlikely. They were also in a fasted state, such that post-
prandial lipid peroxidation would not be investigated.
Furthermore, plasma a-tocopherol standardized for lipids
[i.e., a-tocopherol to cholesterol of 5.96 6 0.91 mmol/l
(TT) compared with 6.156 1.03mmol/l (TC1CC)] was not
associated with significant differences in lipid peroxidation,
because higher lipids in the TC1CC genotype are associated
with higher a-tocopherol concentrations, resulting in com-
parable protection against lipid peroxidation.
In summary, the data presented here indicate that
the APOA5 gene significantly alters the lipoprotein profile
even in healthy subjects. Such an effect is accompanied by
increased circulating vitamin E concentrations as a result
of increased TG concentrations, whereas vitamin E metab-
olism does not seem to be affected. From a health perspec-
tive, the association of increased plasma lipids with an
increase in a-tocopherol concentrations is highly relevant
for ensuring efficient protection against lipid peroxida-
tion. These results should be taken into account when
interpreting plasma vitamin E concentrations in humans.
Given the fact that the 21131T.C variant affects lipid
status and, as a consequence, also alters plasma vitamin E
concentrations, this study further supports the use of vita-
min E standardized for lipids to reliably assess vitamin E
status, particularly in genetic association studies.
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Abstract
Background: Variations of the apolipoprotein A5
(APOA5) gene are strongly associated with hypertri-
glyceridemia. Vitamin E is transported in triglyceride
(TG)-rich lipoproteins and therefore could also be
modulated by apoAV. Patients with type 2 diabetes
have a tendency towards high TG values and
increased oxidative stress.
Methods: We examined the impact of genetic APOA5
variation (–1131T™C) on vitamin E and oxidative stat-
us in 169 non-smoker type 2 diabetic patients. Plasma
samples were analyzed for lipids, lipoproteins, vita-
min E, oxidized low-density lipoprotein (oxLDL), lipo-
peroxides, autoantibodies against oxLDL and diene
formation of LDL.
Results: Vitamin E concentrations were higher in TC
carriers compared with TT carriers (45.48"8.20
mmol/L vs. 40.32"10.47 mmol/L; ps0.02). The prev-
alence of the TC genotype was 2.6-fold higher among
individuals with high vitamin E concentrations
(ps0.02). The APOA5 polymorphism did not deter-
mine any differences in oxidative status. Fasting TG
concentration was a significant 21% higher in carriers
of the TC genotype (ps0.04) due to higher TG con-
centrations in very-low-density lipoprotein (VLDL) and
high-density lipoprotein.
Conclusions: The APOA5–1131T™C polymorphism is
associated with both higher vitamin E concentrations
and higher VLDL-TGs in diabetic patients.
Clin Chem Lab Med 2008;46:453–7.
Keywords: APOA5; oxidation; triglycerides; type 2
diabetes; vitamin E.
Introduction
Lipid oxidation is a crucial mechanism in the patho-
genesis of diabetes and atherosclerosis (1). Diabetes
is associated with increased oxidative stress that con-
tributes to an accelerated predisposition to vascular
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damage. It has been observed by us and others that
oxidative stress plays a casual role in macro- and
microvascular lesions in both experimental and clin-
ical diabetes (2, 3). Although the role of oxidation has
been well established as a pathogenic mechanism for
diabetes complications, the effectiveness of antioxi-
dants is rather controversial. While in epidemiological
studies those populations with high concentrations of
natural antioxidants, such as vitamin E, have less risk
for cardiovascular and metabolic problems (4), the
administration of antioxidant supplements as vita-
mins C and E do not induce a reduction in neither
diabetes predisposition nor cardiovascular complica-
tions (5). This is probably due to the differential effect
of naturally acquired antioxidants vs. pharmacologi-
cal administration (6). Among other effects, oxidative
stress alters lipoproteins. The presence of low-density
lipoprotein (LDL) oxidation markers in plasma is asso-
ciated with vascular disease (7). Oxidized lipoproteins
are incorporated into macrophages leading to foam
cell formation and artery wall inflammation charac-
terized by inflammatory cell recruitment and arterio-
sclerosis plaque progression (8, 9). The oxidative
status results from the imbalance between pro-oxi-
dant and antioxidant mechanisms. Because one of the
main in vivo antioxidant molecules is vitamin E, it
seems important to go deeply into its metabolic
determinants.
Vitamin E is a generic name applied to a group of
tocopherol and tocotrienol molecules that have anti-
oxidant properties. It travels with lipoproteins and is
therefore a good candidate to modulate lipoprotein
oxidative status (10). It is obtained from different
foods, absorbed by the enterocyte and then incorpo-
rated into chylomicrons to reach the blood stream.
Chylomicrons are then catabolized by lipoprotein lip-
ase (LPL); during this process, some vitamin E content
is transferred to extra-hepatic tissues (11). Remnants
are taken up by the liver where vitamin E molecules
are made available to be incorporated into very-low-
density lipoprotein (VLDL). The presence of a specific
protein, a-tocopherol-transfer protein, plays an
important role in selectively delivering a-tocopherol
molecules to triglyceride (TG)-rich lipoprotein (TRL) in
the hepatocyte (12). Vitamin E again reaches the
blood stream inside VLDL; when the lipoprotein inter-
acts with LPL, it is distributed to extra-hepatic tissues.
In the last few years, the apolipoprotein A5 (APOA5)
gene has been strongly associated with plasma TG
concentrations (13). Knockout animals for this gene
have very high concentrations of TG, while transgenic
mice show a low plasma concentration (14). In dia-
betic patients, carriers of APOA5–1131T™C gene
variants are associated with low apoAV plasma con-
centrations (15) and hypertriglyceridemia (16, 17). It
has been suggested that part of its effect could be
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related to LPL activation (18), although it has also
been suggested that the main effect of this apoprotein
takes place intracellularly in the liver during VLDL
formation (19).
Because vitamin E is a liposoluble molecule with a
metabolism closely related to TRL, and apoAV is a key
regulator of TG metabolism, it is interesting to study
if genetic polymorphisms associated with hypertrigly-
ceridemia could be associated with variations in vita-
min E plasma concentration leading to changes in the
oxidative status. These can have more importance in
diabetic patients, because diabetes is a prooxidant
condition and oxidative stress has been causally relat-
ed to both micro- and macrovascular disease.
Secondly, type 2 diabetes is associated with hypertri-
glyceridemia, and those genetic factors influencing
VLDL metabolism can contribute to atherogenic dys-
lipidemia whigh TG, low high-density lipoprotein (HDL)
and accumulation of small and dense LDLx observed
in this group of patients (20). In this paper we have
studied, for the first time, the impact of the –1131T™
C polymorphism of APOA5 on vitamin E plasma con-
centrations in a group of non-smoker type 2 diabetic
patients and its impact on lipid peroxidation status.
Materials and methods
Patients
The study group comprised 169 non-smoker type 2 diabetic
patients (36–79 years) diagnosed in accordance with the
American Diabetes Association (21). They were recruited in
the Hospital Universitari Sant Joan de Reus. A complete
medical history and clinical examination, including anthro-
pometrics, blood pressure and retinal examination, were car-
ried out. The presence of atherosclerosis was assessed by
clinical history of coronary heart disease, stroke or periph-
eral vascular disease and/or when subjects presented at least
one significant arteriosclerotic plaque ()40% stenosis)
assessed by carotid and femoral eco-Doppler and/or when
subjects had an ankle brachial index F0.9 or G1.3. Patients
with type 1 diabetes mellitus, secondary diabetes mellitus,
morbid obesity wbody mass index (BMI) )40 kg/m2x, familial
hypercholesterolemia, diabetic retinopathy and/or nephro-
pathy, malignancy, liver disorders, acute or chronic inflam-
mation and smokers (one cigarette in the last year) were not
included. Informed consent was obtained from all patients
and the protocol was approved by the Ethical Committee of
Sant Joan University Hospital, Reus, Spain.
Chemical analyses
After a 12-h overnight fasting period, 20 mL of venous blood
was taken into EDTA tubes and centrifuged immediately for
15 min at 48C for 1500=g. Plasma lipids, apolipoproteins,
glucose and general biochemical parameters were measured
using standard assays adapted for the Cobas-Mira autoana-
lyzer (Roche Diagnostic, Basel, Switzerland) and HbA1c by
high performance liquid chromatography (HPLC).
Lipoproteins were subfractionated by sequential prepara-
tive ultracentrifugation in a Kontron 45.6 rotor (Kontron
Instruments, Milan, Italy) as described previously (22). Con-
secutive runs were carried out to obtain VLDL, intermediate
density lipoprotein (IDL), LDL and HDL.
We used the solid phase two-site enzyme immunoassay
Mercodia Oxidized LDL ELISA (Mercodia, Uppsala, Sweden)
for the quantitative measurement of oxidized low-density lipo-
proteins (oxLDLs) in plasma. Results were calculated using
the computerized data reduction of absorbance for the stan-
dards vs. the concentration using cubic spline regression; all
results were expressed as U/L. The performance character-
istics for this assay were 6.3% coefficient of variation (CV)
intraassay and 4.7% CV interassay.
For the quantitative determination of anti-oxLDL antibod-
ies (oxLDL-Ab) in plasma, we used an enzyme immunoassay
with IMTEC-oxLDL-antibodies (IMTEC Immunodiagnostika
GmbH, Berlin, Germany). This test permits the synchronous
determination of immunoglobulin (Ig)G and IgM anti-oxLDL
autoantibodies after a subtraction of anti-native-LDL auto-
antibodies. Results were calculated using the computerized
data reduction of absorbance for the standards vs. the con-
centration using lineal regression and were expressed as U/
mL. The performance characteristics of this assay were 7.8%
CV intraassay and 8.6% CV interassay.
We used the colorimetric assay OxyStat (Biomedica, Vien-
na, Austria) for the quantitative determination of peroxides
in plasma (LPO). Results are expressed in mmol/L. The per-
formance characteristics for this assay were 3.1% CV intraas-
say and 5.1% CV interassay.
After extensive dialysis against phosphate-buffered saline
at 48C, the conjugated diene formation in LDL (50 mg/mL)
was analyzed by monitoring the change at 234 nm at 308C
in an Uvikon spectrophotometer 922 (Kontron Instruments)
in the presence of 6 mmol/L of cupric chloride dehydrate.
Absorbance was recorded every 5 min for at least 5 h (23).
Conjugated diene formation was measured in the LDL frac-
tion from each subject.
Vitamin E measurement
Vitamin E (a-tocopherol) content was determined by HPLC
(Hewlett-Packard, 1050 series, Waldbronn, Germany) as
described by Catignani and Bieri (24) using tocopherol ace-
tate as an internal standard (50 mg/mL). The column was
Spherisorb ODS2, 125=4 mm, 5 mm (Teknokroma, Barce-
lona, Spain) and the mobile phase was methanol (100%). The
HPLC instrument was equipped with a UV-visible detector
and absorbance was recorded at 292 nm. The threshold
value for high vitamin E values was chosen according to
local population studies ()38.8 mmol/L for males and
)41.6 mmol/L for females) (25).
DNA extraction and genotyping
Genomic DNA was extracted from whole blood using a
commercial kit (Qiagen, Barcelona, Spain). The APOA5–
1131T™C polymorphism was determined by PCR amplifi-
cation and enzymatic restriction with MseI (14).
Statistical analysis
Analysis was performed using SPSS (version 13.0, SPSS
Inc., Chicago, IL, USA). All data are presented as the mean
(SD). A comparison of variables between groups was per-
formed using one-way analysis of variance (ANOVA). Cate-
gories were compared between groups using the x2-test.
Genotype frequencies were estimated by the x2-test. In
all cases, a p-value -0.05 was considered statistically
significant.
Results
Among the 169 patients, 144 had the TT genotype and
25 were TC heterozygotes. The C allelic frequency
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Table 2 Vitamin E concentrations and lipid peroxidation parameters according to the –1131T™C polymorphism of APOA5
in type 2 diabetic patients.
TT (ns144) TC (ns25) p-Value
Vitamin E, mmol/L 40.32"10.47 45.48"8.20 0.020
Vitamin E/cholesterol, mmol/mol 8.67"1.91 9.59"1.85 0.027
Vitamin E/triglycerides, mmol/mol 27.99"11.69 26.33"12.85 0.519
LDL dienes formation
Lag phase, min 82.70"20.98 78.30"21.54 NS
Maximal rate, mol/min 9.15"2.26 9.57"2.19 NS
Maximum diene formation, mol/mol 648.24"87.98 644.91"77.05 NS
Lipoperoxides, mmol/L 340.78"167.35 307.76"182.27 NS
OxLDL, U/L 68.86"22.13 67.54"16.19 NS
OxLDL-Ab, U/mL 21.83"9.03 22.00"9.18 NS
Values are given as mean"SD. p-Values were calculated by one-way ANOVA.
Table 1 Clinical, metabolic and lipid parameters according to the –1131T™C polymorphism of APOA5 in type 2 diabetic
patients.
TT (ns144) TC (ns25) p-Value
Age, years 63.10"8.98 60.92"11.57 NS
Gender, males (%) 68 (47%) 12 (48%) NS
Diabetes duration, years 14.52"7.77 12.36"6.95 NS
BMI, kg/m2 30.12"4.28 30.70"4.52 NS
Glucose, mmol/L 8.88"2.99 9.42"3.72 NS
HbA1c, % 7.02"1.09 6.87"1.31 NS
Triglycerides, mmol/L 1.69"0.94 2.14"1.29 0.043
Cholesterol, mmol/L 4.68"0.79 4.79"0.63 NS
LDL cholesterol, mmol/L 2.83"0.69 2.68"0.76 NS
HDL cholesterol, mmol/L 1.09"0.28 1.15"0.31 NS
Apolipoprotein A-I, g/L 1.37"0.20 1.48"0.22 0.017
Apolipoprotein B, g/L 0.84"0.16 0.85"0.11 NS
Apolipoprotein C-III, g/L 0.17"0.04 0.19"0.05 0.054
Apolipoprotein E, g/L 0.04"0.01 0.04"0.01 NS
Lipoprotein (a), g/L 0.31"0.32 0.31"0.31 NS
Systolic blood pressure, mm Hg 140.57"18.62 137.83"17.70 NS
Diastolic blood pressure, mm Hg 79.57"11.10 78.08"8.02 NS
Atherosclerosis, yes (%) 63 (44%) 10 (42%) NS
Hypolipidemic treatment, yes (%) 76 (53%) 12 (48%) NS
Values are given as mean"SD, number of patients, or percentage of patients. p-Values were calculated by one-way ANOVA
or the x2-test for continuous and categorical variables, respectively.
was 0.07, which was not different from that predicted
by the Hardy-Weinberg distribution.
Table 1 shows the clinical and biochemical charac-
teristics of the diabetic patients, including risk factors
and therapy according to the –1131T™C polymor-
phism of APOA5. There were no significant differenc-
es between the two groups in terms of BMI, blood
pressure, glucose or HbA1c. All patients were non-
smokers. Plasma concentrations of TG, apolipopro-
tein A-1 (apoAI) and apolipoprotein C-III (apoCIII) were
significantly higher in TC carriers compared with TT
carriers (p-0.05). These results were confirmed when
they were adjusted for hypolipidemic treatment.
Vitamin E concentrations were higher in TC carriers
compared with TT carriers (45.48"8.20 mmol/L vs.
40.32"10.47 mmol/L, respectively; ps0.02) (Table 2).
The ratio of vitamin E to total cholesterol was signif-
icantly higher in the TC carriers compared to TT car-
riers (9.59"1.85 mmol/mol vs. 8.67"1.91 mmol/mol,
respectively; ps0.027). These results were confirmed
when they were adjusted for age, gender and BMI.
Figure 1 shows that the prevalence of the TC geno-
type was higher among those individuals with high
vitamin E concentrations compared to the low vitamin
E group (72% vs. 28%, respectively; ps0.022), while
the TT genotype was similarly distributed. There were
no differences in lipid peroxidation markers (oxLDL,
oxLDL-Ab, LPO, dienes) between TT homozygotes
and TC carriers (Table 2).
Figure 2 shows the TG distribution in plasma lipo-
proteins for APOA5–1131T™C genotypes. As expect-
ed, the fasting plasma TG concentration was 21%
higher in carriers of the TC genotype of APOA5
(ps0.04). This difference was due to higher TG in
VLDL (0.96"0.78 mmol/L for TT carriers and
1.33"1.11 mmol/L for TC carriers; ps0.043) and HDL
fractions (0.14"0.05 mmol/L for TT carriers and
0.17"0.03 mmol/L for TC carriers; ps0.017).
Discussion
Type 2 diabetic patients with the APOA5–1131T™C
polymorphism had increased vitamin E concentra-
tions. This increase in vitamin E was associated with
higher plasma TGs and VLDL and HDL TG concentra-
tions in this group of diabetic patients. The associa-
tion between this polymorphism and hyper-
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Figure 1 Distribution of different APOA5 genotypes in type
2 diabetes according to high and low vitamin E concentra-
tions. The threshold value for vitamin E is 38.8 mmol/L for
males and 41.6 mmol/L for females (25). x2s5.233, ps0.022.
Figure 2 Triglyceride distribution in plasma lipoproteins
for APOA5–1131T™C genotypes (TTs144, TCs25). Aster-
isks represent significant differences between genotypes.
p-Values were calculated by one-way ANOVA.
triglyceridemia confirms other results, showing that
the APOA5 gene is strongly implicated in the regula-
tion of TG metabolism (26–28). This effect is espe-
cially important in this group, because diabetes is a
metabolic abnormality and patients with this condi-
tion are prone to hypertriglyceridemia.
In our study, we showed an increase in the apoCIII
and apoAI levels in C carriers. The increase in the
apoCIII levels correlates with the increase in TG levels
in normolipidemic subjects, which suggests that it is
more a consequence than a cause of the hypertrigly-
ceridemia. These data would be in accordance with a
putative coordinated regulation of the A1-C3-A4-A5
gene cluster. Although around 50% of subjects in the
study were treated with lipid-lowering drugs, the
impact of this treatment on lipids was not affected.
Vitamin E is considered to be the main lipid anti-
oxidant molecule. ApoAV seems to play a role in
hepatic VLDL production (19), hence it could modu-
late the amount of vitamin E incorporated into TRL
and thus rendered to the circulation. In this study, we
observed that the APOA5–1131T™C genetic variant
that is strongly associated with higher concentrations
of TG is also associated with higher concentrations of
vitamin E. The group of patients with this polymor-
phism had higher vitamin E concentrations. Further-
more, among patients with higher vitamin E
concentrations the prevalence of the APOA5–1131T™
C polymorphism was also higher. Interesting enough,
the vitamin E to cholesterol ratio was increased in the
group of patients wearing the rare allele; this is prob-
ably important so as to explain the lipoprotein anti-
oxidant status.
It is already known that vitamin E increases with TG
levels. It has been recently confirmed in relation to the
APOA5 gene (29).
An increase in circulating TG and small dense LDL
could mismatch the molecular ratio necessary for
keeping the antioxidant capacity of vitamin E. In this
study, we show that this is not the case. The same
genetic conditioning that leads to hypertriglyceride-
mia induces a higher presence of vitamin E. In our
study, the higher vitamin E concentration was not
associated with improved antioxidant parameters,
such as peroxide concentration, diene formation,
oxLDL or anti-oxLDL antibodies. However, Jang et al.
(30) found that the presence of the –1131C allele had
significant effects on oxidative parameters in a group
of healthy Korean men. These different findings might
be due to the type of population, presence of smokers
and mainly the marked differences in the frequency
of this particular polymorphism (0.28 in Koreans vs.
0.07 in Spanish). Moreover, vitamin E functions seem
to be beyond anti-oxidation; recently, it has been
shown that vitamin E acts as an intracellular traffick-
ing signal and genetic regulator. In addition, it con-
tributes to anti-inflammatory and immune
mechanisms. The homeostasis of vitamin E seems to
be important in maintaining redox status, as well as
intracellular and intercellular connections (31). The
molecular function of apoAV is not known, therefore
we cannot speculate about the effect of APOA5 on
vitamin E metabolism. The plasma concentrations of
APOA5 appear to be very low and have no correlation
with lipid metabolism. Therefore, it is considered that
the main action of APOA5 should be at the tissue lev-
el, especially in the liver, probably playing a role in
the VLDL assembly process (19). The liver is where
vitamin E should be incorporated into TRL and is
probably influenced by APOA5.
In summary, those genetic situations prone to low-
er APOA5 concentrations (32) will increase a tendency
towards hypertriglyceridemia, but also counterbal-
ance higher vitamin E concentrations, thus modulat-
ing the deleterious pro-oxidant effect of TG-enriched
lipoproteins. This is especially important in oxidation
prone diseases, such as type 2 diabetes. An enhanced
knowledge of the genetic conditioning of vitamin E
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metabolism will help us to better understand the
molecular basis of these mechanisms.
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Protease Inhibitor-Associated Dyslipidemia in
HIV-Infected Patients Is Strongly Influenced by the
APOA5–1131T3C Gene Variation
Montse Guardiola,† Raimon Ferré,† Juliana Salazar, Carlos Alonso-Villaverde,
Blai Coll, Sandra Parra, Lluı́s Masana, and Josep Ribalta*
Background: Hyperlipidemia associated with the pro-
tease inhibitor (PI) component of highly active antiret-
rovial treatment can lead to accelerated atherosclerosis.
The apolipoprotein A-V (APOA5) gene, which affects
VLDL production and lipolysis, may play a role in
PI-induced hyperlipidemia, particularly in individuals
with the APOA5–1131T3C genotype.
Methods: We measured lipoprotein changes in HIV-
positive patients (n  229) who had been followed for 5
years. For statistical analyses, we segregated the patients
with respect to PI treatment and APOA5–1131T3C
genotype.
Results: The frequency of the C allele was 0.08, similar
to that in the general population. We found a strong
effect of the APOA5–1131T3C genotype among pa-
tients receiving PIs. Carriers of the C allele had consis-
tently increased mean (SD) triglyceride concentrations
compared with noncarriers after 1 year [2.11 (1.62) vs 3.71
(4.27) mmol/L; P  0.009], 2 years [2.48 (2.09) vs 4.02 (4.05)
mmol/L, P  0.050], 3 years [2.32 (1.71) vs 4.13 (4.26)
mmol/L; P  0.013], 4 years [2.90 (2.95) vs 5.35 (7.12)
mmol/L; P was not significant], and 5 years [4.25 (5.58) vs
9.23 (9.63) mmol/L; P was not significant]. We observed
the same effect on total cholesterol concentrations: after
1 year [4.93 (1.31) vs 5.87 (1.66) mmol/L; P  0.006], 2
years [5.03 (1.12) vs 6.42 (2.48) mmol/L; P  0.001], 3 years
[5.11 (1.17) vs 6.38 (2.43) mmol/L; P  0.009], 4 years [5.49
(1.71) vs 6.78 (3.03) mmol/L; P was not significant], and 5
years [5.56 (1.75) vs 7.90 (3.60) mmol/L; P was not
significant]. HDL cholesterol showed a progressive re-
duction, leading to a considerably higher cholesterol/
HDL cholesterol ratio after 3 years.
Conclusion: Variability in the APOA5 gene predisposes
patients with HIV, particularly those treated with PI, to
severe hyperlipidemia.
© 2006 American Association for Clinical Chemistry
HIV-infected individuals have higher rates of subclinical
atherosclerosis than the age-adjusted general population
(1 ), and the incidence of cardiovascular events is directly
related to the years of exposure to antiretroviral therapy
(2, 3). The metabolic abnormalities associated with anti-
retroviral therapy (4 ), chronic inflammatory status (5 ),
and the HIV infection itself (6 ) have been postulated as
possible causes of this increased susceptibility to cardio-
vascular disease. Hypercholesterolemia and hypertriglyc-
eridemia, which are well-established, independent, car-
diovascular disease risk factors, are associated with the
use of protease inhibitors, especially in patients undergo-
ing ritonavir or ritonavir-boosted antiretroviral treatment.
Despite similar antiretroviral treatment and demographic
characteristics, however, not all HIV-infected patients
develop these metabolic and cardiovascular complica-
tions. Hyperlipidemia, and more importantly, hypertri-
glyceridemia in HIV patients is highly influenced by
genetic variability (7 ) and, among the candidate genes,
the newly identified apolipoprotein A-V (APOA5)1 has
emerged as probably the most potent modulator of tri-
glyceride (TG)2 metabolism. The role of APOA5 in regu-
lating TG metabolism has been convincingly demon-
strated in animal models (8 ) and in a large number of
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association studies (9 ), in which the –1131T3C is the
commonly used variant. APOA5 is expressed mainly in
the liver and distributed predominantly on TG-rich li-
poproteins such as chylomicrons and VLDL, and also on
HDL. In human plasma, apo A-V is found at lower
concentrations than other apolipoproteins. Its exact func-
tion has not been completely elucidated, but the available
data indicate that it modulates TG metabolism by control-
ling production of VLDL and catabolism of the lipolysis of
TG-rich lipoproteins (10 ). The latter role has been con-
firmed not only in vitro but also in patients who develop
severe hypertriglyceridemia attributable to apo A-V defi-
ciency (11 ).
Because protease inhibitor (PI)-associated dyslipide-
mia is caused by increases in VLDL production (12 ) and
by impaired lipolysis (13 ), we hypothesized that, in
HIV-infected individuals, the APOA5 gene could be an
important indicator of predisposition to PI-related deteri-
oration of the lipid profile. Hence, we analyzed lipid
changes in HIV patients segregated with respect to treat-
ment strategy and APOA5 genotype.
Materials and Methods
patients
A total of 229 HIV-infected patients attending our outpa-
tient clinic gave written informed consent to participate in
the study. The present study is part of a longitudinal
project in which atherosclerosis in HIV-infected patients
is being assessed in a cohort of patients who are followed
regularly in our outpatient clinic. The overall characteris-
tics of these patients have been described previously
(14, 15). Time 0 of the study corresponds to commence-
ment of therapy with PIs (n  148) or without PIs (n  81).
Subsequent time-points are at 1, 2, 3, 4, and 5 years of
treatment follow-up. Clinical and biochemical data and
the APOA5–1131T3C genotype have been measured for
all participants. Exclusion criteria were age 18 years and
AIDS-related opportunistic disease when the study be-
gan. The Ethics and Investigation Committee of our
Hospital approved the study.
lipid profile analyses
We used standard laboratory methods to measure total
cholesterol, HDL cholesterol, and TGs.
high-sensitive c-reactive protein analyses
We measured serum high-sensitive C-reactive protein
(hsCRP) concentrations with a turbidimetric immunoas-
say (Biokit), according to the manufacturer’s instructions.
apoa5 –1131t3c genotype analyses
Genomic DNA was obtained from leukocytes and ex-
tracted with calibrated methods. The –1131T3C variation
in the APOA5 gene was detected with the oligonucleotide
primers AV-1–5-GAT TGA TTC AAG ATG CAT TTA
GGA C-3 and AV-2–5CCC CAG GAA CTG GAG CGA
AAT T-3 to amplify a 187bp segment, and AV-2 primer
forced a site for Mse I (New England Biolabs) enzymatic
restriction. PCR was performed as described previously
(8 ).
statistical analyses
We used a multivariate analysis on patients with com-
plete data available [age, body mass index (BMI), sex, and
lipid data at all time points] being entered into the
analysis. To improve the statistical power of our dataset,
we performed ANOVA analyses of data from every single
time-point, used lipid values as a dependent variable, and
normalized for confounding factors such as sex, age, BMI,
and lipodystrophy. We also performed multivariate anal-
yses of repeated measures, which confirmed the trends
but did not reach statistical significance. For TG and
hsCRP, calculations were performed on log-transformed
values, although nontransformed concentrations are
shown in the Tables and Figs.
We analyzed deviation from Hardy Weinberg equilib-
rium with the 2 goodness-of-fit test. Results are con-
veyed as mean (SD). Statistical significance was accepted
at a value of P 0.05.
Results
The data from a total of 229 HIV-infected patients were
segregated according to APOA5 –1131T3C genotype and
treatment scheme. For statistical purposes, the single
patient homozygous for the C allele was pooled with
those patients who were T/C heterozygote. For lipid
analyses, patients undergoing the PI regimen (n  148)
and those not receiving PIs (n  81) were studied sepa-
rately.
The frequency of the C allele was 0.08, which is similar
to that found in the Spanish general population (0.07)
(16 ). Allelic distribution was in Hardy-Weinberg equilib-
rium.
apoa5-associated changes in lipids and
lipoproteins
The group of patients with the wild-type genotype (TT)
and carriers of the rare variant (TC and CC) were com-
parable at baseline with respect to age, sex, immunologic
status, hsCRP, total cholesterol, HDL cholesterol, and TGs
(Table 1). Only BMI was considerably higher in the
carriers of the wild-type allele.
patients receiving pi therapy
Because hyperlipidemia is strongly associated with the PI
regimen, we focused on the subgroup of 148 patients
receiving PI as a component of their antiretroviral ther-
apy, and we analyzed their lipid profile changes over the
5-year follow-up period. The 2 genotype groups were also
comparable at baseline (pretreatment), including the per-
centage of patients receiving ritonavir (Table 1).
Carriers of the C allele had consistently higher TG
concentrations than noncarriers at 1 year [2.11 (1.62) vs
3.71 (4.27) mmol/L; P  0.009], 2 years [2.48 (2.09) vs 4.02
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(4.05) mmol/L; P  0.050], 3 years [2.32 (1.71) vs 4.13
(4.26) mmol/L, P  0.013], 4 years [2.90 (2.95) vs 5.35
(7.12) mmol/L; P not significant], and 5 years [4.25 (5.58)
vs 9.23 (9.63) mmol/L; P not significant], after adjustment
of the data for age, sex, BMI, and the presence of lipodys-
trophy (Fig. 1).
Results were similar for total cholesterol. Carriers of
the C allele had higher plasma cholesterol concentrations
at 1 year [4.93 (1.31) vs 5.87 (1.66) mmol/L; P  0.006], 2
years [5.03 (1.12) vs 6.42 (2.48) mmol/L; P  0.001], 3
years [5.11 (1.17) vs 6.38 (2.43) mmol/L; P  0.009], 4
years [5.49 (1.71) vs 6.78 (3.03) mmol/L; P  not signifi-
cant], and 5 years [5.56 (1.75) vs 7.90 (3.60) mmol/L;
P  not significant] (Fig. 2). HDL cholesterol concentra-
tions showed a tendency toward decrease in carriers of
the C allele and increase in patients with the wild-type
alleles, but these differences did not reach statistical
significance (data not shown).
The total cholesterol/HDL cholesterol ratio, which was
78% higher in carriers of the C allele than in carriers of the
wild-type allele (Fig. 3), indicated that these lipid changes
increased the risk of atherogenesis.
patients not receiving treatment with pis
To investigate whether the effect of APOA5 on the lipid
profile in HIV patients was influenced by treatment with
PIs or whether the effect was more generalized, we
separately evaluated the 81 patients who were not receiv-
ing treatment with PIs. At baseline, the 2 genotype groups
were comparable (Table 1). There were no differences
between genotypes with respect to total cholesterol, TGs,
HDL cholesterol, or the total cholesterol/HDL cholesterol
ratio over the 5-year follow-up period (Figs. 1–3).
Discussion
Our results show that HIV-infected patients with the
APOA5–1131C allele are predisposed to severe hyperlip-
idemia related to treatment with PIs, i.e., the adverse
effects of PI appear to be exacerbated in patients with the
C allele on the APOA5 gene.
apoa5 enhances pi-associated hyperlipidemia
The PIs used in combined therapies can produce major fat
redistribution, hyperlipidemia, and insulin resistance.
These effects can be mitigated by replacing PIs with other
antiretroviral drugs (17 ). That these abnormalities do not
develop in all patients on PI regimens suggests the
involvement of genetic or environmental predisposing
factors. We focused on the APOA5 gene because it is
probably the strongest genetic determinant of plasma TG
(9 ) identified to date, and few data on the influence of
APOA5 on PI-induced hyperlipidemia are available.
Among the 229 HIV-patients we followed for a period
of 5 years, those receiving the PI regimen tended, as
expected, to have higher concentrations of total choles-
terol and TGs during the treatment period. Despite simi-
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individuals carrying the –1131C variant of the APOA5
gene and undergoing treatment with PIs had the highest
values at all of the follow-up time-points. Conversely,
carriers of the –1131C variant not receiving PI treatment
did not have such strongly increased concentrations of
these lipids. This observation is in accordance with our
previous studies demonstrating that the magnitude of the
effect of the APOA5 gene is more pronounced when
conditions are more metabolically challenging (16 ).
Increased cholesterol concentrations in carriers of the
–1131C allele could also be the result of increased cho-
lesterol delivery by the TG-rich lipoproteins, a well-
described secondary feature of VLDL overproduction.
Although detailed lipoprotein subfractionation was not
available in the present group of patients, it is clear that
increased VLDL synthesis, decreased catabolism, or a
combination of these processes can lead to PI-induced
hyperlipidemia. It is also clear that these metabolic per-
turbations are characterized essentially by an increasing
TG component with a concomitant increase in the choles-
terol concentration in these lipoproteins.
In our study sample, carriers of the APOA5 variant
allele had higher rates of lipodystrophy. The APOA5 gene
may somehow predispose individuals to this lipid and
fatty-tissue redistribution, but this hypothesis is not sup-
ported by our finding that the frequency of lipodystrophy
among APOA5 genotypes in the non-PI group did not
differ from the frequency in the overall patient group.
Fig. 1. Changes in plasma TG concen-
trations over the 5-year follow-up for
carriers of the APOA5 –1131C allele
(solid line) and carriers of the wild-
type allele (dotted line) receiving ei-
ther PI treatment (closed circles) or
treatment not containing PIs (open
squares).
Carriers of the C allele receiving PI treat-
ment have considerably higher TG concen-
trations at 1 year [2.11 (1.62) vs 3.71
(4.27) mmol/L, P  0.009], 2 years [2.48
(2.09) vs 4.02 (4.05) mmol/L, P  0.050],
and 3 years [2.32 (1.71) vs 4.13 (4.26)
mmol/L, P  0.013] of follow-up, repre-
senting 43%, 38%, and 44% of higher
amounts in C allele carriers, respectively.
Data were available for 15 carriers of the C
allele and 96 wt treated with PI, and for 15
carriers of the C allele and 41 wt on alter-
native therapy.
Fig. 2. Changes in plasma cholesterol
over the 5-year follow-up are pre-
sented for carriers of the APOA5
–1131C allele (solid line) and carriers
of the wild-type allele (dotted-line) re-
ceiving either PI treatment (closed cir-
cles) or treatment not containing PIs
(open squares).
Carriers of the C allele receiving PI treat-
ment have considerably higher total choles-
terol concentrations at 1 year [4.93 (1.31)
vs 5.87 (1.66) mmol/L, P  0.006], 2
years [5.03 (1.12) vs 6.42 (2.48) mmol/L,
P  0.001], and 3 years [5.11 (1.17) vs
6.38 (2.43) mmol/L, P  0.009] of follow-
up, representing 16%, 21%, and 20%
higher amounts in C allele carriers, respec-
tively. Data were available for 15 carriers of
the C allele and 96 wt treated with PI and
for 15 carriers of the C allele and 41 wt on
alternative therapy.
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Conversely, after adjustment for the presence of lipodys-
trophy, all of the observed differences with respect to
lipid concentrations remained considerable, indicating
that the hyperlipemic effect was truly associated with the
APOA5 gene and was not influenced by the presence of
lipodystrophy.
A mechanistic approach to this observation could be
that, although the exact function in vivo of apo A-V is not
known, in vitro studies suggest that it acts by decreasing
the assembly of the VLDL particle (18 ) and its secretion
and by stimulating lipolysis in the circulation (10 ). Con-
versely, PI-induced hyperlipidemia has been shown to be
caused by an increase in VLDL production (12 ) as well as
by impaired lipolysis (13 ) as a consequence, in part, of a
direct interaction between the PI and the sterol regulatory
element-binding proteins (SREBP)1 and 2, leading to an
accumulation of SREBPs in the nucleus, which stimulates
lipid synthesis (19 ). Because APOA5 expression is down-
regulated by SREBP1c (20 ), we assume that apo A-V plays
a determining role in PI-induced hyperlipidemia.
Whether the –1131C allele is a functional variant or is
acting as a marker of a functional variant elsewhere in the
gene is not clear (21 ).
apoa5 and atherogenic lipid profile
Patients who are receiving PI-treatment and who carry
the –1131C allele present with a lipoprotein profile that
deteriorates rapidly because of increasing of total choles-
terol and TGs and a decrease in the HDL fraction, with the
atherogenic total/HDL cholesterol ratio reaching the
highest quintile after 3 years in carriers of the mutant C
allele (22 ). This scenario does not occur in patients who
are receiving the same treatment but who carry the
wild-type gene or who are not receiving PI therapy.
One of the limitations of our study is that there were
fewer patients available to follow up at years 4 and 5 than
for the first 3 years because 4 to 5 years ago there was less
concern regarding lipid alterations in individuals with
HIV-AIDS, so the percentage of individuals with HIV-
AIDS being treated for hyperlipidemia was considerably
lower in the first 2 years of recruitment into the present
study. We suspect that the patients who were recruited
were those with more evident dyslipidemia, which might
explain the greater increase in plasma TG concentrations
in year 5. It is important to note, however, that all the
main conclusions of the study were drawn from the data
obtained during 1–3 years of follow-up. Data from 4–5
years of follow-up were included for completeness, and to
indicate that the trends toward increased lipids observed
in the first 3 years continued in the same direction over
the subsequent years of follow-up in those patients, for
whom detailed lipid datasets were available.
In conclusion, our results indicate that variability at the
APOA5 gene variation predisposes HIV patients, particu-
larly those treated with PIs, to severe hyperlipidemia.
Although these results must be confirmed in future stud-
ies, they suggest the possibility of using the APOA5 gene
as a marker of predisposition to severe hyperlipidemia as
a consequence of treatment with PIs. In HIV-positive
individuals found to carry this variation, treatment alter-
natives that exclude PI may need to be considered.
This study was supported by grants from the Instituto de
Salud Carlos III, Red de Centros de Metabolismo y
Nutrición (C03/08), genetic hyperlipidemias (G03/181),
Mediterranean diet (G03/140), and SAF-2002-02781 (Ma-
drid, Spain). Dr. Blai Coll is in receipt of a career devel-
opment award from the Instituto de Salud Carlos III
(Madrid, Spain). Montse Guardiola is a recipient of a
predoctoral fellowship at the Spanish Ministry of Science
and Technology (BES-2003-1090).
Fig. 3. Changes in plasma cholester-
ol/HDL cholesterol ratio over the
5-year follow-up are presented for car-
riers of the APOA5 –1131C allele
(solid line) and carriers of the wild-
type allele (dotted-line) receiving ei-
ther PI treatment (closed circles) or
treatment not containing PIs (open
squares).
Although the 4 categories have comparable
values at baseline, carriers of the –1131C
allele on PI therapy have a considerably
higher ratio (above the 5th quintile) after 3
years of follow-up.
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Introducción. En el desarrollo de la
arteriosclerosis intervienen numerosos factores; en
especial la edad, la dieta y la hiperlipidemia. La
apolipoproteína (apo) A-V desempeña un papel
destacado en el control del metabolismo lipídico.
Nuestro objetivo es estudiar en ratones
hiperlipémicos el efecto que la grasa de la dieta
tiene en la expresión hepática del gen de la apo A-V
(APOA5) y su relación con el desarrollo de la
arteriosclerosis y sus factores de riesgo.
Material y métodos. Utilizamos 72 ratones knock-
out para el gen de la apo E (KO-APOE) separados
en 3 grupos (n = 24): los que recibían dieta
convencional de ratón o dieta rica en grasa
saturada (20% aceite de palma) sola o
suplementada con 0,25% de colesterol. Las
muestras se tomaron a las 16, 24 y 32 semanas de
edad. Las determinaciones analíticas incluyeron
parámetros lipídicos e inflamatorios, la superficie
de lesión arteriosclerótica en la aorta y la expresión
de APOA5 en hígado.
Resultados. La ingesta de dieta rica en grasa
saturada disminuye un 48% (p = 0,001) de media la
expresión hepática de APOA5 y la suplementación
con colesterol revierte este efecto. Estos efectos se
observaron a las diferentes edades de los ratones.
La expresión hepática de APOA5 aumenta
significativamente (p < 0,0001) en función de la
edad, el número de lesiones arterioscleróticas en la
aorta y el grado de inflamación en los ratones.
Conclusiones. La grasa saturada de la dieta
disminuye significativamente la expresión hepática
de APOA5, que a su vez aumenta con la edad a
todas las dietas suministradas y se correlaciona
con el área ateromatosa y el estado inflamatorio.
Palabras clave:
APOA5. KO-APOE. Triglicéridos. Dieta. Arteriosclerosis. MCP-1.
SATURATED FAT FROM DIET
DOWNREGULATES APOA5 HEPATIC
EXPRESSION IN APO E DEFICIENT MICE
Introduction. Many factors are involved in
atherosclerosis development, especially age, diet
and hyperlipidemia. Apolipoprotein (apo) A-V
plays a key role in the control of lipid metabolism.
The aim of this study was to determine the effect of
dietary fat intake on hepatic expression of the apo
A-V gene (APOA5) in hyperlipidemic mice and its
association with risk factors for atherosclerosis
and atherosclerosis development.
Material and methods. We used 72 knock-out
mice for the apo E gene (KO-APOE) divided in
three groups (n=24) that received a chow diet, a
diet rich in saturated fat (20% palm oil) alone, or a
diet supplemented with 0.25% of cholesterol.
Samples were obtained at 16, 24, and 32 weeks.
Laboratory determinations included lipid and
inflammatory parameters, area of atherosclerotic
Este estudio se ha llevado a cabo gracias a un proyecto finan-
ciado por las Becas FEA/SEA 2004 para Investigación básica
en el tema “Aspectos básicos de la arteriosclerosis y sus facto-
res de riesgo”; un proyecto subvencionado por el Fondo de In-
vestigación Sanitaria FIS (PI020032) y una beca predoctoral
del Ministerio de Ciencia y Tecnología (BES-2003-1090).
Correspondencia: Dr. J. Ribalta.
Unitat de Recerca de Lípids i Arteriosclerosi. Facultat de Me-
dicina. Universitat Rovira i Virgili.
Sant Llorenç, 21. 43201 Reus. Tarragona. España.
Correo electrónico: josep.ribalta@urv.cat
Recibido el 9-11-2006 y aceptado el 28-11-2006.
La grasa saturada en la dieta disminuye 
la expresión hepática de APOA5
en ratones deficientes en apo E
Montse Guardiola, Mònica Tous, Joan Carles Vallvé, Anna Rull, Lluís Masana, Jorge Joven y Josep Ribalta
Institut de Recerca en Ciències de la Salut. Hospital Universitari Sant Joan. Universitat Rovira i Virgili. Reus. Tarragona. España.
Originales
04 Original 1105 (22-9).qxp  8/2/07  17:57  Página 22
UNIVERSITAT ROVIRA I VIRGILI 
ROLE OF THE APOA5 GENE IN LIPID AND FAT-SOLUBLE VITAMIN METABOLISM 
Montserrat Guardiola Guionnet 
ISBN:978-84-691-9478-2/DL:T-19-2009 
 
lesions in the aorta, and APOA5 expression in the
liver.
Results. Intake of a saturated fat-rich diet
reduced mean hepatic expression of APOA5 by 48%
(P=0.001), while cholesterol supplementation
reversed this effect. These effects were found at the
different ages of mice. Hepatic APOA5 expression
significantly increased (P=0.001), depending on
age, the number of atherosclerotic lesions in the
aorta, and the degree of inflammation in these
mice.
Conclusions. Saturated dietary fat significantly
downregulates hepatic APOA5 expression, which
also increases with age, in all the diets
administered and correlates with atheromatous
area and inflammatory status.
Key words:
APOA5. APOE-knock-out. TC. Diet. Arteriosclerosis. MCP-1
Introducción
La arteriosclerosis en humanos es un proceso de
desarrollo lento y es la causa principal de las enfer-
medades cardiovasculares y cerebrovasculares, que
causan una elevada mortalidad y morbilidad en los
países desarrollados. La hiperlipidemia, la inflama-
ción, la oxidación y la nutrición son factores clave
en la aparición y progresión de la arteriosclerosis.
Debido a la dificultad de estudiar la arterioscle-
rosis en humanos, el ratón deficiente para la apoli-
poproteína E (apo E) ha sido muy utilizado como
modelo gracias a que su metabolismo lipídico se
parece mucho al de los humanos y a que el desa-
rrollo de su proceso arteriosclerótico es rápido y
reproducible. Además, si estos ratones se alimen-
tan con una dieta enriquecida en colesterol y gra-
sas, los valores de colesterol plasmático y la atero-
génesis aumentan de manera proporcional1.
Las alteraciones del metabolismo de las lipopro-
teínas son un factor de riesgo para la arteriosclero-
sis y pueden producirse como resultado de errores
en la regulación de las apolipoproteínas. En el cro-
mosoma 11 humano existe una región que agrupa
los genes de las apolipoproteínas A-I/C-III/A-IV/A-V,
que ha sido muy estudiada por su implicación en el
metabolismo lipídico. El último de ellos (APOA5)
se ha descubierto recientemente y ha demostrado
tener una influencia especialmente relevante en el
control de la trigliceridemia. Los animales que so-
breexpresan el gen tienen un 60% menos triglicéri-
dos (TG) circulantes, y en los animales que carecen
del gen la trigliceridemia aumenta hasta 4 veces2.
El gen APOA5 se expresa únicamente en el hígado,
donde se postula que reprime la síntesis y/o secre-
ción de las lipoproteínas de muy baja densidad
(VLDL)3. Estudios in vitro demuestran que la apo
A-V estimula la actividad hidrolítica de la lipopro-
teína lipasa unida al endotelio4. En los últimos
años, varios grupos han descrito (mediante estu-
dios de asociación) que los polimorfismos en el gen
APOA5 se asocian a mayores concentraciones de
TG en plasma5, aunque su relación con el riesgo
cardiovascular es todavía controvertida6-8. Otros es-
tudios describen una asociación entre polimorfis-
mos del gen APOA5 y la dieta y sugieren que su ex-
presión está regulada por la alimentación9,10,
aunque este punto no ha sido demostrado.
Nuestro objetivo ha consistido en estudiar el
efecto que produce la dieta en la expresión de
APOA5 en un modelo experimental de arterioscle-
rosis y la influencia de los cambios inducidos en
APOA5 sobre parámetros lipídicos, la propia lesión
arteriosclerótica y las concentraciones circulantes
del marcador inflamatorio clave en ratones, el mo-
nocyte chemotactic protein -1 (MCP-1).
Material y métodos
Ratones KO-apoE y diseño del estudio
La experimentación con los animales se llevó a cabo en las
condiciones que establece la normativa legal vigente (Real De-
creto 223/1998) y la tutela de la Comisión de Experimentación
científica en animales de nuestra universidad.
Se utilizó 72 ratones macho KO-apoE agrupados en jaulas a
21-23 °C, con un grado de humedad del 50-60%, sometidos a
un ciclo de 12 h de luz/oscuridad y con libre acceso tanto al
agua como a la comida.
Los ratones se dividieron en 3 grupos de estudio que reci-
bieron dieta convencional de ratón (pobre en grasa y sin coles-
terol. BK Universal, Barcelona) o dieta rica en grasas satura-
das (20% aceite de palma. Unilever, Bilbao) con diferente
contenido en colesterol (0 y 0,25% p/p. Sigma Chemical Co.,
St. Louis, MO, Estados Unidos) y se han sacrificado a las 16,
24 y 32 semanas de edad. Este diseño nos permite estudiar la
expresión del gen APOA5 en relación con la dieta y con la edad
y, por tanto, observar patrones temporales.
Obtención de muestras
Durante el procedimiento experimental, se obtuvo muestras
de sangre mediante punción en la cola y semanalmente se rea-
lizó el control del peso de todos los animales. Inmediatamente
antes del sacrificio, se administró a los animales 0,1 ml de una
mezcla de ketamina/xilacina para anestesiarlos por vía intra-
peritoneal. Una vez sacrificados, se obtuvo sangre mediante
punción ventricular y también se extrajo el hígado y el cora-
zón, que se congelaron inmediatamente a –80 ºC, hasta su pos-
terior utilización.
Determinaciones lipídicas
Se determinaron los valores de colesterol y TG en plasma
mediante técnicas estándar de laboratorio. Para caracterizar la
composición lipídica de la esteatosis presente en estos anima-
les, se determinó los contenidos de colesterol y TG en homoge-
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nizados de tejido hepático después de la extracción de lípidos
con isopropilo alcohol-hexano11.
Cuantificación de la lesión ateromatosa
La cuantificación de la lesión ateromatosa se determinó se-
gún el método de Tangirala et al12. Después del sacrificio, se
congeló inmediatamente el corazón junto con el origen de la
aorta; los cortes seriados obtenidos mediante un criostato se
han teñido con un colorante con afinidad por los lípidos, el
Sudan IV. La imagen microscópica para medir las áreas teñi-
das con este colorante, correspondientes a las áreas de lesión
ateromatosa, se capturó mediante una cámara de vídeo y la
extensión de la arteriosclerosis se ha cuantificado con un siste-
ma de análisis de imagen automatizado (AnalySIS Soft Ima-
ging System, Münster, Germany).
Concentración plasmática de MCP-1
La concentración plasmática del marcador inflamatorio
MCP-1 se ha determinado utilizando un kit de ELISA (Mouse
MCP-1 ELISA kit, Pierce, Rockford, Estados Unidos), siguien-
do las instrucciones del fabricante.
Extracción de ARN y PCR a tiempo real
La extracción del ARN total de tejido hepático se realizó me-
diante el equipo de extracción ABI PRISM 6100 Nucleic Acid
PrepStation de Applied Biosystems siguiendo las instrucciones
del fabricante. La pureza y la concentración del ARN se han esti-
mado mediante la relación de absorbancia 260 nm/280 nm. Se ha
retrotranscrito 1 µg de ARN a ADNc siguiendo las instrucciones
del fabricante y utilizando el termociclador PE Biosystems 2400.
La expresión del ARN mensajero (ARNm) de APOA5 se ha
cuantificado mediante reacción en cadena de la polimerasa
(PCR) a tiempo real utilizando el equipo ABI Prism 5700 Se-
quence Detector System (Applied Biosystems, Foster City, Esta-
dos Unidos), combinado con la utilización de primers y sondas
Taqman®. Éstos se obtuvieron de Applied Biosystems como pro-
ductos Assays-on-Demand validados y prediseñados. El ARN ri-
bosomal (ARNr) A 18S se utilizó como control endógeno y los
valores de expresión se calcularon de acuerdo con el método de
ct (ABI Prism 7700 Sequence Detection System. User bulletin
n.o 2. Revisión A. Foster city [CA]: Applied Biosystems, 1997).
Análisis estadístico
Los datos se expresan como media ± desviación estándar.
La comparación de medias se ha determinado mediante la
prueba de ANOVA univariante y para las variables categóricas
se utilizó la prueba de la χ2.
Las correlaciones entre la expresión de APOA5, la extensión
de la lesión en la aorta y la concentración plasmática del pará-
metro inflamatorio MCP-1 se han determinado mediante re-
gresión lineal.
Resultados
Efecto de la dieta sobre los lípidos 
y la arteriosclerosis
En la tabla 1 se muestra cómo la administración
de dieta rica en grasa saturada (20% aceite de pal-
ma), al suplementarla con colesterol, hace aumen-
tar significativamente los valores circulantes de co-
lesterol respecto a la dieta convencional en los
ratones KO-apoE (p < 0,0001) y no modifica las
concentraciones circulantes de TG. La suplementa-
ción con colesterol también produce un aumento
significativo de los valores de colesterol y TG en el
hígado (p < 0,0001 y p = 0,013, respectivamente).
La superficie de lesión arteriosclerótica medida
en la aorta y la presencia de esteatosis en el hígado
aumentan significativamente con el contenido en
grasa de la dieta (p < 0,0001) (fig. 1). La concentra-
ción plasmática de MCP-1 también tiende a au-
mentar, pero este incremento no es estadísticamen-
te significativo.
La ingesta de grasa saturada disminuye la expresión
hepática del gen APOA5
Concretamente, la adición de un 20% de aceite
de palma disminuye los valores de ARNm de
APOA5 en el hígado en un 75% (p = 0,020) en los
ratones de 16 semanas, un 35% (p = NS) en los de
24 semanas y un 45% (p = 0,023) en los de 32 se-
manas, respecto a la dieta convencional. Sin em-
bargo, la adición de 0,25% de colesterol a la dieta
rica en grasa saturada evita esta disminución en
los valores de ARNm de APOA5 que no difieren de
los de la dieta convencional tanto en los ratones de
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Tabla 1. Valores basales de parámetros lipídicos y características de todos los ratones según el tipo de dieta
DN DRG DRG + 0,25% COL p
COL (mmol/l) 7,9 ± 2,4 12,4 ± 2,1 20,4 ± 4,4 < 0,0001
TG (mmol/l) 0,8 ± 0,3 0,9 ± 0,2 0,8 ± 0,4 NS
COL en hígado (nmol/l) 4,8 ± 1,0 4,8 ± 0,9 7,6 ± 2,5 < 0,0001
TG en hígado (nmol/l) 5,6 ± 1,4 6,2 ± 2,9 9,4 ± 5,6 0,013
Cuantificación de la lesión  
arteriosclerótica (Um2) 149.691,0 ± 131.747,4 365.996,3 ± 273.294,0 1.117.418,3 ± 734.723,5 < 0,0001
MCP-1 (pg/ml) 161,9 ± 63,4 200,1 ± 114,8 236,2 ± 118,4 NS
Presencia de esteatosis 
(% de ratones) 0 14,3 85,7 0,005
COL: colesterol; DN: dieta convencional; DRG: dieta rica en grasa saturada (20% aceite de palma); MCP 1: monocyte chemotactic protein-1; NS: no
significativo; TG: triglicéridos.
Los resultados se presentan como media ± desviación estándar.
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16 semanas (p = 0,003) como en los de 32 (p =
0,039) (fig. 2).
Efecto de la edad sobre los lípidos 
y la arteriosclerosis
La tabla 2 muestra las diferencias entre los pará-
metros lipídicos determinados en los ratones ali-
mentados con todas las dietas, según la edad a la
que fueron sacrificados.
Vemos que con la edad los valores circulantes de
colesterol no presentan ningún cambio y que los
valores de TG circulantes disminuyen significativa-
mente a las 32 semanas (p = 0,016). Los valores de
colesterol en el hígado tienden a disminuir con la
edad y en cuanto a los TG vemos que disminuyen
significativamente (p = 0,003). El área de la lesión
arteriosclerótica aumenta, tal y como esperába-
mos, así como el grado de inflamación determina-
do con la concentración de MCP-1 en plasma (p <
0,0001 y p < 0,0001, respectivamente). Con la edad
también aumenta el número de ratones que pre-
sentan esteatosis (p = 0,037).
La expresión hepática del gen APOA5 aumenta con
la edad
Los valores hepáticos de ARNm de APOA5 se co-
rrelacionan positivamente con la edad (R2 = 0,405;
p < 0,0001) y negativamente con los valores de co-
lesterol y TG en el hígado (R2 = 0,082; p = 0,047; y
R2 = 0,087; p = 0,040, respectivamente). Los ratones
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Figura 2. Distribución de los valores de expresión hepática de APOA5 en relación con el tipo de dieta que recibían los ratones agru-
pados por edad. La expresión hepática de APOA5 en los ratones alimentados con dieta rica en grasa saturada está significativamen-
te disminuida respecto de la que presentan los ratones alimentados con dieta convencional o dieta rica en grasa saturada suple-
mentada con colesterol en los ratones de 16 (p = 0,020)a, 24 (p = NS) y 32 (p = 0 ,023)b semanas de edad, respectivamente.
Figura 1. Esteatosis en hígado según el tipo de dieta.
Secciones de tejido hepático de ratón KO-apoE de 32 semanas de edad alimentado con dieta convencional (A) y de ratón alimenta-
do con dieta rica en grasa saturada (B) donde se observa una mayor presencia de microvesículas lipídicas.
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de 24 y 32 semanas de edad presentan unos valores
de media del 89,1 y el 282,8% superiores respecto a
la expresión que presentan los de 16 semanas (fig.
3). Este efecto es independiente de la dieta ya que
también se observa si separamos los ratones en los
diferentes grupos de dieta.
Arteriosclerosis
Para intentar comprender el alcance de los cam-
bios en APOA5 inducidos por las distintas dietas,
analizamos las correlaciones entre los valores de
ARNm de APOA5 y de lípidos, la lesión ateromato-
sa y el grado de inflamación en estos ratones.
La expresión hepática de APOA5 no se correla-
ciona significativamente con ningún parámetro li-
pídico determinado en los ratones.
Tal y como muestran las figuras 4 y 5, observa-
mos que la expresión de APOA5 tiende a corre-
lacionarse positivamente con la superficie de lesión
en la arteria aorta de los ratones alimentados con
dieta rica en grasa saturada, y negativamente en los
ratones alimentados con dieta convencional o dieta
rica en grasa saturada suplementada con colesterol.
En el caso de la concentración plasmática de MCP-
1, también observamos el mismo comportamiento
de forma positiva y significativa en los ratones ali-
mentados con dieta rica en grasa saturada y corre-
lacionando negativamente en los ratones alimenta-
dos con los otros 2 tipos de dietas.
Discusión
Nuestros resultados demuestran que la grasa sa-
turada disminuye cerca de un 50% la expresión he-
pática de APOA5 en el ratón KO-apoE. Además, au-
menta con la edad en todas las dietas administradas.
Dieta
La expresión hepática del gen APOA5 disminuye
significativamente en todos los ratones de diferen-
tes edades alimentados con dieta rica en ácidos
grasos saturados; sin embargo, al suplementar esta
dieta con 0,25% de colesterol tal efecto desaparece.
Los modelos animales indican que la sobreex-
presión de APOA5 ayuda a controlar los valores
plasmáticos de TG13. Por lo tanto, la disminución
de hasta un 75% en animales jóvenes de la expre-
sión hepática de APOA5 supondría un efecto adver-
so en los TG. Ello estaría de acuerdo con los estu-
dios que muestran que una dieta rica en grasa
saturada aumenta los valores de TG y que el déficit
de apo A-V en humanos está asociado a hipertrigli-
ceridemia grave14,15. Sorprendentemente, no hemos
observado que la disminución de APOA5 afecte a
los valores de TG. Creemos que ello puede ser una
característica específica de los ratones KO-apoE en
los que sabemos que la vía secretora de TG en los
hepatocitos está alterada16, lo cual podría restar in-
fluencia a APOA5 en la síntesis de VLDL.
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Tabla 2. Valores basales de parámetros lipídicos y características de todos los ratones a las diferentes edades
de sacrificio
16 semanas 24 semanas 32 semanas p
COL (mmol/l) 13,1 ± 5,3 12,8 ± 5,1 14,2 ± 7,2 NS
TG (mmol/l) 0,9 ± 0,3 0,9 ± 0,4 0,6 ± 0,1 0,016
COL en hígado (nmol/ml) 5,8 ± 1,9 6,3 ± 2,8 5,1 ± 1,4 NS
TG en hígado (nmol/ml) 7,8 ± 3,4 8,6 ± 5,5 4,7 ± 1,8 0,03
Cuantificación de la lesión 
arteriosclerótica (Um2) 137.372,3 ± 80.361,0 573.481,8 ± 507.980,2 895.630,4 ± 744.224,9 0,001
MCP-1 (pg/ml) 132,7 ± 46,2 293,4 ± 133,2 211,0 ± 87,5 0,001
Presencia de esteatosis (%) 0 71,4 28,6 0,037
COL: colesterol; MCP-1: monocyte chemotactic protein 1; NS: no significativo; TG: triglicéridos.
































Figura 3. Distribución de los valores de expresión hepática de
APOA5 en relación con la edad a la que fueron sacrificados los
ratones. Los ratones de 32 semanas de edad presentaban ma-
yores valores de expresión de APOA5 en hígado respecto de los
ratones de 16 semanas (p < 0,001).
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Figura 4. Correlación entre la expresión hepática de APOA5 y
la cantidad de lesión en la arteria aorta según el tipo de dieta
con que estaban alimentados los ratones. Los ratones alimen-
tados con dieta convencional presentan una correlación nega-
tiva con la superficie de lesión en la arteria aorta (R2 = 0,202; p
= NS), al igual que los alimentados con dieta rica en grasa más
0,25% colesterol (R2 = 0,182; p = NS). En cambio, los ratones
alimentados con dieta rica en grasa saturada tendían a presen-
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Figura 5. Correlación entre la expresión hepática de APOA5 y
la concentración plasmática de monocyte chemotactic protein 1
(MCP-1) según el tipo de dieta con que estaban alimentados
los ratones. Los ratones alimentados con dieta convencional
tendían a presentar una correlación negativa con la concentra-
ción de MCP-1 en plasma (R2 = 0,583; p = NS), al igual que los
alimentados con dieta rica en grasa más 0,25% colesterol (R2 =
0,013; p = NS). En cambio, los ratones alimentados con dieta
rica en grasa saturada presentaban una correlación positiva
con el área de la lesión (R2 = 0,380; p = 0,025).
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El mecanismo mediante el cual los ácidos grasos
libres y el colesterol actuarían en APOA5 no está
claro; sin embargo, sabemos que los ácidos grasos
regulan la expresión de genes implicados en el me-
tabolismo energético y en este proceso de regula-
ción también están implicados varios tipos de re-
ceptores nucleares encargados del reconocimiento
de secuencias en la zona reguladora del gen. En el
caso de APOA5, sabemos que está regulado, entre
otros, por receptor de la activación de peroxisomas
α (PPARα)17, que tiene como ligandos naturales los
ácidos grasos, y nuestros resultados describen por
primera vez un papel regulador de los ácidos gra-
sos saturados en la expresión de APOA5.
El efecto de la suplementación de colesterol en la
expresión hepática de APOA5 puede explicarse te-
niendo en cuenta que su expresión está estimulada
por el receptor nuclear RORα18,19, cuya actividad
transcripcional está regulada por el colesterol. Está
descrito que las condiciones que afectan al conteni-
do celular de colesterol pueden modular la actividad
de RORα in vitro20, por tanto, es de esperar que el
tipo de dieta que administramos en estos ratones,
que aumenta los valores de colesterol, hace que
RORα sea constitutivamente activo y, por tanto, esti-
mule la expresión de APOA5, por lo que se pierde el
efecto producido por la dieta rica en grasa saturada.
Edad
El ratón KO-apoE alimentado con dieta aterogé-
nica experimentan un deterioro progresivo del hí-
gado (esteatosis e inflamación). La expresión he-
pática del gen APOA5 está significativamente au-
mentada con la edad y este efecto no depende del
tipo de dieta recibida. Sin embargo, debido al dete-
rioro funcional del hígado de estos animales some-
tidos a dietas aterogénicas, creemos que este au-
mento puede deberse a este hecho más que a la
edad per se. Además, los cambios en la expresión
de APOA5 debidos a la edad se correlacionan de
forma negativa y significativa con los valores de co-
lesterol y TG en el hígado. Ello es congruente con
el hecho de que APOA5 es uno de los genes más so-
breexpresados durante el proceso de regeneración
hepática y que ya ha sido considerado como proteí-
na de fase aguda21,22.
Arteriosclerosis
Desde que se descubrió en 2001 el gen APOA5 se
ha asociado a mayores valores de TG circulantes
en varios tipos de poblaciones como diabéticos e
hiperlipémicos; nuestro grupo ha descrito asocia-
ción en pacientes con HLFC y en pacientes infecta-
dos por el virus de la inmunodeficiencia humana
tratados con inhibidores de la proteasa23-25. Tam-
bién se ha asociado a mayor riesgo de enfermedad
cardiovascular y se ha identificado como proteína
de fase aguda, un efecto independiente de los valo-
res plasmáticos de TG.
Como ya se ha comentado, el descenso en la ex-
presión hepática de APOA5 debido a la ingesta de
dieta rica en grasa saturada no se correlacionaba
con los valores de lípidos, posiblemente debido a la
alteración en la vía secretora hepática de TG en los
ratones KO-apoE16. Por ello nos interesó saber si
este efecto se correlacionaba con otros parámetros
implicados con el proceso arteriosclerótico deter-
minados en estos ratones.
La expresión hepática de APOA5 se correlaciona
con parámetros inflamatorios como la concentra-
ción en plasma de MCP-1 y con la superficie de le-
sión arteriosclerótica. Estas correlaciones varían
según el tipo de dieta con que alimentamos a los
ratones, un hecho que refleja la importancia del
efecto modulador de la dieta en la enfermedad car-
diovascular y sus factores de riesgo. Según el tipo
de dieta, observamos que los valores de expresión
hepática de APOA5 presentan un patrón de expre-
sión inverso. Con la dieta convencional de ratón,
los valores de expresión de APOA5 se correlacionan
negativamente con la cantidad de lesión arterios-
clerótica y con el grado de inflamación presente en
el ratón, lo que sugiere cierta asociación con el
riesgo cardiovascular. Con la dieta rica en grasa sa-
turada vemos que se correlaciona positivamente,
tanto con el grado de arteriosclerosis como con el
grado de inflamación de los ratones, y probable-
mente actúa como proteína de fase aguda en con-
diciones de estrés del organismo.
En conjunto, los datos son congruentes con una
doble función del gen de APOA5. Como regulador
del metabolismo de los lípidos, en relación con la
síntesis y secreción de lipoproteínas y el control de
las reservas hepáticas de grasa, y como proteína de
fase aguda con unos valores más elevados de activi-
dad transcripcional, asociados a parámetros infla-
matorios.
En resumen, la grasa saturada de la dieta dismi-
nuye cerca de un 50% la expresión hepática de
APOA5 en el ratón KO-apoE, y por tanto, puede re-
presentar una forma de modificar la expresión de
APOA5 en el hígado.
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APOA5 is a key gene regulating TG levels. The protein product apo A-V is reported to 
be secreted exclusively in the liver where it may regulate TG-rich particle synthesis and 
secretion. Since the same process occurs in the intestine, we postulated that it would 
also express APOA5. We report here the identification of mRNA expression of APOA5 
in the intestine, being the protein concentration approximately one third that in the liver. 
APOA5 was expressed mainly in duodenum and colon, and was inversely correlated 
with APOC3 expression. In the human intestinal TC-7 cell line, APOA5 expression was 
downregulated by mono- and poly-unsaturated fatty acids and upregulated by 
saturated fatty acids. Short-chain fatty acid butyrate increased APOA5 expression 
almost 4-fold while APOB was downregulated by increasing butyrate concentrations. 
When TC-7 cells were incubated with PPARα agonist, APOA5 expression was 
increased by 60%, while the expression of APOB, MTP and APOC3 were decreased 
by 50, 30 and 45%, respectively. Our results demonstrate that APOA5 is expressed in 
the intestine and not, as previously thought, only in the liver. Further, its expression is 
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Alterations in the apolipoprotein (apo) A1/C3/A4 gene cluster on human chromosome 
11 have been tightly linked to the control of TG-rich lipoprotein metabolism [1]. Defects 
in triglyceride (TG) metabolism are key features in the dyslipidaemia associated with 
the metabolic disturbances underlying insulin resistance, metabolic syndrome, diabetes 
mellitus and cardiovascular disease [2]; diseases which account for high morbido-
mortality worldwide. As such, knowledge of environmental and genetic factors 
regulating TG metabolism would help when designing strategies for improved health 
care for the individuals predisposed to these diseases. 
In 2001, two groups identified the apolipoprotein A5 gene as being a component of the 
APOA1/C3/A4 gene cluster. The gene was identified in two different settings, firstly by 
sequence comparison between human and mouse genomes as a putative 
apolipoprotein-like gene [3] and, secondly, when the molecular mechanisms and genes 
governing liver regeneration process in rats were being studied [4]. These studies 
reported that APOA5 was exclusively expressed in the liver. Findings from animal 
model experiments and several association studies in humans showed that it has a 
major influence on circulating TG concentrations [5-8], and it has been proposed as a 
regulator of lipoprotein synthesis and/or secretion during the liver regeneration process 
[4]. The mechanism by which apo A-V would exert such an influence has not been 
clearly delineated. In vitro data suggest that it could inhibit the synthesis and/or 
secretion of very low density lipoprotein (VLDL) particles in the liver [9], stimulates 
lipoprotein lipase (LPL) activity in the presence of APOC2 [10-13], and indirectly 
facilitates TG-rich lipoprotein (TRL) clearance from the plasma compartment [14-15]. 
Apo A-V, in contrast to other apolipoproteins, is found at very low levels in the 
circulation [16] and is distributed in TRL and HDL particles [16].  APOA5 expression in 
animal models correlates inversely with TG concentrations while, in the majority of the 
studies in humans, circulating apo A-V concentrations correlate positively with TG 
concentrations [17-19] and, as well, with APOB in post-prandial chylomicrons (CM) and 
VLDL particles [20]. However, in view of its low concentrations, it is a matter of debate 
whether it can play a major role in determining the concentrations of circulating TRL. 
 
We hypothesize that, regardless of whether its function is the intracellular control of 
TRL synthesis or the modulation of TG hydrolysis and lipoprotein clearance in 
circulation or both, it should also be expressed in the intestine where TRL are also 
secreted but where, to-date, apo A-V has not been identified. 
 
3. Material and methods 
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TC-7 cell culture 
Human colon carcinoma TC-7 cells (subclone of CaCo-2 Cells) were purchased from 
Celltec (Barcelona, Spain). Cells were routinely grown in 75 cm2 plastic flasks to a 
density of 1.25 x 104 cell/cm2 and cultured in Dulbeco's modified Eagle’s medium 
supplemented with 20% (v/v) heat-inactivated foetal bovine serum, 100 U/ml penicillin 
and 100 μg/ml streptomycin at 37ºC in a humidified atmosphere containing 5% CO2. All 
items were purchased from Invitrogen (Carlsbad, USA). When approximately 80% 
confluent (4-5 days after seeding) cells were trypsinised, collected and redistributed for 
the cell-culture experiments. The RNA experiments were performed in cells cultured 
(as described below) in 6-well culture dishes (Nunc, Wiesbaden, Germany). For the 
Western blot experiments, cells were grown in 10 cm2 culture dishes. In all 
experiments, after reaching confluence (6-7 days after seeding), cells were grown for 
an additional 21 days for full differentiation. The culture medium was replenished three 
times per week.  
RNA PolyA+ 
Human poly A+ RNA samples from liver, small intestine, duodenum, jejunum, ileum, 
ileocaecum and colon were obtained from BD Biosciences Clontech (Franklin Lakes, 
USA). 
Pigs 
Female pigs were fed semi-synthetic diet formulated to contain a very low level of fat 
and were slaughtered when an average weight of 100 kg was reached. Samples from 
liver and neck subcutaneous fat tissues were taken at slaughter, immediately frozen in 
liquid nitrogen, and then stored at -75°C until analysis. Experimental procedures were 
approved by the ethics committee of Institut de Recerca i Tecnologia Agroalimentàries 
(IRTA). All procedures were within the guidelines of the IRTA, which are based on the 
Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals, 
incorporated in the Institute for Laboratory Animal Research (ILAR) Guide for Care and 
Use of Laboratory Animals.  
 
3.2. Preparation of FA sodium salt and FA-BSA complex for cell culture experiments 
The long-chain fatty acids studied were palmitic acid (PA, C16:0), oleic acid (OA, 
C18:1), linoleic acid (LA, C18:3), arachidonic acid (AA, C20:4), eicosapentaenoic acid 
(EPA, C20:5) and docosahexaenoic acid (DHA, C22:6). All were purchased from 
Sigma (St. Quentin Fallavier, France) and were subsequently prepared for the 
experiments according to the method of Wu et al [21], with some modifications. Briefly, 
10 mg of FA were mixed with 0.5 ml ethanol (Merck, Darmstadt, Germany) and 5M 
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NaOH (Fluka, St. Quentin Fallavier, France) in a volume adjusted so that the ratio of 
FA to NaOH was 1:1. The mixture was dried under nitrogen and then dissolved in 2 ml 
of sterile water (“stock solutions” of FA). To avoid FA oxidation, 1 μM butylated 
hydroxytoluene (Sigma, St. Quentin Fallavier, France) was added to the stock solutions 
of FA. When required, the stock solutions of FA were complexed to 5 mM of bovine 
serum albumin (Sigma, St. Quentin Fallavier, France) in a volume adjusted so that the 
ratio FA to BSA was 3:1. These FA-BSA solutions were sterile-filtered (0.22 μm) and 
used fresh. 
Butyrate, the short-chain fatty acid studied, was purchased as an anhydrous sodium 
salt from Sigma (St. Quentin Fallavier, France). The stock solution was prepared at a 
concentration of 180 mM in sterile water, sterilized through a 0.22 μm filter and used 
fresh. Stock solutions were diluted with FBS-free culture medium and used fresh. 
 
3.3. Effects of fatty acids and PPARα agonist on mRNA expression 
Effect of fatty acids on gene expression 
TC-7 enterocytes were incubated for 24h in FBS-free medium with a wide range of 
concentrations of FA-BSA (50,100, 200 and 300 μM) and with sodium butyrate at 2 and 
5 mM. After incubation, the culture medium was collected and stored at -80ºC for 
subsequent analyses. The cells were used for total RNA and protein extraction. Cells 
incubated with vehicle alone were designated as control. 
Effect of PPARα agonist on gene expression 
TC-7 enterocytes were incubated with 100μM PPARα agonist, the synthetic fibrate Wy 
14,643 (Calbiochem, Darmstadt, Germany), in a serum-free medium. After 24h 
incubation, the culture medium was collected and stored at -80ºC for the subsequent 
analyses. The cells were used for total RNA extraction. Cells incubated with vehicle 
alone (DMSO; Sigma, St. Quentin Fallavier, France) were designated as control.  
 
3.4. Cytotoxicity 
The cytotoxic effects of the FAs studied and the synthetic fibrate were measured as the 
amount of lactate dehydrogenase (LDH) released into the culture medium. LDH was 
measured in an automated analyzer (Cobas-Mira; Roche, Switzerland) using an 
enzymatic method (Roche Molecular Biochemicals). Cytotoxicity was defined as the 
LDH release significantly greater than that measured in cells not treated with each FA 
or the PPARα agonist. LDH was expressed as units per litre (U/L). Alterations in cell 
morphology were evaluated using phase contrast microscopy. 
 
3.5. RNA extraction and real-time quantitative PCR 
UNIVERSITAT ROVIRA I VIRGILI 
ROLE OF THE APOA5 GENE IN LIPID AND FAT-SOLUBLE VITAMIN METABOLISM 
Montserrat Guardiola Guionnet 
ISBN:978-84-691-9478-2/DL:T-19-2009 
 
Total RNA was extracted from cultured cells and pig liver tissue using the ABI PRISM 
6100 Nucleic Acid PrepStation extraction system (Applied Biosystems; Foster City, 
USA) according to the manufacturer’s instructions. Total RNA was extracted from pig 
adipose tissue using 1.5 ml TRIZOL (Invitrogen, Carlsbad, USA) according to the 
manufacturer’s instructions. 
The purity and concentration of RNA was estimated by the 260 / 280 nm absorbance 
ratio. RNA (1 μg) was retrotranscribed into cDNA using random hexamers with the 
reverse transcriptase SuperScript II (Invitrogen, Carlsbad, USA) following the 
manufacturer’s instructions and using the PE Biosystems 2400 thermocycler (Foster 
City, USA). 
The mRNA expression of the genes under study was semi-quantified by real time PCR 
using the ABI Prism 5700 Sequence Detector System (Applied Biosystems, Foster 
City, USA), combined with primers and Taqman® probes obtained from Applied 
Biosystems as pre-designed and validated "Assays-on-Demand" products. The 
GAPDH gene was used as endogenous control and the expression levels were 
calculated using the ΔΔct method (ABI Prism 7700 Sequence Detection System; user 
bulletin nº2. Revision A. Foster City (USA): Applied Biosystems, 1997). 
 
3.6. Protein extraction and Western Blot of apo A-V  
TC-7 enterocytes were cultured as described above and were incubated with the FA-
BSA complex (EPA and DHA 200μM) for 24h after which whole cell lysates (WL) were 
obtained by repeated freezing and thawing in homogenisation buffer containing PBS 
pH 7.4 and complete mini protease inhibitors (Roche, Manheim, Germany). Samples 
were stored at -80ºC for subsequent assay. Total protein was measured using the 
Bradford method [22]. Electrophoresis and blotting was performed using NUPAGE® 
Protein Analysis System (Invitrogen, Carlsbad, USA). Blotting membrane was blocked 
with 4% ECL Advance Blocking Reagent (Amersham Biosciences, Bucks, UK) and 
then incubated with the anti-apo A-V antibody at 1:2500 dilution (Novus Biologicals, 
Littleton, USA). Antigen-antibody complexes were detected by incubating the 
membrane with polyclonal goat anti-mouse Immunoglobulins/HRP (1:20000, P0447, 
Dako, Glostrup, Denmark). Signals were detected with ECL advanced reagent mixture 
and the bands were visualized on film by autoradiography. Banding patterns were 
captured using a Versadoc 4000 imaging system and analysed using the Quantity One 
software (Bio-Rad Laboratories, Hercules, California, USA). Actin was used to 
normalise the results obtained in each sample. The protein sizes were confirmed by 
comparison with molecular weight standards (Invitrogen Ltd, Paisley, UK). 
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3.7. Statistical analysis 
A Pearson Correlation was calculated examining the relationship between variables. 
The expression of APOA5 gene in TC-7 cells incubated with long-chain fatty acids was 
statistically evaluated using the ANOVA test to compare the effects of the different 
groups of FA (saturated, monounsaturated, polyunsaturated ω-3 and ω-6). Data from 
the incubation of the TC-7 cells with different concentrations of short-chain butyrate 
were from a one-off experiment. Data from the incubation of the TC-7 cells with 
different concentrations of the PPARα agonist were statistically evaluated using 
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4.1. APOA5 in TC-7 cells and human intestine 
Using quantitative real time RT-PCR with the GAPDH gene as the endogenous control, 
we evaluated APOA5, APOB, MTP and APOC3 gene expression in human poly A+ 
RNA from samples of duodenum, jejunum, ileum, ileocaecum and colon. We took the 
highest expression levels observed for each gene in the intestinal segment as the 
reference value. We were able to detect APOA5 expression in the concluding cycles of 
amplification (which indicates a low level of expression) and found that APOA5 is 
expressed mainly in duodenum and colon. Conversely, APOB was found to be 
expressed mainly in duodenum, jejunum and ileocaecum with MTP in duodenum and 
jejunum, and APOC3 in jejunum (Figure 1). We found an inverse correlation although 
non-significant between APOA5 and APOC3 gene expression in every human 
intestinal section analysed (r=-0.555, p=0.166). 
A Western blot was optimised to detect apo A-V protein levels in whole lysates 
obtained from TC-7 cells, from hepatic HepG2 cells used as positive control, and from 
monocyte THP-1 cells used as a negative control. These results confirmed those 
obtained from the gene expression assays i.e. the existence of apo A-V in intestinal 
TC-7 cells at approximately one third of that found in liver cells (Figure 2), and the 
absence of apo A-V in monocytes. 
 
4.2. Incubation of TC-7 cells with fatty acids 
The positive results obtained in human intestine were confirmed in cultured cells and, 
in view of the low expression levels, we tested whether its expression was modifiable 
by factors known to affect lipid metabolism, such as diet and certain pharmacological 
agents. Initially, we incubated TC-7 cells for 24h with long-chain fatty acids (palmitic 
acid as saturated FA, oleic acid as monounsaturated FA, eicosapentaenoic acid and 
decosahexaenoic as polyunsaturated ω-3 FA, linoleic and arachidonic acids as 
polyunsaturated ω-6 FA) at increasing concentrations (from 50 to 300 μM). Relative to 
control cells (i.e. those not incubated with any fatty acid) and with the exception of 
palmitic acid, the level of APOA5 expression was decreased by fatty acid addition in a 
weak dose-dependent manner, and the effect of saturated fatty acid on APOA5 gene 
expression was significantly different from that caused by PUFA ω-3 and ω-6 fatty 
acids (p=0.012 and p=0.004, respectively) (Figure 3). 
 
Based on its known role in regulating TG metabolism, we tested the effect of the short-
chain fatty acid butyrate on intestinal APOA5 gene expression by incubating TC-7 cells 
with butyrate at 2 and 5 mM for 24 hours. The 5mM butyrate incubation induced almost 
UNIVERSITAT ROVIRA I VIRGILI 
ROLE OF THE APOA5 GENE IN LIPID AND FAT-SOLUBLE VITAMIN METABOLISM 
Montserrat Guardiola Guionnet 
ISBN:978-84-691-9478-2/DL:T-19-2009 
 
4-fold increase in APOA5 gene expression. The measured APOB mRNA levels were 
found to be down-regulated by increasing concentrations of butyrate (1.27 vs. 0.72, 2-
ΔΔct at 2 and 5 mM respectively, relative to expression levels in control cells) (Figure 4). 
 
4.3. Incubation with PPARα agonist 
Fibrates are the treatment-of-choice for lowering TG concentrations. To test whether 
intestinal APOA5 gene expression responds to fibrates, we incubated TC-7 cells with 
the synthetic fibrate Wy 14,643 at 100 μM for 24h. Incubation with Wy 14,643 
increased APOA5 expression by 60% relative to control cells (p=0.008). Under the 
same conditions APOB expression was decreased by 50% (p<0.0001), MTP was 
decreased by 30% (p=0.002) and APOC3 also decreased by 45% (p=0.004) (Figure 5). 
 
4.4. Animal model 
In humans, APOA5 is expressed exclusively in the liver; the main site of lipid synthesis. 
We used the porcine model because the adipose tissue, not the liver, is the main site of 
lipid synthesis [23]. We hypothesised that APOA5 would be present in the adipose 
tissue but not in the liver. 
Since APOA5 has, as-yet, not been described in the pig, we initially searched for high-
homology sequence regions in APOA5 mRNA between species (human and mouse) 
on the assumption that these could be used as pre-designed and validated TaqMan® 
Gene Expression Assays (Applied Biosystems, Foster City, USA) for human and mice 
APOA5 and, as such, could be applied in the porcine model. In line with this proposal, 
we were able to detect APOA5 expression in the adipose tissue, but not in the liver, of 
the pig. 
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We hypothesised that apo A-V is not exclusively expressed in the liver. Our present 
findings confirm that apo A-V is also expressed in human intestine and in TC-7 cells. 
Moreover, its expression is modulated by fatty acids and PPARα agonist. 
 
5.1. APOA5 expression in human intestine 
We found that APOA5 is expressed at low levels in the TC-7 intestinal cells, and also in 
human duodenum and colon. This implies that all genes of the A1-C3-A4-A5 gene 
cluster are transcribed in the intestines [24]. Apo A-I and apo C-III participate in HDL 
and TG metabolism, whereas apo A-IV, the amino acid sequence of which bears 
strong similarity to that of apo A-V, is involved in intestinal lipid absorption, mainly in 
duodenum and jejunum [25].  
Whether such low intestinal expression of APOA5 can be functional, and what could be 
its function, remains an unanswered question. 
APOA5 is the one component of the APOA1/C3/A4/A5 gene cluster that is not 
transcriptionally regulated by the APOC3 enhancer and which may explain, in part, the 
low expression levels. Also, we believe that a certain difference in apo A-V 
concentrations between intestine and liver, in favour of the liver, would be expected 
considering that the liver is the main organ in the body that mobilises endogenous 
lipids and controls lipid homeostasis [26]. Indeed, Western blot analyses in TC-7 cells 
indicate that, despite low transcription rates, apo A-V protein concentrations amount to 
approximately one third that of liver cells. 
We are aware that the mere presence of apoA-V in the intestine does not indicate its 
potential function i.e. control of TRL synthesis and secretion, or TG hydrolysis and 
remnant particle clearance. For example, apoA-V may be produced in the intestine to 
be secreted with HDL for subsequent transfer to TG-rich particles. Also, as has been 
proposed by others [27] it may be secreted within TRL derived from the intestine in 
order to stimulate TG hydrolysis, like an antagonist to the intestinal apoC-III. This is in 
accord with the strong inverse correlation between the levels of APOA5 and APOC3 
gene expression we observed in the different human small intestine sections. Another 
function could be to regulate the assembly and secretion of intestinal lipoproteins, 
replete with dietary lipids. In support of this function was our observation that its 
expression is affected by FA and, as such, favours the description of its role in TG 
metabolism in which it is modulated by dietary factors [28].  
However, our findings support the notion that APOA5 is expressed in those tissues 
which synthesise and secrete lipids i.e. the liver as well as the intestine. Conversely, in 
the pig, in which lipid synthesis and secretion take place mainly in the adipose tissue 
UNIVERSITAT ROVIRA I VIRGILI 
ROLE OF THE APOA5 GENE IN LIPID AND FAT-SOLUBLE VITAMIN METABOLISM 
Montserrat Guardiola Guionnet 
ISBN:978-84-691-9478-2/DL:T-19-2009 
 
rather than the liver [29], we found that APOA5 is expressed in adipose tissue, and not 
in the liver. This is very much in line with data reported from another animal model, the 
chicken. In this model it is the kidney which is a very active site of lipoprotein synthesis; 
immunoreactive apoA-V being identified in various chicken tissues and with the highest 
expression being in the kidney [15]. 
 
5.2. APOA5 responds to fatty acids and PPARα agonist 
To seek further evidence of its possible functionality, we assessed the responsiveness 
of expression of intestinal apo A-V to agents that would affect its low expression i.e. 
agents such as dietary fatty acids or a PPARα agonist.  
We studied the modulatory effect of long-chain fatty acids on intestinal APOA5 
expression in the CaCo2 / TC-7 cell model based on the observation that long-chain 
fatty acids are specific ligands for PPAR nuclear transcription factors, to which APOA5 
is responsive [30, 31]. We found that monounsaturated and polyunsaturated fatty acids 
tended to decrease intestinal APOA5 expression while saturated fatty acids tended to 
increase the expression. This would imply that apo A-V would downregulate intestinal 
lipid mobilisation in a situation of high intake of saturated fat. 
The site for the formation of short-chain fatty acids from dietary soluble fibre, which 
have a lowering effect on triglycerides and cholesterol [32], is the colon. In view of the 
relatively high APOA5 expression in the colon, we evaluated the modulatory effect of 
short-chain fatty acids (i.e. butyrate) on intestinal APOA5 expression. Butyrate 
decreases hepatic and intestinal protein expression of APOB and MTP [33] and which, 
in our cell culture experiments, induced a 4-fold increase in APOA5 gene expression. 
This is consistent with its potential role of inhibiting TRL production. 
And finally, as has been described in human hepatocytes [30], we have found that 
APOA5 gene expression in intestinal TC-7 cells is also upregulated by a PPARα 
agonist. This result is of considerable clinical interest because fibrates, which are 
PPARα agonists, are the best therapeutic option to reduce TG and to increase HDL-c 
[34]. Activated PPARα heterodimerises with other nuclear transcription factors such as 
retinoid X receptor (RXR) and up-regulates the LPL, APOA1 and APOA5 genes and 
down-regulates APOC3. The outcome is a decrease in plasma TG concentrations due 
to a combined action of reduced triglyceride synthesis as well as increased catabolism.  
 
In summary, our results demonstrate that APOA5 is not exclusively synthesised in the 
liver, but also in the intestine, where is expressed at low levels and is responsive to 
fatty acids and fibrates.  
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Figure 1: Human polyA+ RNA from the different sections of intestine was obtained 
from BD Biosciences Clontech to perform the real time RT-PCR for APOA5 (panel A), 
MTP (panel B), APOC3 (panel C) and APOB (panel D) to determine gene expression 
levels. 
 
Figure 2: Cell lysates from intestinal TC-7 cells, hepatic HepG2 cells (as positive 
control) and from monocytes THP-1 (as negative control) were used to detect apo A-V 
protein levels by Western blot. Intestinal apo A-V levels are approximately one third of 
that in hepatocytes. 
 
Figure 3: Total RNA from intestinal TC-7 cells incubated with different long-chain fatty 
acids [palmitic acid (PA), oleic acid (OA), linoleic acid (LA), arachidonic acid (AA), 
eicosapentaenoic acid (EPA) and decosahexaenoic (DHA)] at different concentrations 
[50μM (black), 100μM (white), 200μM (grey) and 300μM (striped)] over 24h was 
isolated to determine APOA5 gene expression levels by RT-PCR and compared to 
control cells (not incubated with any FA). * APOA5 expression significantly different 
among saturated FA and PUFA ω-3 (p=0.012); ** APOA5 expression significantly 
different among saturated FA and PUFA ω-6 (p=0.004). 
 
Figure 4: APOA5 (panel A) and APOB (panel B) gene expression dose response (2 
and 5 mM) to short-chain fatty acid butyrate incubation in intestinal TC-7 cells for 24h, 
analysed by RT-PCR, and compared to control cells (not incubated with butyrate acid). 
 
Figure 5: Effects of 100 μM Wy 14,643 (PPARα agonist) incubated over 24h in TC-7 
cells on APOA5, APOB, MTP and APOC3 gene expression analysed by RT-PCR, and 
compared to control cells (not incubated with Wy 14,643). Expression level of APOA5 
was significantly upregulated by the agonist (p=0.008). Conversely, APOB, MTP and 
APOC3 expression were downregulated (p<0.0001, p=0.002 and p=0.004, 
respectively). 
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- The strong and consistent association between APOA5 and the levels of TG 
demonstrated in several published studies can be explained by an increase in the 
content of VLDL in circulation. 
 
- The genetic variant -1131T>C of the APOA5 gene is associated with higher 
concentrations of circulating α-tocopherol. The metabolism of vitamin E occurs in 
parallel to that of the TG-rich lipoproteins and, as such, we postulate that the effect 
of APOA5 on the levels of vitamin E is probable due to the effect of the variant of the 
gene on VLDL. 
 
- The effect of APOA5 on the levels of vitamin E is not accompanied by differences in 
the oxidative status of the subjects because, although the individuals have high 
levels of oxidative substrate (TG), they also have a greater quantity of antioxidant 
(vitamin E). 
 
- The -1131T>C variant predisposes to hyperlipidemia in patients with HIV treated 
with protease inhibitors. The differences with respect to the atherogenic profile 
between genotypes are not reflected in the sub-clinical arteriosclerosis measured 
over a period of two years of follow-up. 
 
- The diet rich in saturated fatty acids decrease the hepatic expression of the APOA5 
gene in mice deficient in APOE, and the addition of cholesterol reverses this effect. 
The hepatic expression of APOA5 in this animal model correlates with the 
arteriosclerosis and with inflammation. 
 
- The APOA5 in APOE deficient mice has a minimum effect on the concentrations of 
plasma TG, probable explained by the defect in the secretion route of TG in the liver 
in this animal model. 
 
- The hepatic expression of APOA5 increases with age in APOE deficient mice, and is 
in the same direction as the relationship between APOA5 and the grade of 
arteriosclerosis and inflammation, given that these processes worsen with age in 
these animals.  
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168   Conclusions    
- APOA5 is not expressed solely in the liver and, although it is expressed in the 
human intestine at low levels, its expression can be modified by the intake of fatty 
acids and the use of fibrates. This suggests that it can play a role in the regulation of 
lipid metabolism in response to dietary and pharmacological interventions. 
 
- The in vivo expression of APOA5 in the intestine correlates inversely with that of 
APOC3. 
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